Dynamics of the T cell response to solid tumors under anti-CD40 treatment by Appel, Lena Maetani
Dissertation
submitted to the
Combined Faculty of Natural Sciences and Mathematics
of the Ruperto Carola University
Heidelberg, Germany
for the degree of
Doctor of Natural Sciences
Presented by
Lena Maetani Appel, M.Sc.
born in: Summit, New Jersey, USA
Oral Examination: May 13, 2020

Dynamics of the T cell response to solid tumors under anti-CD40 treatment
Referees:
Prof. Dr. Thomas Höfer
Prof. Dr. Ursula Kummer

Contents
Zusammenfassung V
Summary IX
1. Introduction 1
2. Analysis of proliferating cells and modeling techniques 11
2.1. Analyzing dye dilution measurements . . . . . . . . . . . . . . . . . . . . . 11
2.1.1. Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11
2.1.2. A mixture model for the analysis of cell proliferation measurements 13
2.1.3. Accounting for overlapping peaks in the model . . . . . . . . . . . 19
2.2. Estimating errors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20
2.3. Estimating proliferation dynamics from cell division profiles . . . . . . . . 21
2.3.1. Properties of the cell proliferation ODE model . . . . . . . . . . . 22
2.3.2. Estimation of the proliferation dynamic from cell division profiles
with an ODE model . . . . . . . . . . . . . . . . . . . . . . . . . . 23
2.3.3. Mean number of divisions as a summary statistic of the cell division
profiles . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 24
3. T cell dynamics in a melanoma mouse model 25
3.1. Results of the melanoma mouse experiments . . . . . . . . . . . . . . . . . 26
3.1.1. Experimental setup . . . . . . . . . . . . . . . . . . . . . . . . . . . 26
3.1.2. Changes induced by the anti-CD40 treatment and common features
of the experiments . . . . . . . . . . . . . . . . . . . . . . . . . . . 28
3.2. Mathematical model describing the T cell dynamics in a melanoma mouse
model . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 33
3.2.1. Basic model structure construction . . . . . . . . . . . . . . . . . . 34
3.2.2. Alternative models . . . . . . . . . . . . . . . . . . . . . . . . . . . 38
III
Contents
3.2.3. Model selection for the identification of treatment induced changes 45
3.2.4. Best minimal model for the time-resolved experiment . . . . . . . . 47
3.2.5. Best minimal model for the proliferation-resolved experiment . . . 52
3.3. Comparison of the results obtained from the melanoma mouse model ex-
periments . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 57
3.3.1. Adaptations of the model and differences between the experiments 57
3.3.2. Comparison of the parameter estimates . . . . . . . . . . . . . . . 58
3.3.3. Concluding remarks on the results of the melanoma mouse model . 62
4. T cell dynamics in a pancreatic ductal adenocarcinoma mouse model 63
4.1. Results of the pancreatic ductal adenocarcinoma mouse experiments . . . 64
4.1.1. Experimental setup . . . . . . . . . . . . . . . . . . . . . . . . . . . 64
4.1.2. Changes induced by the anti-CD40 treatment and common features
of the experiments . . . . . . . . . . . . . . . . . . . . . . . . . . . 65
4.2. Mathematical model describing the T cell dynamics in a pancreatic cancer
mouse model . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 71
4.2.1. Basic model structure construction . . . . . . . . . . . . . . . . . . 71
4.2.2. Alternative models . . . . . . . . . . . . . . . . . . . . . . . . . . . 73
4.2.3. Model selection for the identification of the treatment induced
changes in the second experiment . . . . . . . . . . . . . . . . . . . 78
4.2.4. Model selection for the identification of the treatment induced
changes in the third experiment . . . . . . . . . . . . . . . . . . . . 83
4.3. Review of the results of the pancreatic ductal adenocarcinoma experiments 88
4.3.1. Challenges when fitting the sparse data of the PDAC experiments 88
4.3.2. Comparison of the results of the PDAC and melanoma experiments 89
5. Discussion 95
Bibliography 105
Acknowledgments 123
A. Supplementary information to the solution of ordinary differential equations
for birth models 125
B. Supplementary information to the melanoma experiments and models 131
C. Supplementary information to the pancreatic ductal adenocarcinoma experi-
ments and models 143
IV
Zusammenfassung
Immunmodulatorische Ansätze in der Krebstherapie, die sich die T-Zell-Antwort des
Patienten zunutze machen, haben sich als eine vielversprechende Behandlungsoption
erwiesen. Allerdings zeigt die Unvorhersehbarkeit des Therapieergebnisses, dass die
Wirkungsweise und die Faktoren, die den Erfolg einer Immuntherapie bestimmen, nicht
ausreichend verstanden sind. Durch die datengetriebene Entwicklung eines mathema-
tischen Modells zur Beschreibung der T-Zell-Antwort auf einen Tumor, wollen wir in
dieser Arbeit einen Einblick in die zugrunde liegenden Mechanismen gewinnen. Das
Augenmerk liegt hierbei auch auf dem Einfluss einer immuntherapeutischen Interven-
tion auf diese Dynamik. Zu diesem Zweck werden Daten aus einem Mausmodell für
das Melanom und das Pankreaskarzinom verwendet. Das Melanom ist dafür bekannt,
gut auf Immuntherapien anzusprechen und stellt somit eine Art Prüfstand für neue
Therapieansätze dar; das Pankreaskarzinom hingegen ist eine Krebsart für die drin-
gend neue therapeutische Ansätze benötigt werden. Die in dieser Arbeit untersuchte
Behandlungsmethode mit einem agonistischen Antikörper gegen CD40 zeigte bereits
vielversprechende Ergebnisse in präklinischen Studien zum Pankreaskarzinom und wird
außerdem in klinischen Studien der Phase I für verschiedene Tumorindikationen verwen-
det. Allerdings herrscht keine klare Meinung darüber, wie diese Intervention genau die
T-Zell-Antwort beeinflusst. Diese Dynamik wurde bisher auch nicht mit der Hilfe von
datengetriebenen mathematischen Modellen untersucht.
Zunächst entwickeln wir eine akkurate Analysemethode für in vivo Proliferationsmes-
sungen, da sich unser Modellierungsansatz stark auf diese Daten stützt. In diesem
Zusammenhang werden Zellen zu Beginn einer Messung gefärbt, z.B. mit CFSE, und die
Anzahl der darauffolgenden Teilungen kann durch die sich halbierende Farbstoffinten-
sität nachvollzogen werden. Die hieraus folgenden Intensitätsverteilungen sind bei Daten
aus in vitro Messungen klar unterscheidbar und die meisten aktuellen Modellierungssan-
sätze wurden für diesen Fall optimiert. Hierbei reicht es oftmals aus, die Daten durch
parametrische Verteilungen zu beschreiben. Allerdings stammen unsere Daten aus in
vivo Messungen, sodass die Analyse durch stark überlappende Intensitätsverteilungen
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von Zellen erschwert wird und wir herkömmliche Ansätze nur bedingt anwenden kön-
nen. Aus diesem Grund entwickeln wir eine Analysemethode, die die datenspezifische
Intensitätsverteilung berücksichtigt, indem sie den Daten inhärente Informationen wie
die Hintergrundhelligkeit und die Verteilung der Farbstoffintensität ungeteilter Zellen
verwendet. Des weiteren ermöglicht sie die flexible Kombination von Proben, um ro-
buste Optimierungsergebnisse zu erhalten und wird erfolgreich mit sechs Datensätzen
getestet, die von unseren Kooperationspartnern zur Verfügung gestellt wurden. Dadurch
können wir den prozentualen Anteil der Zellen in verschiedenen Generationen verlässlich
bestimmen, auch wenn die Verteilungen stark überlappen.
Als nächstes konstruieren und validieren wir ein mathematisches Modell, das die T-Zell-
Antwort auf ein Melanom in Mäusen beschreibt, die mit anti-CD40 oder einer Isotypkon-
trolle behandelt wurden. Dabei wird das Modell durch die Daten aus zwei Mausmodell-
Experimenten motiviert, welche von unseren Kooperationspartnern durchgeführt wur-
den. Die Messungen werden zu verschiedenen Zeitpunkten nach dem Transfer naiver T-
Zellen durchgeführt und liefern absolute Zellzahlen sowie sich ergänzende Informationen
zur Zellproliferation, die durch die neu beschriebene Methode analysiert werden. An-
hand der Datensätze werden verschiedene plausible mathematische Modellalternativen
getestet und der wahrscheinlichste Mechanismus identifiziert. Unsere Untersuchungen
zeigen, dass sich die Proliferation der T-Zellen im Wächterlymphknoten im Laufe der
Zeit abschwächt und weisen auf einen Teilungsstopp nach vier bis sechs Generationen
hin. Im Tumor ist ein Stopp nach einigen Teilungen ebenfalls wahrscheinlich, aber er
variiert stärker zwischen den Experimenten: In einem Fall teilen sie sich insgesamt sechs
Mal und im anderen Fall teilen sich die Zellen zweimal nach Eintritt in den Tumor. Die
Proliferation im Tumor ist schneller als im Lymphknoten und stellt somit einen Kontrast
zum abrupten Teilungsstopp dar. In einem nächsten Schritt bestimmen wir Mechanis-
men, die durch die anti-CD40 Behandlung verändert werden. Dabei finden wir eine
verstärkte Aktivierung naiver T-Zellen – ein Effekt, der im Einklang mit der Literatur
steht – und zusätzlich eine verzögerte Auswanderung aus dem Wächterlymphknoten.
Schließlich untersuchen wir die gemessene T-Zell-Dynamik in einem Mausmodell
für Pankreaskarzinom und zeigen, das sie durch ein ähnliches mathematisches Modell
beschrieben werden kann. Dieses Modell bestätigt einen Teilungsstopp der T-Zellen im
Tumor und in den Wächterlymphknoten. Aber bis zu diesem Stopp, der nach insgesamt
sechs Teilungen einsetzt, ist die Proliferation schneller als im Melanommodell. Das ist
besonders im Wächterlymphknoten ausgeprägt, da sich die Teilungsaktivität im Laufe
der Zeit nicht abschwächt. Dem gegenüber steht die Tatsache, dass sowohl das Modell als
auch die Daten auf ein allgemein erhöhtes Sterben der T-Zellen im Pankreaskarzinom-
Mausmodell hindeuten – ein Phänomen, das in unseren Untersuchungen zum Melanom-
modell auf den Tumor beschränkt zu sein scheint. Außerdem stellen wir fest, dass die
Teilungsrate durch die anti-CD40 Behandlung erhöht wird und finden zusätzlich Hin-
weise auf eine verstärkte Aktivierungsrate. Dies wirft die Frage auf, ob anti-CD40 auch
die Proliferation bereits aktivierter T-Zellen beeinflusst. Da die Migrationsrate durch
die Daten nicht gut bestimmbar ist, können wir keine Aussage daüber treffen, ob die
Behandlung die Auswanderung der Zellen aus dem Lymphknoten verzögert.
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Insgesamt stellen wir in dieser Arbeit eine Möglichkeit vor, in vivo Fluoreszenzmessun-
gen sich teilender Zellen zu analysieren. Darüber hinaus bestimmen wir Eigenschaften
der naiven T-Zell-Antwort auf zwei unterschiedliche Tumortypen und untersuchen die
Auswirkungen einer anti-CD40 Behandlung auf diese Dynamik. Diese mechanistischen
Erkenntnisse können dazu beitragen, die Art und Weise zu verbessern, in der anti-CD40
bei der Behandlung von Krebs eingesetzt wird.
VII

Summary
Immunomodulatory approaches harnessing the patient’s T cell response against cancer
have established themselves as a promising treatment option. Nevertheless, the poor
predictability of a patient’s response shows our limited understanding of the factors that
determine whether immunotherapy works. To gain an insight into the underlying mech-
anisms we develop a data-driven mathematical model of T cells responding to tumors
under an immunotherapeutic intervention. To this end, we analyze data obtained from a
murine model for melanoma, which is a responsive tumor with respect to immunotherapy
and thus, a suitable testbed for new treatment options. In addition, we study the T cell
response in a murine model of pancreatic ductal adenocarcinoma—in the clinical setting
a tumor for which new therapeutic approaches are urgently needed. The treatment with
an agonistic antibody against CD40, which is investigated in this thesis, shows promis-
ing results in preclinical studies with pancreatic cancer and is applied in clinical phase I
studies for several tumor indications. Still, it is not well understood how this intervention
shapes the T cell response and a data-driven modeling approach has not been attempted
yet.
First, we develop a method for the accurate analysis of dye dilution measurements of
dividing cells in vivo, since our modeling approach strongly relies on proliferation data.
For these measurements cells are initially stained with a fluorescent dye, such as CFSE,
and their proliferative activity can be traced due to a halving of the dye intensity with
every division. The resulting dye intensity peaks are usually clearly separated if the data
are obtained from in vitro measurements and most analyzing approaches have been opti-
mized for this case. In these methods it often suffices to use parametric distributions to
describe the data. However, our data stems from in vivo experiments and has strongly
overlapping peaks, such that its analysis is difficult with these approaches. For this rea-
son, we develop a method where data-inherent information like the background intensity
and the distribution of the dye intensities of undivided cells is used to account for the
data specific shape of the peaks. It furthermore allows for the flexible combination of
samples to obtain robust optimization results and is successfully tested with six data
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sets provided by collaboration partners. In this way, we can reliably discern the relative
fractions of cells in different generations, even if the peaks are strongly overlapping.
Secondly, we introduce and validate a data-driven mathematical model describing the
anti-tumor T cell response. The model is devised with data obtained from two murine
melanoma experiments performed by our collaboration partners, in which also the effect
of anti-CD40 has been investigated. The measurements are conducted at various time
points post naive T cell transfer and provide absolute cell counts, as well as comple-
mentary information on cell proliferation, which we analyze with our newly described
method. Overall, these two data sets enable us to test various plausible mathematical
model alternatives and to identify the most likely mechanism. In the draining lymph
node our investigation reveals that the proliferation of T cells is attenuated over time
and provides evidence of a division stop after four to six generations. In the tumor a
cessation of proliferation is likely, but varies more between the experiments: We find a
total of six or more divisions in one case and in the other case two further divisions after
the cells enter the tumor. The proliferation in the tumor is faster than in the draining
lymph node and stands in contrast to this abrupt division stop. Subsequently, we deter-
mine mechanisms which are changed by the treatment with anti-CD40. We find evidence
for an enhanced activation of the naive T cells, which has been suggested previously. In
addition, we identify a delayed egress from the draining lymph node due to the treatment.
Thirdly, a similar mathematical model can explain the measured T cell dynamic in a
murine pancreatic cancer model. In this model, we also confirm a division stop, both in
the tumor and the draining lymph node. However, in contrast to the melanoma setting
we find a faster proliferation before it ceases after six divisions. The difference of the
proliferative activity is particularly pronounced in the draining lymph node, where it is
not attenuated over time. Interestingly, for the pancreatic tumor both the model and the
data point to an increased overall death of T cells, which in the melanoma setting was
mainly confined to the tumor. Furthermore, we determine that the anti-CD40 treatment
increases the proliferation rate and also find evidence for an enhanced activation. This
raises the question whether the treatment is affecting the proliferation of already activated
T cells, too. As the egress rate is not well constrained by the data, we cannot determine
whether the drug slows egress also in this tumor model.
Overall, in this work we introduce a method to analyze in vivo cell proliferation dye
measurements. We also reveal properties of the naive T cell response to two different
tumor types and the effects of anti-CD40 treatment on these dynamics. These mecha-
nistic insights may help improve the way in which anti-CD40 is applied in the treatment
of cancer.
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CHAPTER 1
Introduction
Until quite recently cancer therapy held very few options: either surgery, radiotherapy or
chemotherapy and in most cases a combination of these. While this is still true for many
cancers, over the last three decades a promising approach harnessing the body’s own
immune system to combat malignancies has established itself as a further and promising
treatment option. Still, both the scope and the mode of action are not well understood,
which is reflected in the unpredictability of the patient’s response to the treatment. Yet,
with the intensive research conducted in the field, it doesn’t seem overly optimistic to
expect substantial progress in the near future.
First therapeutic approaches along these lines were conducted in the late 1980ies by
treating metastatic melanoma with the patient’s own immune cells [1]. In the early 90ies
Honjo and Allison recognized the potential of immunomodulating biomolecules as a ther-
apeutic option against cancer. The latter two were awarded with the nobel prize in 2018,
creating widespread attention to cancer immunotherapy. Nowadays there is a multitude
of immune-therapeutic options, which can be categorized as: 1) cell based therapies,
where selected immune cells are infused into the patient; 2) monoclonal antibody based
therapies; 3) vaccination approaches; 4) modulation of the immunosuppressive tumor
metabolism and environment; 5) immunostimulatory cytokines [2]. In this thesis we
focus on a member of the group of monoclonal antibody based therapies, which offer
a plethora of different options for modulating the response of immune cells and most
prominently of T cells.
Monoclonal antibodies can be divided into two groups: antibodies specifically targeting
the tumor and antibodies which directly interact with immune cell receptors. The latter
can again be subdivided into agonistic antibodies, which stimulate the immune response,
and antagonistic antibodies, which inhibit the downregulation of immune cell activity.
The last subgroup comprises the immune checkpoint blockades targeting CTLA-4 and
PD-1, which were FDA approved in 2011 and 2014 for melanoma and subsequently for
1
Chapter 1. Introduction
a range of different tumors and have brought substantial progress in cancer therapy.
In contrast, agonistic antibodies frequently target members of the tumor necrosis
factor-receptor (TNFR) family, where one of the best studied receptors is CD40. This
receptor has been known for some time as a potential treatment option and is expected to
be a good augmentation to other cancer therapeutic approaches [3], like the established
immune checkpoint blockades [4].
The role of CD8+ T cells Many immunotherapeutic agents, like CD40 and the check-
point blockades, are investigated with respect to their effect on the T cell compartment
[5, 6, 7].
T cells are an integral part of the adaptive immune response, which has the ability
to specifically recognize and remember antigens and combat the associated pathogens.
To this end, each T cell expresses many copies of the same T cell receptor on their cell
surface, which recognizes a certain antigen with a high specificity. There are only a few
T cell clones with the same receptor [8], equipping the human organism with a repertoire
of more than 107 different T cell receptors at any given time.
T cells, which have not encountered their antigen yet (so-called naive T cells) circulate
through the body via the blood and lymphatic system. They sample antigen presenting
cells (APCs), most prominently dendritic cells, in the quest of the antigen which is
recognized by their T cell receptor. In the course of an adaptive immune response, antigen
presenting cells are activated at the site of inflammation, where they also ingest antigens,
and subsequently migrate to a local lymphoid tissue—in most cases the draining lymph
node. There they present the antigen and activate naive T cells with the corresponding T
cell receptor. The activation, the subsequent differentiation and proliferation of a naive
T cell after its initial antigen encounter is often referred to as priming. There are two
important functional subclasses of T cells: CD4+ and CD8+ T cells. Upon activation
CD4+ T cells orchestrate the immune response by interacting with different immune
cells, mostly with those of the myelomonocytic lineage. In contrast, primed CD8+ T
cells directly kill infected cells presenting the specific antigen—and with this also tumor
cells, if the antigen is specific to these. Antigens, which are unique to the tumor, are
called tumor specific antigens or neoantigens and if they are relatively restricted to the
tumor, they are referred to as tumor associated antigens.
Hence, the focus on CD8+ T cells in immunotherapy can be explained by the fact that
these cells are known to be direct mediators of antitumor activity due to their ability
to kill targeted tumor cells [9]. In addition, the fact that properties of the CD8+ T cell
response are related to prognostic markers in the immune therapy of cancer, like the
composition of CD8+ T cell subsets [10, 7], their infiltration of the tumor [11, 12] and
the distribution of their clone sizes [13], underlines their importance for the success of
the therapy. Furthermore, the success of the checkpoint blockades, which are reported
to enhance CD8+ T cell immunity, contributed to the interest and continued research
on the role of CD8+ T cells in the tumor context [7, 6].
2
Treatment of tumor with anti-CD40 monoclonal antibodies and checkpoint
blockades
The importance of the constant region of monoclonal antibodies In immunotherapy
monoclonal (and therefore identical) therapeutic antibodies with a certain specifity are
widely used and can be produced in large quantities. They consist of a target antigen-
specific variable domain and a constant region with varying IgG isotypes. Depending
on the type of Fcγ receptors on the recipient’s immune cells with which the IgG isotype
interacts, the triggered immune response can be the opposite [14, 15]. If it interacts
with activatory Fcγ receptors, the cross-linking can induce antibody dependent-cellular
cytotoxicity (ADCC) and the targeted cells are killed subsequently. This effect is needed
if the antibody is targeting tumor associated antigens like CD20 (rituximab) and HER2
(trastuzumab). If, on the other hand, an immunostimulatory pathway should be targeted,
it is reported to be benefitial, if the constant region binds to an inhibitory Fcγ receptor
[16, 17]. Since this interaction does not require intracellular signaling, it is assumed that
the agonistic effect is mediated via cross-linking of immune cells [18]. Apparently there
are also various monoclonal antibodies, which do not require any interaction with Fcγ
receptors. These are thought to either “only” block immune checkpoints or assemble the
targeted immunestimulatory receptors on the cell surface by a specific configuration of
their hinge region [19, 15].
In our mouse model experiment, which is presented in chapter 3 & 4, we use two agonis-
tic anti-CD40 antibodies called clone 3/23 mIgG1 (mouse IGg1) and the commercially
available FGK45. Both depend on cross-linking via inhibitory Fcγ receptors [20, 18].
3/23 mIgG1 is a chimeric version of the commercially available clone 3/23 developed in
the group of Prof. Glennie (University of Southhampton), where the rat IgG part has
been changed to a mouse IgG, making it more potent with respect to the T cell response
[18]. Unfortunately, a direct comparison to FGK45 is not available, but personal commu-
nication suggests that the agonistic effect is similar. It is still important to keep in mind
that although both antobodies apparently interact with the same Fcγ receptor [18, 21],
the difference in the IgG of FGK45 with a rat IgG2a and clone 3/23 with a mouse IgG1
can lead to a difference in the cross-linking behaviour, which in turn can modulate the
immune response differently.
Immune checkpoint blockades A multitude of receptors tightly regulate the activation
of the immune system via “checkpoint” receptors. These are usually found on activated T
cells and are thought to be a control against an excessive immune response and essential
for maintaining central and peripheral tolerance to avoid autoimmune responses [22, 23].
But through the continued exposure to antigen in a tumor environment and by cancer
cells utilizing this immune suppressive mechanism [24, 25] T cells are brought into an
exhausted state. This state is marked by the dysfunction of T cells, which in the best
case can be reversed by the inhibition of these immune checkpoints and leads to tumor
rejection: Most prominently this has been shown with blockades of the surface proteins
“cytotoxic T-lymphocyte-associated protein 4” (CTLA-4) and “programmed cell death
protein 1” (PD-1) [23, 10, 7]. Anti-CTLA-4 was the first checkpoint inhibitor to be
3
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approved by the FDA in 2011 and improved the long-term survival rates of unresectable
metastatic melanoma from 10% to 20 − 30% [26, 27, 28]. Shortly after, in 2014, the
first anti-PD-1 was approved for various solid tumors and Hodgkin’s lymphoma. The
treatment via PD-1 blockade has good clinical responses with a 5-year survival rate in
melanoma of 34− 41% [29], and less severe adverse events compared to an anti-CTLA-4
treatment [30]. A combination of both therapies is reported to have an increased overall
survival rate over each monotherapy [31].
Still, the responses between different tumor types, as well as the individual responses of
patients with the same tumor are varying strongly, such that there is an ongoing debate
about predictive markers for treatment success with immune checkpoint blockades. In
the recent years a variety of factors contributing to a successful treatment have been
discussed. On the one hand the (induced) immunogenicity of the tumor is thought to
be important [32, 33], as well as mutations which make the tumor cells resistant to the
attacks from immune cells [34]. On the other hand various characteristics of the immune
and especially T cell repertoire responding to the tumor are reported to be predictive,
as has been discussed above.
Many predictive features, like the infiltration of the tumor by a responding immune
cell repertoire, are closely linked to the tumor microenvironment. If it is packed with
immunosuppressive cells and has a dense extra cellular matrix, neither immune cells nor
drugs can infiltrate or access the tumor cells [35]. These tumors were defined to be
immunologically cold by Sharma and Allison [36] as opposed to T cell infiltrated tumors,
which are referred to as hot tumors.
These findings in turn raise the question how immunotherapeutic strategies should be
adapted for tumors, which do not respond to immune checkpoint blockades. One of the
considered additional treatment options is to target CD40 [4].
The effect of CD40 on CD8+ T cells CD40 is expressed most prominently on antigen
presenting cells, like B cells and dendrictic cells, but also on myeloid cells and non-immune
cells including fibrolasts and endothelial cells. The activation of CD40 by its ligand
CD40L, which is expressed mainly on CD4+ T cells, is generally associated with enhanced
cell survival, inflammatory responses and cytokine production [37]. The widespread
expression of CD40 on different immune cells suggests that it has a broad role in the
immune system [5].
The CD40/CD40L axis is in particular important during the initiation of an adaptive
immune response (Fig. 1.2 station 2)). Although dendritic cells can activate CD8+ T
cells in some infections without any further help, in most cases they need the support
from CD4+ T cells [38]. This requires an interaction between dendritic cells, CD4+
and CD8+ T cells. CD4+ T cells express CD40L upon recognizing the antigen-MHC II
complex and costimulatory ligands (B7) on dendritic cells, see Fig. 1.1a. In consequence,
CD40L binds to CD40 on the dendritic cells and the latter are subsequently stimulated
to express further stimulatory receptors (4-1BB ligand and B7). These in turn bind to
receptors on CD8+ T cells (4-1BB and CD28) and enhance their activation, see Fig. 1.1b
and ref. [39].
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Figure 1.1.: CD40 dependent CD8 T cell stimulation mediated by dendritic cells. a) CD4 T
cell is activated by a dendritic cell presenting an antigen-MHCII complex and an costimulatory
ligand. It upregulates CD40L. b) CD40 binding to CD40L increases the expression of B7 and
4-1BB-L on dendritic cells. This binds to CD28 and 4-1BB on CD8 T cells providing additional
stimulation. (adpated from ref. [38])
Indeed, many studies have shown that CD40 plays a major role for CD8 T cells,
especially through this interaction, in the course of which APCs are licensed [40, 41, 42,
43] and can thus support the priming of CD8+ T cells [44, 45, 46, 47]. It also has been
shown that CD40 activation can substitute CD4+ T cells in the activation of a CD8+
T cell mediated immune response [44]. Other studies report a crucial role of CD40 in
CD8+ T cell memory formation [48, 49, 50].
CD40 therapy in the clinical setting The immunomodulatory ability of CD40 is em-
ployed in the treatment of autoimmune diseases [37] as well as cancer. The latter com-
prises two rationales [51]: On the one hand, CD40 is targeted on CD40 expressing tumors
triggering cell mediated killing or transducing a pro apoptotic signal to induce their death.
On the other hand agonistic anti-CD40 antibodies are applied to stimulate the immune
cells. In this thesis we will focus on the latter mechanism in the CD8+ T cell context.
As early as 2007 first clinical trials with an agonistic anti-CD40 antibody (CP-870,893)
showed objective partial response rates of 27% in melanoma patients [52]. CP-870,893
activates without depending on cross-linking with Fcγ receptors, which is the likely rea-
son for its potency [19], but can cause severe adverse events. In the following, a sec-
ond generation of anti-CD40 antbodies with a constant domain binding to inhibitory
Fcγ receptors were introduced (Chi Lob 7/4, ABBV-428, APX005M, SEA-CD40) in
the hope of lessening side effects, while increasing the therapeutic potency [53]. Many of
these antibodies (APX005M, SEA-CD40, but also CP-870,893) are in ongoing or recently
completed phase I clinical trials for various solid tumors, amongst them melanoma and
pancreatic ductal adenocarinoma. They are mostly combined with other cancer ther-
apeutic agents (checkpoint blockades and vaccination strategies), but are also used as
monotherapies, see clinicaltrials.gov:#NCT02482168, #NCT03123783, #NCT02376699,
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Figure 1.2.: T cell response to tumor. The role of the CD40-CD40L axis in station 2) and 3) is
well established, see Fig. 1.1. There are multiple ways in which anti-CD40 treatment is thought
to directly or indirectly affect the T cell response (blue boxes).
#NCT01103635 and #NCT03597282 and refs. [54, 55] .
In the light of the many attempts to apply anti-CD40 in a clinical setting for a variety
of tumors with different co-therapeutic agents, it is pressing to better understand the
effects of an anti-CD40 treatment. For this reason the effect of anti-CD40 has been
investigated in various mouse models highlighting different mechanisms of action.
CD40 treatments effects on CD8+ T cells in murine tumor models Many murine
tumor model studies agree that agonistic CD40 therapy generates protective tumor im-
munity. While some studies claim that anti-CD40 mainly acts on myeloid cells and
macrophages [56, 57], others confirm the beneficial effect of anti-CD40 treatment on
CD8+ T cells [47, 58, 59]—by enhancing activation and avoiding peripheral tolerance of T
cells [60, 61, 62] and by inducing proliferation and the infiltration of tumors [63, 64]. How-
ever, most studies agree that the general effect of a anti-CD40 monotherapy on the tumor
is subtle and that full potential can only be achieved if it is combined with other therapies,
like immune checkpoint blockades, radiotherapy or chemotherapy [57, 63, 60, 64, 65]. For
example, Byrne and Vonderheide suggest in ref. [63], that the chemotherapy releases the
necessary antigens to support the CD40-mediated priming and activation of T cells, that
this combination also has a positive effect on the macrophage, myeloid and dendritic cell
compartment and that it supports the recruitment and expansion of T cells, the conse-
quences of which can be observed in the tumor environment. Indeed, the many ways
in which anti-CD40 is thought to act (see Fig. 1.2) raises the hope that an anti-CD40
treatment can turn an immunologically cold tumor into a hot one by acting on various
immune cells and modifying the tumor microenvironment [4, 63].
Obviously, although anti-CD40 treatment has been investigated in many studies, the
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exact effect on CD8+ T cells in a tumor context remains unclear (e.g. priming new T
cells VS only boosting preexisting responses) [4]. Indeed, a mechanistic and time resolved
understanding of the effects on naive T cells has not been the focus in the field, perhaps
also because the effects of a monotherapy are subtle. With quantitative methods like
mathematical modeling on the other hand, it is possible to highlight small changes of
the measured and fitted T cell dynamics, which is done in this thesis. A more thorough
understanding of the individual treatment effect can contribute to develop well-founded
therapeutic strategies including an anti-CD40 therapy in a meaningful way.
Treatment success in different cancer types: The special role of melanoma
Melanoma as a model for immune responses to cancer Melanoma was a rare skin
cancer in the 50ies, but incidences have risen annually by 4 - 6% among the fair-skinned
populations [66], an increase higher than for almost any other tumor [67]. Although
treatable when in early stages, the median survival for metastized tumors is low. Even
after the introduction of immunotherapy, especially the immune checkpoint blockades,
around 50% of the patients do not respond to a treatment [68, 69].
And yet melanoma is in principle a “hot” tumor and relatively responsive to im-
munotherapy. This is probably due to 1) the high immune cell infiltrate, especially
with CD8 T cells, which are thought to mediate the immune response to tumor to a
large degree [70] 2) the high immunogenicity/ mutational load [71, 72] and 3) the rel-
atively small stromal tumor microenvironment [73]. As a consequence, a large part of
the advances and understanding gained in the field of tumor immunotherapy are first
described in the context of malignant melanoma [74].
But even in a well studied tumor like melanoma the conditions for a successful im-
munotherapy and optimal support of the immune response are still unpredictable [72]
and thus, better therapeutic approaches are needed. These do not necessary need to be
new targets, but already an informed combination and timing strategy could change the
efficacy substantially [75]. If these are once established in melanoma, it can be expected
that lessons learned in this tumor model can be transferred to other tumor types as well.
To this end, in this thesis we employ the frequently used syngeneic B16 melanoma cell
line in C57/BL6 mice and study its treatment with anti-CD40. It is well established in
preclinical studies and used as a subcutaneous melanoma model to investigate the treat-
ment of human melanoma [76] due to its highly invasive nature and its characterization
to be “difficult to treat” [77, 78]. In order to study the T cell response to this tumor a
B16 cell line expressing ovalbumin, B16/OVA, is applied together with so-called OT-I
CD8+ T cells recognizing an ovalbumin derived antigen.
The need for new therapies for pancreatic ductal adenocarcinoma Pancreatic ductal
adenocarcinoma (PDAC) stands in stark contrast to melanoma, being a tumor with low
T cell infiltration and a dense extracellular matrix including various immunosuppressive
cells [73]. In consequence, it is a cancer with an exceptionally poor prognosis having a 5
year survival rate of only 7-9% [79, 80]. Further reasons for the dismal prognosis are a late
diagnosis and spread of metastasis at early stages leading to 80% of the patients having
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already acquired unresectable tumors at the time of presentation. Most therapeutic
options show little to no effect, including immune checkpoint blockades [81, 82, 83]. To
reverse this phenotypically cold tumor into a tumor with a high T cell infiltrate and a
less hostile and more permeable tumor microenvironment is a main goal for the research
on combinatoric therapies with anti-CD40 [4]. Indeed, there is reason to believe that
PDAC is a case for immune therapy, as it has an intermediate mutational load [71] and
as it has been shown that PDAC are not void of infiltrating T cells, which furthermore
respond to their autologous tumor [84].
In this thesis, to mimic the characteristics of the PDAC and to study the effect of an
anti-CD40 treatment in a mouse model, our collaboration partners developed a murine
PDAC cell line which has a similar histopathology to the human PDAC. Similarly to the
melanoma cell line, it expresses a tumor specific antigen (ovalbumin), which was achieved
by retroviral transfer.
Mathematical modeling in immuno-oncology
Mathematical modeling in support of preclinical and clinical studies in oncology has
co-evolved with the advances in this field and aims at resolving various research ques-
tions. Initial efforts often focused on describing tumor growth. The generalization of
Gompertzian tumor growth [85] predicting the growth pattern from early tumor size
measurments, was a first remarkable milestone. With the wake of immunotherapy in
oncology in the 90ies many efforts focused on describing the interaction between tumor
and immune cells in order to provide an insight into possible mechanisms governing the
dynamics of the different players. It started with two to three component predator-prey
like models, where the immune cells (very often T cells) are the predator and the tumor is
the prey [86, 87, 88, 89]. Depending on the correctness of the assumptions, these models
can explain the influences of the players on the observed phenomena in a general way, but
may not be very useful for research relevant questions due to strong simplifications. The
complexity of most mechanistic modeling approaches grew rapidly with the discovery of
more cells and cytokines contributing to the immune surveillance and editing of the tu-
mor. But in this case, most mechanistic modeling attempts suffer from the lack of data to
inform these complex models. Hence, parameters are estimated from published data and
assumptions with respect to the interactions are taken from the literature [89, 90, 91, 92]
and many studies focus on investigating the emergent theoretical properties of the model,
by conducting sensitivity and stability analysis [93, 94, 95, 96]. But the validity of the
predictions and analysis in all these models depend strongly on the model assumptions
and the chosen parameters from publications, as only little data is used to calibrate the
model. Thus, the choice of the involved cell types can often be challenged by new findings
and furthermore, in these models it is difficult to account for the fact that parameters
from different publications are depending on their experimental setups and might not
be compatible. Still, these models reveal interesting emergent properties of the observed
system, which can give valuable hints about the underlying mechanism of an observed
phenomenon.
On the other hand, there are classical “fit for purpose” [97] modeling approaches in
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immuno-oncology like pharmacokinetic/pharmacodynamic (PK/PD) models, which are
concerned with optimal dosing schedules by predicting the distribution, uptake and degra-
dation of a medication [98]. These can partially replace dose selection trials [99], as has
been done in the case of pembrolizumab [100, 101], a PD-1 checkpoint inhibitor. All in
all, these are pragmatic and very helpful approaches, which provide informative predic-
tions, but rely strongly on prior knowledge about the system and provide a limited new
insight into the mechanisms of action of the investigated treatment.
A third option are data driven models, which aim at describing small and measurable
aspects of an interaction mechanistically. This requires a cooperation in close coordina-
tion between experimentators and modelers, since the data that can be provided and the
required information in order to calibrate the model must be well matched. Especially
in the field of quantitative immunology, there are many data driven models studying
the T cell division kinetics in acute infection settings [102, 103, 104], the T cell dif-
ferentiation [105] and T cell responses to vaccines [106]. Importantly the mechanisms
regulating T cell death, quiescence and proliferation has been successfully described with
cellular machines (cyton model) and the concept of a so-called division destiny, which
is the predestined number of divisions an activated lymphocyte does post activation
[107, 108, 109, 110]. Many studies succeeded in assessing the T cell proliferation dynam-
ics by analyzing cell proliferation dye measurements [111, 112]—often with a mixture
model approach [113, 114]. Furthermore, stochastic dynamic models have been success-
fully applied to understand the underlying mechanisms producing robust T cell responses
on a population level in acute infection settings [115] and the composition of the T cell
ages has been investigated thoroughly by combing T cell fate mapping and mathematical
modeling [116]. In addition, T cell activation and interaction with tumor cells at the level
of molecular pathways is also studied with mathematical models, such that the emerging
behavior can be explained [117, 118].
Thus, by focusing on the studied system and uniting or, if possible, ignoring negligible
other influences, one can obtain mechanistic insights into the dynamics in question. These
detailed studies can then eventually inform more complex models. To our knowledge the
naive T cell response under an anti-CD40 treatment in a tumor context has not been
studied so far, but would provide a valuable contribution to inform combination strategies
with immune checkpoint blockades. Since we focus on the CD8+ T cell response, we
confine ourselves to investigate the effects of anti-CD40 on the stations 3) - 6) in Fig. 1.2.
Aims of this thesis
In this thesis we strive to understand the effect of the immunomodulatory antibody anti-
CD40 on the early T cell response to melanoma and pancreatic ductal adenocarcinoma.
Importantly, since the success and informative value of a model depends crucially on
the type of data, the experiments were planned in close collaboration with Lena Kranz
and Mustafa Diken at TRON (Translational Oncology at the University Medical Center
of the Johannes Gutenberg University) in Mainz, Germany and Isabel Poschke at the
dkfz (German Cancer Research Center) in Heidelberg, Germany, who also conducted the
experiments.
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The ability to distinguish different model mechanisms and parameters, furthermore,
critically depends on the preprocessing of the data. Hence, the first chapter is dedicated to
the introduction of a mixture model using data inherent information, which we developed
for analyzing noisy in vivo measurements of cell proliferation dyes. This is applied to
the T cell measurements in murine melanoma and pancreatic ductal adenocarcinoma
experiments such that we obtain data which can be used in the second and third chapter.
In the second chapter we establish a data driven model with the results of the melanoma
experiment, which reveals dynamical properties of the T cell response to tumor, while
ruling out other model options. In addition, a model selection successfully points out anti-
CD40 treatment effects in this model framework. The same model successfully describes
results of the pancreatic ductal adenocarcinoma experiment, where comparable findings
with respect to the dynamics and anti-CD40 treatment effect could be identified.
With this mechanistic data driven modeling approach, we not only provide insights
into the early T cell response in a tumor setting and the subtle effects of an anti-CD40
treatment on this dynamics, but can also point at the underlying differences between the
two tumor models.
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Analysis of proliferating cells and modeling techniques
This chapter mainly discusses methods which have been employed in this PhD project to
deduce the number of cell divisions from dye intensity measurements and to subsequently
obtain the proliferation dynamics via modeling.
In the first part a mixture model is developed for the analysis of the cell dye mea-
surements, such that the proportion of cells, which have undergone different numbers of
divisions, i.e. are in different generations, can be distinguished. The second and third
part are focusing on the modeling of cell proliferation and the fit of these models to the
frequencies of cells in each generation, which are obtained from the first part.
2.1. Analyzing dye dilution measurements
2.1.1. Introduction
If the proliferative process of cells cannot be observed directly, proliferation monitoring
and analysis is usually conducted with either the help of molecules which are taken up
during DNA synthesis by proliferating cells (e.g. Bromodeoxyuridine, in short BrdU) or
with cell dyes, which are diluted with each cell division [111]. For the latter approach
cells are dyed at the beginning of the experiment and the dye intensity halves with
every division, such that the number of divisions after the dye has been applied can
be deduced. Frequently used fluorescent dyes are carboxyfluorescein succinimidyl ester
(CFSE), CellTraceTM Violet (CTV) and Cell Proliferation Dye eFluorTM 450 (CPD).
The fluorescent intensity of the cells is measured with flow cytometry. In the following
we will only speak of CFSE, which has been applied in all experiments discussed in this
thesis, but the analysis works analogously for all dyes. As the dye intensity is halved
with each division, the distribution of the CFSE intensities of cells (CFSE profile) under
optimal conditions consists of equidistant proliferation peaks on a log scale, which can
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Figure 2.1.: Two exemplary CFSE profiles in vivo with mixture models fitted to the data
with the program FlowJoTM (v10) a) Distinct proliferation peaks are fitted well. b) Without a
clear undivided peak the fit needs time intensive manual adjustments of the model parameters to
achieve a mediocre fit, even if the shape of the peak is informed from other well distinguishable
CFSE profiles. Experimental data: Lena Kranz and Mustafa Diken.
be clearly distinguished from each other (Fig.2.1a).
These CFSE profiles are usually analyzed by separating the individual peaks with
vertical lines (gating) or by fitting a mixture model to this profile.
However, when analyzing the CFSE profiles two limitations have to be taken into con-
sideration. First, the applicable dye concentration is limited due to cytotoxicity. Thus,
the number of distinguishable generations is limited, because the peaks overlap increas-
ingly as their CFSE intensity decreases, due to the contribution of the autofluorescence of
cells. Secondly, the peaks often overlap already in early generations due to the variability
in the brightness of the initially dyed undivided cells. This becomes more pronounced
in in vivo experiments (Fig. 2.1b). Thus, methods, that have been optimized for the
analysis of in vitro data cannot be used for the data obtained and analyzed in this thesis.
For instance, the widely used software FlowJoTM, which assists the evaluation of flow
cytometry measurements, contains a module for fitting and analyzing CFSE profiles
with a mixture model consisting of lognormal distributions [119]. A strong overlap of the
CFSE profile peaks, the approximation of single cell peaks with a parametric distribution
and/or not accounting for the autofluorescence, made it difficult to obtain a reasonable
fit to the data. Adjustments of the mixture model parameters by hand were needed
and resulted in a fit, which nevertheless does not describe the data correctly (Fig. 2.1b),
although the program performs well when peaks are clearly distinguishable (Fig. 2.1a).
Indeed, in other approaches using mixture models to fit in vitro CFSE profiles, we
can see that it is sufficient to approximate the autofluorescence and the undivided cell
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intensity distribution with lognormal distributions [113] or leave out the contribution of
the autofluorescence [114], to obtain reasonable fits to the data.
Additionally, in these studies the CFSE profile fitting procedures are integrated into
label-structured cell proliferation models. In this way, CFSE profiles are directly used
as observables at successive time points to inform the models. This modeling approach
also exploits the fact that time resolved measurements are easily available for in vitro
experiments, such that the dynamics of the label loss and the proliferation dynamics can
be better substantiated with data. For our model, however, which describes the dynam-
ics of cell proliferation and absolute cell numbers in different organs simultaneously, it
is useful to separate the CFSE profile fitting and obtain the proliferative information
independently.
In the following, we will present a method that exploits data-inherent information for
the analysis of CFSE profiles and for obtaining the frequencies of cells in each genera-
tion. To this end, it uses information on the undivided cell intensity and auto-fluorescent
intensity distributions without having to assume a parametrized distribution. It, fur-
thermore, flexibly accounts for the variability of the CFSE intensities in different groups
of samples.
2.1.2. A mixture model for the analysis of cell proliferation measurements
A mixture model consisting of proliferation peaks and a fitting procedure are developed,
with which overlapping peaks in the CFSE profile can be distinguished. Thus, the infor-
mation on the number of cells in each generation can be obtained. This was written and
implemented with the programming language R [120].
Section A provides an overview of the algorithm applied to single samples and sub-
stantiates the fitting procedure. A more detailed step-wise explanation of the algorithm
is given in the section B. Section C explains how the results from B are brought together
to finalize the optimization.
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Figure 2.2.: Workflow to fit CFSE data a) An undivided cell peak (red) and a peak of unstained
cells (blue), which are both obtained from the data, are used to inform our algorithm. b) The
undivided cell peak is used as a model peak for undivided cells. Its fluorescence intensities are
divided by factors of two—to mimic the intensity which is halved in every division—in order to
obtain model peaks of higher generations. c) By sampling CFSE intensities from the unstained
cells (blue) and adding them to the intensities of the model peaks in b) we account for the
contribution of autofluorescence to the peaks. Dimmer peaks broaden. d) Binned model peaks
with equal weights (red points, connected by lines) and binned data (grey bars), to which the
model needs to be fitted. Green box: Fitted model after optimizing the weights of the peaks and
finding the correct position on the x-Axis, i.e. the correct CFSE brightness for the undivided
cells: e) Binned model peaks. f) Summed peaks from e). Experimental data: Lena Kranz and
Mustafa Diken.
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A: Algorithm overview for a single sample and rationale
Data preparation: The sample data are pre-processed by binning the CFSE inten-
sities and we obtain a histogram (Fig. 2.2d, grey bars).
Model creation: First, the CFSE intensities of an undivided cell peak in the data is
taken, which is used as an “undivided model peak”, i.e. a model peak for undivided cells.
We shift this peak to some position p on the CFSE intensity axis, which we assume to
be close to the undivided cell peak of the sample (Fig.2.2a, red). We will come back to
the details of shifting the peak when the optimization is discussed.
Second, the undivided model peak intensities are divided by 2n (n = 0, 1, 2, ...), such
that we obtain model peaks of the 0, 1, 2, ...th generation, which are equidistant on a log
scale (Fig. 2.2b, red and black).
Third, we add CFSE intensities sampled from an autofluorescence peak to each peak
in the data (Fig. 2.2a-c, blue), i.e. the two peaks are convoluted in a discrete manner. As
a result the peaks of higher generations of our mixture model are broadening (Fig. 2.2c,
broadening is more obvious with binned model peaks, see Fig. 2.4). The autofluorescence
peak is part of the mixture model as well (Fig. 2.2c, blue).
Finally, this multi-peak model (Fig. 2.2c, all peaks) is binned with the same boundaries
as the CFSE intensities of the sample (Fig. 2.2d, red points, connected by lines), such
that the difference between the model and the data can be calculated for each bin and
combined to obtain a chi-square statistic.
Optimization: Two types of variables of the mixture model need to be optimized to
obtain a good fit to the data (Fig. 2.2 e & f): First, the absolute CFSE intensity of the
model peaks, meaning the position p of the undivided model peak on the CFSE intensity
axis, and second, the relative weights of the peaks.
The optimal position of the undivided model peak is determined by a step-wise increase
of possible positions p. After setting a position the model is created as described above
and the weights of the model peaks are optimized using a general purpose optimizer
optim, [120]. Finally, the result for each position p (optimized weights for each peak and
corresponding minimized chi-square statistic) is saved for this sample.
Reason for separately optimizing the undivided model peak position in a discrete
manner It proofs to be expedient to separately optimize the mixture model for different
undivided model peak positions in appropriate intervals and choose the optimal position
in a second step. The range, in which undivided model peak positions are tested, can be
guessed by examining the profile to be fitted.
This procedure enables us to determine the optimal offset, i.e. undivided model peak
position, not only for each sample specifically, but flexibly for combinations of samples
by summing their chi-square statistic for each offset. Thus, depending on the sample
combination, we obtain different best offsets. In this way samples can be combined,
which are expected to have the same offset, e.g. samples measured on the same day and
from the same organ. In principle, these samples are best fitted simultaneously to obtain
a common best fit and corresponding offset. Unfortunately, this does not always work.
Samples, where we expect the offset to be the same, can sometimes still differ in their
15
Chapter 2. Analysis of proliferating cells and modeling techniques
0
200
400
600
800
2.5 3.0 3.5 4.0 2.5 3.0 3.5 4.0 2.5 3.0 3.5 4.0
0
500
1000
1500
2.5 3.0 3.5 4.0
0
500
1000
1500
2.5 3.0 3.5 4.0 2.5 3.0 3.5 4.02.5 3.0 3.5 4.0
0
200
400
600
800
2.5 3.0 3.5 4.0
Sa
m
e 
un
di
vi
de
d 
m
od
el
 p
ea
k 
po
si
tio
n 
fo
r b
ot
h 
sa
m
pl
es
In
de
pe
nd
en
t  
un
di
vi
de
d 
m
od
el
pe
ak
 p
os
is
tio
ns
Sample 1, draining lymph node, day4 Sample 2, draining lymph node, day4
log10 CFSE intensity
log10 CFSE intensity log10 CFSE intensity
log10 CFSE intensity
ce
ll 
co
un
t p
er
 b
in
ce
ll 
co
un
t p
er
 b
in
ce
ll 
co
un
t p
er
 b
in
ce
ll 
co
un
t p
er
 b
in
a) b)
c) d)
Figure 2.3.: Exemplary model fit (red dots with connecting line) to CFSE profiles from samples
(grey bars), which were treated in the same way experimentally, but where the same undivided
model peak position cannot be assumed: Both samples from two different mice are recovered
from the draining lymph node and analyzed 4 days post CFSE staining and transfer. a) & b)
The undivided model peak position resulting from a joint optimization of both samples is used
for the model fits. This position is determined by adding the chi-square statistic of both samples
for each undivided model peak position and taking the position which is minimizing this sum.
c) & d) The undivided model peak position which minimizes the chi-square statistic for each
sample individually is used for the model fits. We can see that in c) & d) the model fit looks
better, especially for Sample 1.
undivided cell peak position, such that different offsets need to be taken. We encounter
such a case in the third Melanoma experiment discussed in section 3.1. The OT-I T cell
samples of different mice, which were taken from the same organ and on the same day
post staining, need a different zero peak position. If the samples are fitted simultaneously,
the CFSE profile cannot be described correctly, see Fig. 2.3. In other cases a whole group,
where we expected the offset to be the same, has no clear undivided cell peak, such that
we need to combine it with another group of samples to find a common plausible offset.
B: Detailed description of the algorithm applied to each sample
Step 1: Pre-processing of the CFSE intensities of the sample The logarithm of the
CFSE intensities of each cell is taken and the cell intensities are binned, such that we
obtain a histogram. The number of bins ktot is determined by Doane’s formula [121]
ktot = 1 + log2(m) + log2(1 + |g1|/σ). (2.1)
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Here σ =
√
(6 ∗ (m− 2))/((m+ 1) ∗ (m+ 3)), m is the number of cells in the sample
and g1 is the skewness of the distribution. As this frequently proved to be too few
bins, especially for small m, we added the option to multiply this by a factor, which
was between one and two for the samples analyzed in this thesis. The bins with their
boundaries will be referred to as bk = (bk,lower, bk,upper), where k = 1, 2, ...ktot.
A maximum bin width max(bk,upper − bk,lower) ≤ 2/3 · log10(2) is set, which ensured
that the bin width is not larger then 2/3 of the distance between two peaks. The factor
of 2/3 can be changed easily in our algorithm, but for the samples used in this thesis, it
was a appropriate choice. The number of cells per bin bk will be denoted with ak.
Samples with m ≤ 15 are excluded from the analysis.
Step 2: Choice of the tested positions
• The CFSE intensities of an undivided sample in the data are taken and these are
introduced to the algorithm as a vector ~x0, which is now the undivided model
peak (Fig. 2.2a, red peak). If this cannot be obtained from the data, this peak
is sampled from a lognormal distribution, which has also been applied in similar
studies ([113, 119]).
• A plausible area for the position of the undivided model peak is determined by com-
paring its original position p and the assumed position of the undivided cells of the
sample psample. As we only need a rough estimation of both positions p and psample,
these can be guessed by examining the profiles. Then ∆p = log10(psample/p) is cal-
culated, which is the shift needed on a log10 scale to get from p to psample.
• For our data the appropriate distance between each tested offset, i.e. undivided
model peak position, turned out to be 0.015 on a log10 scale. This is a 1/20th
part of the distance between peaks and is sufficiently dense to find a good fit
to our samples. To this end we determine offset factors qj = 100.015j+∆p, with
j = −10,−9, ...9, 10. Multiplying qj with the CFSE intensities of the undivided
model peak will result in this peak’s position being shifted by incrememts of 0.015
for increasing js on a log10 scale around log10(psample).
The following steps 3 and 4 are performed for each j
Step 3: Creation of the model peaks and pre-processing
• The undivided model peak intensities, ~x0, are multiplied with qj .
• By dividing each entry of the vector ~x0 by 2n, one obtains multiple vectors
~xn representing the brightness of cells having divided n = (0, 1, 2...ntot) times
(Fig. 2.2b, black peaks). In our samples we mostly chose ntot = 10. Al-
though the model fit is relatively robust with respect to the choice of ntot,
in an extreme case, where the initial CFSE intensity was particularly bright,
increasing this number was necessary to fit the data. Each of these strings
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will be referred to as different model peaks and each entry corresponds to the
CFSE intensity of cells in different generations.
• To each entry of the model peaks ~x0...~xn,tot an autofluorescence (Fig. 2.2a-
c, blue peak) intensity is sampled and added (Fig. 2.2c, black peaks). The
autofluorescence peak is taken from undyed cells, which ideally are of the same
cell type as the dyed cells and taken from the same sample.
• The autofluorescence peak is included into the multi-peak model. We now
have model peaks ~xn with n = 0, ..., ntot + 1, i.e. ntot + 2 model peaks. For
convenience we will rename these to ~xl, with l = 1, ..., ltot, ltot = ntot + 2 and
l = n+ 1.
• The log of the intensities of all model peaks is taken.
• The kernel density estimate for each model peak is calculated and we obtain
a smooth function.
• The proportion of each model peak which falls into the bin boundaries of bk is
calculated by numerical integration. One obtains a matrix C ′ = (c′k,l), where
the columns represent different peaks and the rows contain the proportions
of cells in bin bk. Proportions of the model peak outside the binned area are
mapped into the first and last bin respectively. As the distribution of cells
for low CFSE intensities becomes sparse in the log10 space, the proportion of
cells falling into b1 are calculated without smoothing and integrating and are
entered directly into the first row of C ′, i.e. c′k=1,l .
• Finally each column, which represent a model peak, of C ′ is multiplied with
the total cell number found in the CFSE profile and we obtain C.
Step 4: Fitting of the peak weights We introduce the weights ~ϑ with entries
(ϑ1, ϑ2, ...ϑl,tot) for each model peak. The quantity of interest predicted by the
model is the number of cells per bin bk and will be referred to as dk. This will be
fitted to the binned CFSE intensities of the sample, namely ak. dk is calculated by
dk(~ϑ) =
∑
l
ck,lϑl, (2.2)
where the weighted sum of the peaks is taken for every bin.
• ~ϑ is optimzed by minimizing the chi-square statistic
arg min
~ϑ
χ2 = arg min
~ϑ
∑
k
(
ak − dk(~ϑ)
)2
dk(~ϑ)
= ϑˆ. (2.3)
Here it turns out to be quicker to first optimize all ~ϑ simultaneously, al-
though they are dependent as they should sum to one. In a second fit
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this dependency is accounted for by only optimizing (ϑ1, ϑ2, ...ϑn−1), such
that ~ϑ =
(
ϑ1, ϑ2, ..., ϑl−1, 1−
(∑l−1
i=1 ϑi
))
, which sometimes improved the fit
slightly.
• Thus, for each offset qj , we obtain the minimum chi-square estimate ϑˆj and a
corresponding minimized chi-square statistic χ2j .
Step 5: Save the result for this sample The set of optimized weights ϑˆj with corre-
sponding χ2j for each tested offset qj is saved for this sample.
C: Finding the optimal offset factor qjˆ
For a single sample the optimal offset factor qjˆ can be determined by comparing the
minimized χ2j and choosing the qj belonging to the smallest χ
2
j . For a group of samples
G the optimal offset qjˆ can be calculated easily: The χ
2
j is summed over all samples in
the group G for each j, i.e. χ2j,G =
∑
g∈G χ
2
j,g, and the offset qjˆ corresponding to the
minimal χ2
jˆ,G
is taken.
In the following chapters the group of samples, where we expected the offset to be the
same, are samples taken on the same day after CFSE application and from the same
organ in the mouse. As some organs had only highly proliferated cells and no clear
undivided cell peak, we combine these with other organs of the same day, where we find
enough undivided cells. In some rare cases, samples of the same day and same organ
differ strongly, such that we take the individual offsets for these samples.
The resulting distribution of normalized weights ~ϑ = (ϑ1, ϑ2, ...ϑl,tot) plotted against
the corresponding number of divisions will be referred to as the cell division profile.
2.1.3. Accounting for overlapping peaks in the model
As discussed in the introduction the model peaks for higher generations overlap stronger
such that the weights for these peaks become hard to identify. Thus, we introduce a
threshold for the overlap between peaks of neighbouring generations (n, n + 1), with
n = (0, 1, ...), above which the weights of these peaks are merged.
To this end, we first calculate the model peaks for each sample using its optimal
undivided model peak position qjˆ and its corresponding background, but with equal
weights for each peak. They are binned (Fig. 2.4) and for each two neighbouring peaks
(n, n+1) the overlap o is calculated from the fraction of cells shared in these bins. Then,
for each (n, n+1) the mean < o > and standard deviation sdo of the overlap is calculated
for all the samples from the same time point and organ. If (< o > +sdo) > 0.66 for
(n, n+1), we merged the weights of all peaks ≥ n for each of these samples and will refer
to them as generation n+. sdo is added to < o >, as the overlap varies strongly in some
cases. Like this we obtain a conservative estimate for our threshold. An overview over
the generations merged in each experiment is found in Tab. 3.2 in section 3.1.2 and in
Tab. 4.2 in section 4.1.2, where the analyzed data from our experiments are described.
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Figure 2.4.: Example of equally weighted binned model peaks and the corresponding number
of cells per bin (points) connected by a line to guide the eye.
2.2. Estimating errors
The changing number of cells over time is modeled with the help of ordinary differential
equations, where the cells in different compartments are the states ~x(t) and the the rates
are given by a set of parameters ~Θ. We obtain a set of differential equations
~˙x(~Θ, t) = f
(
~x(~Θ, t), ~Θ
)
. (2.4)
From the solutions of the differential equation one can calculate the quantities of
interest with the observation function ~y(t), which can be compared to experimentally
measured observables (yi):
~y(~Θ, t) = g
(
~x(~Θ, t), ~Θ
)
(2.5)
To determine how well the model fits a given set of data, a likelihood function L(~Θ|~y)
is introduced. For a given set of parameters ~Θ and data ~y this likelihood function is equal
to the probability density function p(~y|~Θ) to measure these data given the parameter set
~Θ and the model.
If the measurements are independently normally distributed it takes the form:
L(~Θ) =
∏
i
 1√
2piσ2i
exp
(
−(yi − yi(
~Θ))2
2σ2i
) . (2.6)
However there are cases where the errors σi are not known or the errors estimated from
the data cannot be trusted, which would lead to a biased fit to the data. A possibility to
fit the data in these cases is the estimation of the errors, where they become a function
of the model parameters: σi = σi(~Θ).
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Calculating the negative loglikelihood l(~Θ) = −log
(
L(~Θ)
)
we thus obtain:
l(~Θ) = const.+
1
2
∑
i=1
2log(σi(~Θ)) +(yi − yi(~Θ)
σi(~Θ)
)2 . (2.7)
The maximum likelihood estimate Θˆ is the parameter vector minimizing the negative
loglikelihood function and provides the best fit given the model and the data.
2.3. Estimating proliferation dynamics from cell division
profiles
Introduction
The process of proliferation in a simple birth model can be described with the following
ordinary differential equation (ODE)
G˙0(t) = −kG0(t)
G˙1(t) = 2kG0(t)− kG1(t)
G˙2(t) = 2kG1(t)− kG2(t),
... (2.8)
where k is the proliferation rate and Gi are the number of cells in the ith generation.
This intuitive modeling approach and its implicated results are used because of its com-
parative simplicity [122, 123, 124]. A solution of this ODE with time dependent rates is
discussed in the first part (section 2.3.1).
Still, it is important to keep in mind, that this way we implicitly introduce an expo-
nentially distributed waiting time for each division, although cells have a finite minimal
interdivision time [125]. Indeed, in vitro measurements of interdivision times show smaller
coefficients of variation (CV) than an exponential distribution [126]. Although in vivo
interdivision times are assumed to have a larger CV due a heterogeneous environment, it
is unlikely to exceed the CV of an exponential distribution. In consequence we often see
the distribution resulting from the solution of the ODE to have a higher variance than
the cell division profile obtained from the data, which worsens the fit. This problem will
be discussed in the second part (section 2.3.2) and an alternative to using the frequen-
cies of the cell division profile as observables will be discussed in the third part (section
2.3.3), which circumvents this issue. It is worthwhile mentioning that deBoer and Perel-
son even argue in ref. [125] that fits of the ODE model to the cell proliferation data, lead
to an overestimation of the average interdivision time, because the exponential waiting
time leads to a division cascade of cells dividing without intermission, which needs to be
slowed down.
In general, in order to include more realistic interdivision times, one can introduce a
Smith-Martin like model with a fixed delay in the cell cycle [127, 128, 129, 130], one
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can include cell age dependent rates [111, 113, 131] or introduce other (not exponential)
distributions for the division times [131, 132, 107]. If one wants to stay within the
formalism of ODEs, it is possible to introduce multiple compartments for one state with
the same transition rate leading to consecutive exponential waiting times, such that the
effective interdivision time would be gamma-distributed. The choice of the modeling
approach strongly depends on the type of data—e.g. do we only consider means or also
higher moments—and more importantly, the level of detailed information one hopes to
obtain from the data. Our in vivo experiments have multiple sources of noise and the
focus will therefore lie on understanding which proliferation dynamics are in principle able
to describe the data in different organs rather than an accurate estimate of interdivision
time distributions. As we find reasonable fits with our simple modeling approach, we
thus do not consider more complicated modeling options in our later models, and we
have to keep the limitations of this approach in mind.
2.3.1. Properties of the cell proliferation ODE model
It is easy to see that the solution of (2.8) results in Poisson distributed frequencies of
cells in different generations [122]
Gn(t)
Gtot(t)
=
(2kt)n
n!
e−2kt, (2.9)
where Gtot is the total cell number.
The models in the following sections required time dependent proliferation rates k(t)
and we try to understand the influence of the exact form of k(t) on the CFSE profile in
order to make informed choices for our rate.
Solving (2.8), with a time-dependent proliferation rate k(t), we can show (see suppl.
section A.1), that the number of cells in each generation Gn(t) is defined by
Gn(t) =
2nG0
n!
K(t)ne−K(t), (2.10)
where K(t) :=
∫ t
0k(t
′) dt′. The total number of cells is Gtot(t) = G0eK(t), which is the
solution to G˙tot(t) = k(t)G(t) and can be solved analogously to the first part in suppl.
section A.1. Thus, the frequency of cells in each generation is given by
Gn(t)
Gtot(t)
=
(2K(t))n
n!
e−2K(t) =
λn
n!
e−λ, (2.11)
with λ = 2K(t). We see that the frequencies of cells in different generations are again
Poisson distributed and only dependent on the integral K(t) of the proliferation rate
k(t).
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Figure 2.5.: Model fits to cell division profiles with and without error estimation. The bars
indicate the frequency of cells in each generation (cell division profile) and the points are repre-
senting the solution of the ODE, which has been fitted to the data. a) The last generations with
small errors dominate the model fit. b) Reasonable fit, where the errors were estimated, but
the discrepancy between the solution of the ODE and the data becomes obvious. Experimental
data: Lena Kranz and Mustafa Diken.
2.3.2. Estimation of the proliferation dynamic from cell division profiles
with an ODE model
Two limitations have to be taken into consideration, if we want to leverage the information
contained in the cell division profiles, i.e. the percentages of cells in each generation, by
fitting them directly with our ODE model.
First, the shape of the cell division profile, especially at early time points, deviates
from a Poisson distribution due to less variable (non-exponential) interdivision times as
discussed in the introduction. For example, we can often observe an abrupt decrease of
frequencies in higher generations. This is likely a consequence of the finite interdivision
time of each cell [111] resulting in a lack of cells beyond the maximum number of divisions
which a cell can do in a given time.
An extreme case of this characteristic is observed in the first melanoma experiment
introduced in section 3.1, which is analyzed as described in section 2.1. Due to the abrupt
decrease of frequencies in higher generations with additionally very small errors (last
generation < sd >= 0.002), this leads to a model fit dominated by the last generations
(see Fig. 2.5a). On the other hand, similarly extreme cell division profiles are not observed
in other experiments in section 3.1, which casts doubts on the correctness of the small
errors. We can thus fit the cell division profile while estimating errors as mentioned
in section 2.2: Although the model fit looks better than in Fig. 2.5a, one sees now
the discrepancy between the shape of the cell divisions profile and the fit. The model
prediction exhibits a flatter profile with a higher variance (Fig. 2.5b). As a consequence,
when using the cell division profiles directly for the fit, there is a possibility that trying
to fit different aspects of the exact shape leads to more local minima of the likelihood.
Second, it is problematic that our observables, i.e. the different generations of the CFSE
profile, are not independent. If they are all used for fitting, the information gained from
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fitting these observables is overestimated. Thus, when fitting the profiles directly at least
one generation is omitted, which would be completely dependent from the frequencies in
the other generations. In cases where 2 or more generations only make up ≤ 2% of the
total frequencies, we omitted these generations.
To circumvent these problems, for cases where a fit to the cell division profile is not
necessary, we introduce and use a summary statistic as an observable instead. This is
discussed in the next section.
2.3.3. Mean number of divisions as a summary statistic of the cell division
profiles
In order to omit the necessity to describe the exact shape of the data with our model and
circumvent the problems mentioned in the section before, the mean number of divisions
can be calculated and used as an observable. We define this as the sum of cell frequencies
weighted with the number of divisions they have done. It is
MDivn+ =
x1 + x2 · 2 + ...xn−1 · (n− 1)∑n−1
i=1 xi
, (2.12)
where xi is the number of cells in generation i. The last generation n+ which is the
sum of all cells larger than n − 1 is omitted, as one would have to guess a weighting
factor, which is not known for the data. Instead the fraction of n+ cells is used directly
as an observable.
Furthermore the 0th generation is omitted from the normalization of the mean number
of divisions and is used directly as an observable as well. This turns out to be useful,
because the 0th generation contains information on the activation rate/ time-to-first-
division, which is distinct from the proliferation rate.
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T cell dynamics in a melanoma mouse model
In this chapter it is our aim to both qualitatively and quantitatively understand the
initial dynamics of T cells upon tumor encounter and the effects of an agonistic anti-
CD40 treatment on this dynamics through mathematical modeling. To this end three
similar experiments with Melanoma mouse models and adoptively transferred T cells
(OT-I T cells) recognizing the tumor have been conducted. The first is the most extensive
experiment, where we have four measurement time points. It is referred to as Exp. 1
or the “time-resolved” experiment and a mathematical model is developed to describe
its OT-I T cell dynamics. The analysis of this experiment leaves the need to confirm
differences observed between the data from the treatment and control experiments and
to give more precise answers regarding the proliferation and activation rate estimates:
The second experiment, referred to as Exp. 2 or the replicate experiment, is a limited
repetition and is used to confirm the subtle differences observed between the data of
anti-CD40 treated and control mice. But it is not used for a model fit as it contains only
two measurement time points with few cells for the CFSE analysis and no additional
measurements of the proliferation dynamics to inform our model. We aim to answer the
questions regarding the activation and proliferation dynamics with a second follow-up
study. In Exp. 3 or the “proliferation-resolved” experiment, the proliferation of OT-I T
cells is assessed in more detail with an additional cell proliferation dye. This data is not
only compared to the original study, but a slightly adapted model is fitted to the data,
such that conclusions drawn from the results of the first fit can be tested and refined.
The chapter is structured as follows. Section 3.1 highlights common differences between
the treatment and control data and furthermore, discusses differences between the results
of the three experiments. The presented cell division profiles have been analyzed with
the methods introduced in the previous chapter (see section 2.1). In section 3.2 the
developed mathematical model and its fit to the data is discussed: We first introduce
the basic model structure for Exp. 1 and Exp. 3. Second, we discuss alternative model
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structures, which have been considered to fit the data. Third, by fitting the basic model
structure to the treatment and control data simultaneously and conducting a model
selection, we determine mechanisms which need to be different between the two settings
and thus, can assumed to be influenced by the anti-CD40 treatment.
Finally, we present and discuss the best model fit to each experimental data set. In
section 3.3 the results for both experiments are compared.
All experiments in this chapter have been conducted by Lena Kranz and Mustafa Diken
at TRON (Translational Oncology at the University Medical Center of the Johannes
Gutenberg University) in Mainz, Germany. The experiments and the analysis of the flow
cytometry data were jointly discussed in order to obtain adequate data for modeling.
3.1. Results of the melanoma mouse experiments
3.1.1. Experimental setup
In all three experiments the tumor grown from the well established Melanoma cell line
B16-OVA expressing ovalbumin (OVA) as a model antigen was inoculated subcutaneously
into mice. This tumor site has the advantage that the tumors could be monitored and
measured at all time points during the experiment. After 14 or 21 days, when the tumor
had a size between 87±11mm3, 38±5mm3 and 350mm3±62mm3 respectively, the mice
were divided into a control and a treatment group of equal sizes, such that 3-5 mice could
be sacrificed on each read out day in each group (see Fig. 3.1). On the day, on which
the mice were grouped and which is referred to as day 0, 5 million CFSE-dyed OT-I
T cells recognizing an OVA derived peptide (SIINFEKL) have been injected. Together
with the OT-I T cell transfer one group received an isotype control (RatIG2a) and the
other group was treated with 500µl of an agonistic anti-CD40 antibody (FGK45). A
large number of transferred cells was necessary in order to recover enough OT-I T cells
in different organs for a sound statistical analysis. By varying the time between tumor
inoculation and cell transfer (14 days, 21 days and 21 days) our collaboration partners
tried to achieve similar tumor sizes for all experiments on the day of cell transfer, but
still they remained significantly different.
Samples from the blood, the tumor and the draining lymph node (where the whole
organ can be used as a sample) were read out on day 2, 3, 4 & 7, day 2 & 4 and day 3 &
4 post OT-I cell transfer, respectively (see Fig. 3.1). In these samples the OT-I T cells
and endogenous T cells were identified and analyzed with flow cytometry. Their number
was extrapolated to the sample and eventually to the whole organ via true count beads.
In this context, the mice were all assumed to have 1500µl of blood. The proliferation
information is obtained from the measurements of the CFSE intensity in all experiments
and additionally BrdU in the third experiment, which was given i.p. 14h prior to the
measurement.
The CFSE measurement quantifies how often cells have divided. BrdU, on the
other hand, is only incorporated by dividing cells, such that we can additionally check
whether cells in different generations are having varying fractions of dividing cells
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Table 3.1.: Exact times, when samples were taken
Exp. “Day 2” “Day 3” “Day 4” “Day 7”
1 40h/ 64h/ 88h/ 160/
1.7d 2.7d 3.7d 6.7d
2 40h/ - 86h/ -
1.7d - 3.6d -
3 - 66h/ 90h/ -
- 2.75d 3.75d -
at the time point of measurement.
The exact times when the samples were taken vary, such that, when referring to the
data taken on day X, this implies slightly different times for different experiments, see
Tab. 3.1. In figures and fits we only use the exact times.
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Figure 3.1.: Overview over the three murine melanoma experiments. The number of available
mice at different time points in the control (black) and treatment (orange) groups are indicated.
Experiments conducted by Lena Kranz and Mustafa Diken.
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Figure 3.2.: Absolute OT-I T cell numbers measured for the treatment (dashed) and control
(solid) in the a) draining lymph node and b) tumor in Exp. 1 (orange), Exp. 2 (light blue) and
Exp. 3 (purple). Experimental data: Lena Kranz and Mustafa Diken.
3.1.2. Changes induced by the anti-CD40 treatment and common
features of the experiments
Despite the biological variability of the experiments, it is possible to distinguish common
tendencies in the data obtained from treated mice.
Absolute cell numbers An unexpected difference between the treatment and control is,
that the absolute OT-I T cell numbers in the tumor are lower for the treatment setting
(Fig. 3.2b). Intriguingly, especially in the first experiment we can see that the anti-CD40
treatment has an effect on the tumor growth (significant differences in tumor sizes on day
1.7 and 3.7) and is hinting towards a contained tumor growth in the follow-up studies
(Fig. 3.3b). The smaller numbers of OT-I T cells in the tumor is not only a consequence
of the smaller tumors, but indeed the T cells are less densely populating the tumor in the
anti-CD40 treated mice (suppl. Fig. B.1). For the absolute cell numbers in the draining
lymph node we cannot discern a shared tendency induced by the treatment between the
experiments (Fig. 3.2a).
Cell division profiles and information on the proliferation dynamics The CFSE in-
tensity measurement is analyzed as described in the previous chapter (section 2.1). The
generations which are merged according to the criteria in section 2.1.3 are found in tab.
3.2. As discussed in section 2.1 we only use CFSE samples for analysis with more than
15 cells and here, we only show data where a minimum of three samples is available.
This data is also used for the model fitting in section 3.2.
The cell division profiles do not change in Exp. 1 and Exp. 3 after day 2.7/2.75 in
the draining lymph node and thus the proliferation of the OT-I T cells seems to be
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Figure 3.3.: a) Fraction of undivided OT-I T cells in the draining lymph node derived from
the CFSE measurements and b) tumor sizes in Exp. 1 (orange), Exp. 2 (light blue) and Exp.
3 (purple) for the treatment (dashed) and control (solid). Experimental data: Lena Kranz and
Mustafa Diken.
attenuated over time in this organ (Figs. 3.4 and 3.6). Another explanation would be,
that with higher generations the proliferation stops or the egress from the draining lymph
node increases. But the decrease of the BrdU+ fraction from day 2.75 to day 3.75 in
Exp. 3 hints at a decreasing proliferation in the draining lymph node over time (Fig. 3.7).
Contrasted to our observation in the draining lymph node, it seems that the division in
the tumor is ongoing (Figs. 3.4 - 3.6 and Fig. 3.7). Again, it is not clear from the cell
division profiles whether this is due to a continued proliferation in the tumor or due to
a preferential migration of proliferated cells from the draining lymph node. However the
increasing fraction of BrdU+ cells in the tumor as opposed to the draining lymph node
hints at a steady or even increasing proliferation over time. Regarding the cell division
profiles, there is a marked difference between the first experiment and the third. The
sudden decrease of cells in higher generations in the draining lymph node and the peaked
fraction of cells in generation 4 in the tumor in Exp. 1 (Fig. 3.4) are at odds with the
cell division profiles in Exp. 3. Exp. 2 seems to have an intermediate characteristic. As
the tumor sizes are consistently smaller in the first and second experiment, this might
be part of the explanation.
The lack of BrdU+ cells in the undivided generation and the increased fraction of
BrdU+ cells with higher generations (Fig. 3.6) can be understood with the following
consideration: The availability of BrdU is reported to be short in [133], i.e.  14h. If
the S, G2 and M phase together are distinctly shorter than 14h (which is very likely
for activated T cells, see [125, 126, 102]), then all cells in S phase at the time point of
BrdU availability, will have divided by the time they are measured. In consequence, the
fraction of BrdU+ cells at the time point of measurement depends on the number of cells
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Table 3.2.: Generations, of which the weights from the CFSE intensity data anal-
ysis (section 2.1), can be trusted
Exp. Day 2 Day 3 Day 4 Day 7
dLN tumor dLN tumor dLN tumor dLN tumor
1 0-5 0-5 0-5 0-5 0-4 0-4 0-4 0-4
2 0-5∗ 0-5∗ - - 0-4 0-4 - -
3 - - 0-5 0-4 0-4 0-4 - -
*Here the weights could be measured for 0-6, but for simplicity and comparability
it is reduced to 0-5
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Figure 3.4.: Cell division profiles of OT-I T cells derived from the CFSE measurement data
of Exp. 1 for control (left) and treatment (right) and for the draining lymph node (upper panel)
and tumor (lower panel). Experimental data: Lena Kranz and Mustafa Diken.
in S phase in the previous generation 14hrs ago. So, if the previous generation has more
cells, which is the case for higher generations, it receives a comparatively high number of
BrdU+ cells until the time point of measurement. And the undivided generation is left
by all its BrdU+ cells and obviously receives none from a lower generation.
Fraction of undivided cells If cells are governed by a common proliferation rate, we
expect more or less Poisson distributed frequencies in the cell division profile, (see section
2.3.1). If we bear this in mind, the remarkably high undivided cell fraction (Fig. 3.4 -
3.6) hints at a distinct time-to-first-division. We take a closer look at the dynamics of
the undivided cells in the draining lymph node, where the activation of naive cells is
supposed to take place (Fig. 3.3a). Here, we see that the fraction is lower for the anti-
CD40 treatment setting, which hints at an increased activation rate due to the treatment.
This would be in line with the reports describing CD40 to support the priming of T cells
[44, 45, 46, 47]. All the more it is surprising to see the elevated fraction of undivided
cells on the third day for the treatment setting in the first experiment (Fig. 3.3a), which
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Figure 3.5.: Cell division profiles of OT-I T cells derived from the CFSE measurement data
of Exp. 2 for control (left) and treatment (right) and for the draining lymph node (upper panel)
and tumor (lower panel). Experimental data: Lena Kranz and Mustafa Diken.
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tumor (lower panel). Fractions of all cells are grey and the fraction of BrdU+ and BrdU- cells, if
known, are blue and light blue respectively. Experimental data: Lena Kranz and Mustafa Diken.
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Figure 3.7.: Fraction of BrdU+ OT-I T cells from Exp. 3 in draining lymph node (green) and
tumor (red) for the treatment (dashed) and control (solid) setting. Experimental data: Lena
Kranz and Mustafa Diken.
we could see in all mice of this experiment. But as this dynamic was not reproducible in
the follow-up experiments, it remains questionable, whether this is not an artefact. In
the tumor, on the other hand, an infiltration by undivided cells or a distinct activation
rate seems unlikely and it remains unclear by what the dynamics of the undivided cells
(Fig. 3.4 - 3.6) are governed.
Mean number of divisions The mean number of divisions, see section 2.3.3, show a
slightly enhanced proliferation for the anti-CD40 treatment setting in the draining lymph
node in all experiments (see Fig. 3.8). In order to have a comparable measure for all days,
the mean number of divisions MDiv5+ is shown, as the 4th generation is the maximum
number of generations up to which we can trust the CFSE analysis on all days and in all
experiments (see also Tab. 3.2). This is not always conveying a good idea of how much
cells have divided, as it has no contribution from the highly proliferated generations (here,
generation 5+). Especially on day 4 in the third experiment, this leads to a putatively
low mean number of divisions in the draining lymph node in the treatment setting as a
large part of the cells are already in generation 5+ and not contributing to the MDiv5+.
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Figure 3.8.: Mean number of divisions of the OT-I T cells for treatment (dashed) and control
(solid) in the draining lymph node (green) and tumor (red). Experimental data: Lena Kranz
and Mustafa Diken.
3.2. Mathematical model describing the T cell dynamics in
a melanoma mouse model
We aim at developing a comprehensive but simple model, which can describe the OT-I
T cell dynamics and explain the differences between treatment and control data, which
we observe in the first (time-resolved) and third (proliferation-resolved) experiment. The
experiments contain complementary information: The first describes the T cell dynamic
over an extended period of time, but lacks precise information on the proliferation dynam-
ics. To augment this the proliferation-resolved experiment was conducted and focuses
on the proliferative activity of the T cells in each generation at a given time point, but
contains only two measurement time points.
The first section 3.2.1 motivates the construction of our “basic model structure”, which
is kept as simple as possible. Subsequently, in section 3.2.2 we discuss other plausible
model structures, which have been considered and we motivate our choice of the “basic
model structure”. With “model structure” we refer to the set of differential equations and
the used observation functions (see section 2.2), which can describe both the treatment
and the control data separately. If we fit a certain model structure, i.e. our “basic
model structure”, to the treatment and control data simultaneously, we can test many
nested models. These nested models differ only with respect to the parameters which
are different between the treatment and control. Choosing the best model among these
means to find the parameters, which need to be different between the treatment and the
control, i.e. are influenced by the treatment. Thus, in section 3.2.3 a model selection
among the nested models is conducted and we define and present the best models of
both experiments in sections 3.2.4 and 3.2.5. Finally, in section 3.3 the parameters of
the best models of each experiment are compared.
33
Chapter 3. T cell dynamics in a melanoma mouse model
3.2.1. Basic model structure construction
In this section the basic model structure (Fig. 3.9) used for our best model fits in sections
3.2.4 & 3.2.5 is presented. Some tested alternative model structure options are briefly
outlined here, but the more arguable decisions are discussed separately in the next section
3.2.2.
A common model structure for both experiments
For the basic model structure (Fig. 3.9) the focus lies on the draining lymph nodes, where
the naive OT-I T cells are primed and proliferate, as well as on the tumor, where the cells
are expected to egress to and presumably take up their proliferative activity again [134].
Here, we expect to see the most pronounced effects of an immunomodulatory anti-CD40
treatment.
A source term describes the influx of naive cells into the draining lymph node. We also
consider a time-dependent decrease of the source term. The time dependence improves
the fit to the first experiment (∆ AIC= 3.9), but worsens the fit to the third experiment
(∆ AIC= 3.3). In the first experiment the fit without a decreasing source term performs
already well and in addition the number of undivided cells in the blood, which is a
plausible source for the influx, stays constantly high (see suppl. Fig. B.2b). Thus, we
decide to stay with a constant source term over time.
As discussed in section 2.3.2, we expect the time-to-first-division to be different and
we introduce an activation rate for undivided cells in the draining lymph node, to govern
their dynamics.
The undivided cells in the tumor cannot be explained by a simple migration of acti-
vated cells from the draining lymph node with our constructed model (tested for first
experiment, not shown) and an infiltration of the tumor by naive undivided cells from
the blood would be unexpected. Yet we see a non-negligible fraction of naive cells in this
undivided cell population (percentage of CD44-CD62L+ cells: 0.135 ± 0.002 in Exp. 3;
no CD44 measurement in Exp. 1). In consequence, treating them as an artefact resulting
from an unphysiologically high number of transferred OT-I T cells, which were circulat-
ing in the organism, is the simplest model assumption. In our basic model structure, we
introduce a constant number of naive cells in the tumor, which does not change over time.
Indeed, the number of undivided cells stays constant until day 4 in the first time-resolved
experiment (suppl. Fig. B.2a).
Due to the observed decrease of the BrdU+ fraction in the draining lymph node
(Fig. 3.7) and a seemingly attenuated proliferation seen in the cell division profiles (Fig.
3.4-3.6), we introduce an exponentially decreasing proliferation rate over time with
pdLN (t) = pdLN,0 e
−αt, (3.1)
where pdLN,0 is the proliferation rate at t = 0 and α is the decay rate. α is constraint to be
positive, such that we only consider constant or decreasing proliferation rates over time
in the draining lymph node. An increased proliferation rate would be unexpected, as the
proliferative activity of T cells should be strongest after antigen encounter and priming
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and then decline over time [135, 102, 136]. Other model options for the proliferation rate
are discussed in section 3.2.2.
Due to the observed increasing BrdU+ fraction in the tumor (Fig. 3.7), we never-
theless test a time dependent increase of the proliferation in this compartment for the
proliferation-resolved experiment. We find—as is discussed in section 3.2.2—that no sig-
nificant improvement of the fit is observed and conclude that there is not a strong enough
indication for an increasing proliferation in the tumor as well.
Fitting errors The errors of our data stem from a small number of mice (three to
four) such that they are not reliable and we decide to estimate them instead, see also
section 2.2 on error estimation. For example, the errors of the absolute cell numbers in
the draining lymph node and tumor (Fig. 3.2) appear to be very variable without any
evident explanation.
We choose relative errors for the absolute cell numbers and distinct absolute errors for
the mean number of divisions and the frequency of cells in different generations. For the
latter the errors of the draining lymph node and the tumor are allowed to be different.
The reason behind this is that the CFSE intensity analysis of the tumor data is more
challenging due to lower cell numbers on early days and due to the comparatively small
number of undivided cells on later days, see section 2.1. In consequence, we trust these
frequencies resulting from the CFSE data analysis less than the ones obtained from the
analysis of the data from the draining lymph node. As the number of mice for each data
point, i.e. each time point and treatment setting, is similar (three to four mice), we did
not adapt the errors according to the number of mice contributing to it.
Adaptations of the model structure for the different experiments
Four points need to be adapted for the basic model structure of the time-resolved exper-
iment and the proliferation-resolved one. By and large, all adaptations can be regarded
as simplifications/expansions of the same model structure—see also the discussion in
section 3.3, where the results are compared:
First, we choose a time-dependent and growing egress rate edLN (t) for the time-resolved
experiment. This dynamic egress rate is not needed for the proliferation-resolved exper-
iment, where the model is only calibrated with data from two subsequent days. For a
discussion of alternative options with respect to the egress rates, see section 3.2.2. As
the egress needs an upper bound we use a logistic growth function:
edLN (t) =
edLN,max · edLN,0 · exp(βt)
(edLN,max + edLN,0 · (exp(βt)− 1)) , (3.2)
with edLN,max and edLN,0 defining the upper and lower bound respectively and β shaping
the inclination and the time scale of the increasing egress rate.
Second, in the model for the time-resolved experiment a division stop mechanism is
introduced. Otherwise it is not possible to explain the abrupt decrease of frequencies
after the fourth generation in the draining lymph node and a prominent accumulation of
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cells in the fourth generation in the tumor. The model is implemented such that the cells
can divide four times in the draining lymph node and twice after their egress into the
tumor (abbreviated with “Gen 1 - 4” and “Gen +2”). For the model of the proliferation-
resolved experiment no proliferation stop has been implemented. Again, other tested
options can be found in section 3.2.2.
Third, in order to accurately reflect the incooperation of BrdU we subdivide the pro-
liferation rate into rates determining the progression through the cell cycle phases. We
follow the idea that the S, G2 and M-Phase resemble a fixed program, which runs through
once it is started and that the length of the G1 phase can be subject to changes through
which the cell cycle length is predominantly determined [127, 137, 112]. Thus, we combine
the G2 and M-phase with the S-phase and this is referred to as S/G2/M phase, with the
corresponding rate pS . The mean of the rate pS is assumed to be constant over time and
the same in the draining lymph node and the tumor, i.e. pS = pS,dLN = pS,T = constant.
The progression through the G1-phase is governed by the rate pG1. The rate pG1 of the
G1 phase on the other hand can change. In our basic model structure it is time dependent
in the draining lymph node (pG1,dLN (t) = pG1,dLN,0 exp(−αt)) and is determined by a
different rate in the tumor pG1,T , which is constant over time. Alternative dependencies
of pG1,dLN and pG1,T are tested in section 3.2.2.
With this implementation we implicitly assume that the length of the phases are inde-
pendent, which is in good agreement with the modeling approaches in ref. [127, 137, 112],
although this is a matter of debate [126]. With the phase distinction it is possible to
distinguish the fraction of cells taking up BrdU at a given time point, which are the cells
in S-Phase. Because the time spent in the G2/M-phase is reported to be small against
the time spent in the S-phase [112], we assume that all cells in the S/G2/M-phase of our
model are taking up BrdU. In addition the BrdU availability is reported to be short [133],
such that we simplify this by assuming BrdU to be available only at the time point of its
administration, i.e. 14h prior to the measurement, and that all cells in the S/G2/M-phase
of our model instantaneously take up BrdU at this time point (Fig. 3.10).
Finally, for both experiments we fit different observables, i.e. quantities in the data to
which the outcome of the model is compared to during the fitting procedure (see section
2.2). For the first experiment, besides the absolute cell numbers, we are fitting the mean
number of divisions MDivn+ (which is calculated from the relative frequencies of cells in
generation 1 to n− 1) and the relative frequencies of cells in the 0th and n+ generation.
For the proliferation-resolved experiment we want to make full use of the information on
the fractions of BrdU+ cells in each generation and thus fit these directly. To test the
robustness of these fits, we switch the observables, i.e. we fit each generation of the cell
division profile in the time-resolved experiment andMDivn+ in the proliferation-resolved
experiment, and discuss this in the section introducing the best model (see section 3.2.4
and 3.2.5).
Summary of the basic model structures
The schematic figure of the basic model structures for both experiments can be seen in
Fig. 3.9.
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For the time-resolved experiment we have in total r=13 parameters: source rate, acti-
vation rate, proliferation rate in the draining lymph node pdLN defined by the parameters
pdLN,0 and α, proliferation rate in the tumor pT , egress rate edLN defined by the param-
eters edLN,0, edLN,max and β, the number of inactive cells in the tumor and four error
parameters: a relative error for the absolute cell numbers sdabs, an absolute error for
the mean number of divisions sdMDiv and absolute errors for the frequencies of cells in
generation 0 and n+ in the draining lymph node sddLN and tumor sdT . We have 61
observables (see suppl. section B.2).
For the proliferation-resolved experiment we have in total r=11 parameters: source
rate, activation rate, proliferation rate in the draining lymph node pG1,dLN & pS , where
pG1,dLN is defined by the parameters pG1,dLN,0 & α, proliferation rate in the tumor
pG1,T (& pS), egress rate edLN , the number of inactive cells in the tumor and three
error parameters: a relative error sdabs for the absolute cell numbers and absolute errors
sddLN & sdT for the frequencies of cells in all generations in the draining lymph node
and tumor. We have 79 observables (see suppl. section B.2).
e     (t)  
Draining lymph node 
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Gen 0  
Inactive, 
Gen 0 
pdLN (t)
 
pdLN (t) source  act. Active, 
Gen 1 ...  
Tumor 
Inactive, 
Gen 0 
Active, 
Gen 1 ... 
pT  
dLN  
Figure 3.9.: Basic model structure applied for both experiments. States are in black and
parameters are in blue. States: Active generations continue dividing in the model for the
proliferation-resolved experiment. In the time-resolved experiment model division stop after 4
divisions in the draining lymph node and after 2 additional divisions in the tumor. Parameters:
Logistic growth of the egress rate edLN (t) for the time-resolved experiment. For the proliferation-
resolved experiment edLN is constant. Exponential decay of proliferation rate in the draining
lymph node pdLN (t) in both experiments, where pdLN (t) is subdivided into pG1,dLN (t) & pS
in the proliferation-resolved experiment. The detailed model for the BrdU uptake during the
proliferation (orange boxes) for the proliferation-resolved experiment can be seen in Fig. 3.10.
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Figure 3.10.: Schematic figure for the model describing the BrdU uptake of dividing cells in the
draining lymph nodes. Analogous mechanism is applied in the tumor albeit without undivided
cells (cells with “0 divisions”). At the time point of BrdU administration (t = tBrdU) all cells in S
phase instantaneously become BrdU+, but not anymore at later time points, which is reflecting
the short BrdU availability. After this the proliferation continues independently for BrdU+ and
BrdU- cells.
3.2.2. Alternative models
In the following, alternatives to the basic model structure for both experiments, which
have been introduced in the preceding section (section 3.2.1 and Fig. 3.9), are modified
and tested. For each model structure we compare the model fit, where the data of the
treatment and control experiments are fitted simultaneously with all parameters being
different, but for the errors and the source term. The latter parameters are equated, as
there is no plausible reason, why they should be affected by the anti-CD40 treatement.
Due to the fact that almost all parameters can be different, it is comparable to fitting
the model structures to the treatment and the control data separately.
Of course we cannot look at all possible model modifications, such that we focused
on replacing questionable assumptions, e.g. the division stop mechanism and time de-
pendent rates, with plausible alternatives. We furthermore, pursue the question whether
proliferation in the tumor is necessary.
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General considerations
Two types of rate modifications: generation dependent and time dependent mecha-
nisms In our alternative model structures we use two types of rate modifications. One is
to introduce a time dependency and the other is to use a generation dependency, in which
the rates—in a simple case—depend on the number of divisions a cell underwent. If we
want to test alternative time dependent mechanisms to the ones we have, there are a few
obvious choices (i.e. constant, exponential, logistic), which are easily implemented and
which we use in the following section. Our division stop mechanisms in the time-resolved
experiment, however, is a special case of a generation dependency of the proliferation
rate and if we want to test alternatives, it is important to see how our current mecha-
nism compares with other generation dependent mechanisms. This is discussed in the
following.
Our division stop mechanism is a special case of a division destiny Generally, with
division destiny we refer to a mechanism, in which the number of divisions a cell can do
is determined before its first division. Thus, our division stop mechanism in the draining
lymph node is a way to implement a simple case of a division destiny, as all cells are
determined to stop after four divisions. This is abbreviated with „Gen 1-4“. In the tumor
two further divisions after entering this compartment are allowed. This is referred to as a
local division stop mechanism. This can be viewed as a realization of a local and special
case of a division destiny, which is determined upon entering the tumor and is denoted
with “Gen +2”.
Cases where our division stop can be generalized with a simple generation depen-
dent proliferation The obvious generalization of a simple division stop is a generation
dependent proliferation, where every generation has its own proliferation rate. Thus, it
comprises the possibility of the proliferation to cease after any number of divisions. In
consequence, the division stop in the draining lymph node (“Gen 1-4”) is straightforward
to generalize with a generation dependent proliferation. This is done in the alternative
model structures in order to make the division stop more flexible.
However, the local division stop in the tumor cannot be generalized by replacing it with
a simple generation dependent proliferation. This follows from the fact that here, the rate
is not only dependent on the number of generations but also on the history of the cell, i.e.
in which generation it entered the tumor. But combining the history with a generation
dependent rate adds a lot to the complexity to the model. So, when we test alternatives,
we try to replace this local division stop mechanism with a simple generation dependent
proliferation, knowing that this is not a generalization, but a different mechanism.
It is interesting to note that a generation dependent decrease of the proliferation rate
can be seen as a generalized division stop mechanism. It is not the number of divisions
a cell can do, which is predetermined, but the number of divisions from which the cells
starts to slow down its proliferation rate.
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Death rate The information on cell death at hand is the fraction of dead OT-I T
cells in the life/dead gate of the flow cytometry analysis. Generally, it is difficult to
introduce this information into the model, because the dead cells in the life/dead gate
have died and accumulated in an unknown time range before the measurement. Hence,
the fraction of dead cells is not straightforward to interpret or compare: The number of
dead cells depends on the number of cells which lived in that unknown time range and
thus contributed to the measured dead cells, but these are compared to the number of
cells living at the time point of measurement. Comparisons between different organs and
time points are still possible, if we assume the time range in which the cells accumulate
not to be large or the relative change of the absolute cell numbers at different time points
and organs to be tolerably similar.
When introducing a death rate into the basic model structure, we have to keep in mind
that, for example, a uniform death rate is difficult to identify: This rate is introducing
an exponentially decreasing scaling factor with time in all compartments and thus, can
be largely compensated by a source term (see section A.2). Nevertheless, for consecutive
time points we should be able to discern a death rate.
We find dead cells in the draining lymph node and tumor with a generally higher frac-
tion in the latter. This induced us to fit two simple model extensions to both experiments:
to the basic model structure we either add a uniform death rate for all compartments or a
death rate only in the tumor. We fit this model simultaneously to the treatment and con-
trol data with all parameters being different between the treatment and control, but for
the source term and the errors. In the case of the time-resolved experiment the additional
death rate does not improve the fit. In consequence, as these models are more complex
than the basic model structure, they perform worse with respect to the AIC. In contrast,
a fit including a death rate in the tumor—but not an overall death rate—improved the
fit to the data of the proliferation-resolved experiment by ∆AIC = 1.5.
Nevertheless, as the difference is not large and as we want to keep the basic model
structures of both experiments comparable and simple, we decide to not include death
rates. Still, it is noteworthy, that the model fit also provides evidence for a death rate
in the tumor, albeit only in the case of the proliferation-resolved experiment. And,
furthermore, these results do not mean that there is no or little cell death in the time-
resolved experiment: It can be the case that we cannot identify this rate with the given
model and data.
Proliferation in the tumor It has been reported that there is significant ongoing pro-
liferation at the sight of inflammation [134, 138], but the question remains, whether
this also holds for tumor sites, as the environments are known to be immunosuppressive
[139, 140]. For this reason it is important to test, whether the proliferated cells in the
tumor can be explained without a proliferation in the tumor. As we will see in both
experiments we find that this is not the case.
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Alternative Models for the time-resolved experiment
All modifications are changes to the basic model structure of the time-resolved experiment
(see Fig. 3.9). This model structure includes a division stop in both draining lymph node
and tumor and a time dependent egress as well as a time dependent proliferation rate
in the draining lymph node. The here presented modified model structures and the
basic model structure are fitted to the data of the treatment and control experiments
simultaneously with all parameters being different between the treatment and the control,
but for the errors and the source term. The fit with the basic model structure returns a
negative loglikelihood of 90.3 and an AIC of 358.4.
It is our aim to test, whether 1) the division stop can be omitted entirely, 2) whether
time dependent proliferation rates can replace the division stop mechanisms, 3) whether
only division stop mechanisms or a generation dependent proliferation can replace the
time dependent proliferation, 4) whether the proliferation in the tumor can be replaced
and 5) whether the time dependency of the egress rate can be replaced by a generation
dependency. 1) - 3) are partly motivated by the fact that we combine a time dependent
and a generation dependent mechanism to explain the attenuated proliferation dynamics
in the draining lymph node, which renders the model complex. In consequence, we try to
replace one or the other mechanism such that we only have either a time dependency or
a generation dependency for our proliferation in both tumor and draining lymph node.
In the following, we find that a model with a generation dependent proliferation rate
instead of a time dependent one in the draining lymph node and a model without pro-
liferation in the tumor, but with a generation dependent egress rate, perform worse,
∆AIC= 7.2 & 8.7, but cannot be rejected entirely. We also find evidence for a genera-
tion dependent egress rate instead of a time dependent one.
1) Leaving out the division stop results in a significantly worse fit Implementing
a continued proliferation instead of a division stop mechanism and making no other
changes to the model structure returns an AIC of 378.5 and a negative loglikelihood of
100.4, which is significantly worse than our basic model structure fit (∆AIC= 20.1).
2) A time dependent decrease of the proliferation cannot replace the division stop
mechanism Here we try to explain the attenuated proliferation with only a time de-
pendent decrease of the proliferation.
To compensate for discarding the division stop mechanism, we try time dependent
proliferation decrease mechanisms in both the tumor and the draining lymph node. More
precisely, we try an exponential decrease of the proliferation rate in both compartments
pdLN (t) = pdLN,0 e
−αt and pT (t) = pT,0 e−γt, with individual decay rates α and γ. We
also try a logistic decrease of the proliferation rate,
pdLN (t) = pdLN,max − pdLN,max · pdLN,0 · exp(αt)
(pdLN,max + pdLN,0 · (exp(αt)− 1)) , (3.3)
resulting in the dynamic shown on the right side of Fig. 3.11. The equation is simply a
substraction of the logistic growth function from its upper bound pdLN,max. α shapes the
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decay. We set pdLN,0 = 0.001/d to ensure that the proliferation rate is small after the
decay and thus, skipped the necessity to estimate this parameter. The proliferation in
the tumor is modeled analogously with its own decay parameter γ and an upper bound
pT,max.
An exponentially decreasing proliferation rate in both compartments performs better
then a logistic decrease, but still significantly worse than our basic model (∆AIC= 17.9)
and returns AIC= 376.3 and a negative loglikelihood of 94.2.
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Figure 3.11.: Different time dependent proliferation decrease mechanisms, which are imple-
mented instead of a generation dependent proliferation stop.
3) A generation dependent proliferation performs worse than a time dependent
proliferation and division stop, but cannot be rejected. The local division stop
mechanism in the tumor is needed. Here we try to explain the attenuated proliferation
with only generation dependent mechanisms.
First, we introduce a generation dependent proliferation (linearly and exponentially
decreasing), in the draining lymph node and tumor. In the draining lymph node this is
replacing the time dependency. Both options perform worse with ∆AIC>> 10.
In a next step we keep the “Gen +2” local division stop mechanism in the tumor. If
this mechanism is combined with a generation dependent exponential decrease of the
proliferation rate in the draining lymph node we obtain an AIC = 365.6 and a negative
loglikelihood of 93.9. This is still worse by ∆AIC= 7.2 than our basic model fit, but
cannot be rejected thus.
We conclude that, although less likely, the attenuated proliferation in the draining
lymph node could be the result of a generalized division stop mechanism, as well. For
this reason, the same modification is tested for the proliferation-resolved experiment and
the results are discussed in detail in section 3.3.
4) Replacing the proliferation in the tumor with a generation dependent egress
performs worse but cannot be rejected If the proliferation in the tumor is left out, we
need to omit the division stop in the draining lymph node, as cells in higher generations
in the tumor can now only stem from the draining lymph node. We try linearly and
exponentially increasing generation dependent egress rates, as we need the cells in higher
generations to egress faster in order to be able to explain the more highly proliferated
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cells in the tumor. Furthermore, independent egress rates for each generation including a
factor are tested, where the latter transforms the individual egress rates of the control to
the ones of the treatment, as otherwise the model would have too many parameters. This
model structure performs best. Indeed, the independent rates are estimated to increase
with the number of generations and we obtain AIC= 367.1 and a negative loglikelihood of
97, which is worse by ∆ AIC= 8.7 than our basic model fit, but can just not be rejected.
5) A generation dependent egress rate performs worse than a time dependent one but
cannot be rejected It is our aim to test an alternative for the time dependent egress
rate. We replace it with generation dependent, linearly and exponentially increasing
egress rates, as well as independent rates as described in 4). The exponentially increasing
egress rate performs best and has the same AIC of 358.2 and a negative loglikelihood of
94.8.
The fit, i.e. the negative loglikelihood, performs worse, but the AIC is the same, since
we use less parameters when modeling the exponential generation dependent increase
compared to the time dependent logistic increase.
To make these two model structures better comparable we reduce the parameters,
which are different between the treatment and the control, to the ones, which are nec-
essary to explain the data. More precisely, we do a forward selection as is described in
the next section 3.2.3 and compare the best minimal models. The best minimal model
of the generation dependent egress model is worse by ∆ AIC=4.4 and thus we decide for
our basic model structure.
Alternative Models for the proliferation-resolved experiment
The basic model structure of the proliferation-resolved experiment has no division stop
mechanism, but a proliferation which decreases with time in the draining lymph node
and it has no other time dependent rates (Fig. 3.9). We modify this basic model structure
and fit the alternative model structures to the treatment and control data simultaneously.
For this comparison all parameters are different for the treatment and control, but for
the errors and the source term. The fit with the basic model structure returns a negative
loglikelihood of 34.8 and an AIC of 258.9.
We would like to answer the following questions here: 1) Can a generation dependent
proliferation rate replace the time dependent proliferation rate in the draining lymph
node, since this option could not be rejected for the time-resolved experiment? 2) Can
the proliferation in the tumor be replaced? 3) Does a time dependent proliferation in the
tumor improve the fit? This question is explored, as we see an increasing proportion of
BrdU+ cells in the tumor, see Fig. 3.7. 4) Does a time dependent egress improve the fit?
5) Does a division stop mechanism improve the fit? 4) and 5) are motivated by the fact
that these mechanisms are needed to describe the data of the time-resolved experiment
such that we are interested whether these mechanisms would improve the fit to the data
of the proliferation-resolved experiment, as well.
In the following, we confirm a proliferation in the tumor and a time dependent decrease
of the proliferation rate in the draining lymph node. Furthermore, we conclude that the
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time dependent egress and the division stop mechanisms included in the basic model
structure of the time-resolved experiment cannot be rejected.
1) A generation dependent proliferation cannot replace the time dependency The
time dependent proliferation rate in the draining lymph node is replaced with generation
dependent proliferation rates (linearly, exponentially decreasing and independent rates)
in the same way as it is done for the alternative models of the time-resolved experiment
in 3). Here, the best AIC is achieved with exponentially decreasing proliferation rates,
but it performs significantly worse than the time dependent proliferation and returns
an AIC of 331.5 and a negative loglikelihood of 71.1. As opposed to the results from
the time-resolved experiment, here we can reject the replacement of the time dependent
proliferation by a generation dependent one. This is not surprising when we consider the
decreasing proportion of BrdU+ cells in the draining lymph node from day 3 to day 4
(Fig. 3.7).
2) The proliferation in the tumor cannot be replaced with a generation dependent
egress rate The proliferation in the tumor is left out and instead a generation dependent
egress rate is introduced to explain the large fraction of cells in higher generations in the
tumor. The tried generation dependent egress rate mechanisms are implemented in the
same way as it is done for the alternative models of the time-resolved experiment in 4).
All fitting results with these model structure modifications are within an ∆AIC= 0.5,
i.e. perform similar, but are far worse than the fit with our basic model structure. The
slope of the linear and exponential increase is estimated to be small, indicating that the
generation dependence is not needed.
We obtain an AIC of 282.7, a negative loglikelihood of 41.5 and a ∆AIC of 23.8.
As opposed to the results from the time-resolved experiment, here we can clearly reject
this possibility to replace the proliferation in the tumor and thus, have an indication of
a continued proliferation in the tumor.
3) A time dependent increase of the proliferation rate in the tumor cannot be re-
jected The increasing number of BrdU+ cells in the tumor induced us to check whether
a time dependent exponential increase of the proliferation rate can improve our fit. Some
improvement is achieved, but as the model is more complex the AIC is slightly worse
(∆AIC = 0.8, AIC = 259.7 and negative loglikelihood = 31.8). As the initial prolif-
eration after antigen encounter and priming is thought to be fast [135, 102, 136], an
increasing proliferation rate over time is unexpected and we decide for a constant prolif-
eration.
4) A time dependent egress rate as is used in the basic model structure of the time-
resolved experiment and a generation dependent egress rate cannot be rejected
We try whether the introduction of a time dependent logistic increase of the egress rate,
which is part of the basic model structure of the time-resolved experiment, improves the
fit. We find that it improves the fit, but due to the increased complexity the AIC is worse
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by ∆AIC = 2.5 (AIC = 261.4, negative loglikelihood = 29). An exponentially increasing
generation dependent egress rate is tested as well, since it could not be rejected, while
testing alternative models for the time-resolved experiment. We find, that it improves
the fit less than the time dependent egress and—albeit being the less complex model—
the AIC is worse. The difference to the fit with the basic model structure is ∆AIC = 4.9
(AIC = 264, negative loglikelihood = 34), such that out of these two egress rate options
the time dependency is more likely, but still performs worse than the fit with the basic
model structure.
Although we thus stay with the simpler model, i.e. a constant egress rate over time, it
is interesting to note that there is evidence for the time dependent egress rate mechanism,
which is employed in the time-resolved experiment. But due to the small time window
in which the measurements are performed and the lack of further information about the
dynamics, this can neither be confirmed nor rejected.
5) A division stop mechanism improves the fit slightly The division stop mechanism
is confirmed in the alternative models for the time-resolved experiment and we therefore
decide to test this for the proliferation-resolved experiment, too.
Looking at cell division profiles a division stop before the 6th generation does not make
sense. So we test a division stop for both compartments after six divisions, a division
stop only in the draining lymph node as well as a division stop after six generations in
the draining lymph node and two further divisions in the tumor (“Gen 1 - 6” and “Gen
+2”). The latter is motivated by the basic model structure used for the time-resolved
experiment. The exclusive proliferation stop in the draining lymph node is motivated
by the dynamics of the fraction of BrdU+ cells, see Fig. 3.7, which points at an attenu-
ated proliferation in the draining lymph node and a continued proliferation in the tumor
respectively. The division stop after six generations in both compartments worsens the
AIC by ∆AIC = 2.4 and the division stop, which only takes place in the draining lymph
node improves the AIC by ∆AIC = 1 (AIC = 258 and negative loglikelihood = 34.3),
which is an indication for this model, but by no means significant. To introduce a gener-
ation stop just after the generations, which we are able to observe, seems arbitrary and
as the difference is small, we decided for the default option of a continued proliferation.
Nevertheless we take from this, that a division stop mechanism is not unlikely in this
experiment, too.
3.2.3. Model selection for the identification of treatment induced changes
In the previous sections 3.2.1 and 3.2.2 the basic model structure is constructed such that
separate fits to the data from control and treatment work well, which result in indepen-
dently optimized parameter sets. We now ask the question, in which way the anti-CD40
treatment is reshaping the OT-I T cell response. With regard to our model this means,
that we would like to find the parameters θdiff (treatment-dependent parameters), which
need to be different for the treatment and control, when fitting the basic model struc-
ture to both data sets simultaneously. As mentioned in the introduction to this section
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(section 3.2) fitting both data sets simultaneously gives rise to a group of nested models:
These differ with respect to the parameters, which are assumed to be different between
the treatment and the control. If we have r parameters in our basic model structure, we
obtain 2r nested models, as each parameter θ = (θ1, θ2, ..., θr) can set to be either the
same or different.
Forward selection As the fitting procedure of a single model is time intensive, a forward
selection is applied [141, 142], which identifies locally optimal models among a set of
nested models. In general, out of a set of nested models one starts with the simplest
model and the complexity of the model is increased in each round. In every round all
possible additional parameters are tried one by one and the best combination(s) are
kept and taken into the next round, where again all kept combinations are tried with all
possible additional parameters.
In our case, the simplest model is the model, where the same parameters are used to
fit the data of the treatment and control setting. Additional parameters are introduced
by allowing parameters to be different between the treatment and control. Whether
one only takes the best model or considers more combinations in each round (e.g. all
within an ∆AIC ≤ 10 of the best model) is determining how global the search is. In
this model selection all models within an ∆AIC ≤ 10 of the best model in each round
are considered. Computing the optimal negative loglikelihood of the model, where all
parameters are allowed to be different between treatment and control (referred to as a
full model), we learn the smallest possible negative loglikelihood, which can be expected
for any model complexity. Thus, we have a lower bound for the AIC, which can be
theoretically achieved in each round, i.e. for each model complexity, and we can stop,
when no further improvement of the AIC can be expected by an increased complexity.
Choice of the best minimal model After the forward selection we consider all models
within an ∆AIC ≤ 4 of the best model in terms of AIC. Like this we can consider all
models, which cannot be rejected [141]. Among these we choose the model with the least
complexity, to which we refer as the best minimal model (BMM).
For both experiments this model had two interesting features: It is unique in the
sense, that no other model of the same complexity is within ∆AIC ≤ 4 of the best
model. Furthermore, all parameters found to be different θdiff,BMM are a subset of the
θdiff of the other best models within ∆AIC ≤ 4. This confirmed that θdiff,BMM indeed
need to be different to describe the differences in the anti-CD40 treated setting.
In the following two sections (3.2.4 and 3.2.5) the BMMs of both experiments are
discussed, in the course of which the profile likelihood of the estimated parameters and
the prediction profile likelihood [143] of time-dependent parameters are calculated and
shown as well. The parameters are often presented as rates in 1/d or 1/h. Sometimes
their inverse is used, which is the expectation value of the corresponding exponentially
distributed waiting time, and is referred to as the “(average) waiting time” or “(average)
interdivision time”. The latter is used for the inverse of proliferation rates.
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3.2.4. Best minimal model for the time-resolved experiment
The treatment dependent parameters in our best minimal model (θdiff,BMM ) for the
time-resolved experiment are the parameter shaping the egress rate β and the undivided
cell number in the tumor.
For the global best model, which is ∆AIC = 1.8 better than our BMM, the θdiff
additionally includes the proliferation rate in the draining lymph node, i.e. pdLN,0 and α.
It predicts a higher initial proliferation rate, but a faster decay for the treatment. Calcu-
lating the integrated proliferation rate for this model, which determines the cell division
profiles (see section 2.3.1), we see that the proliferation is stronger for the treatment until
day 5.3.
It is also important to mention that just above the threshold of ∆AIC = 4 , we find
models of a similar complexity as our BMM, for which either edLN,max, pdLN,0 or α differ
in addition to the undivided cells in the tumor. In these models pdLN,0 is larger and α is
smaller for the treatment, indicating a slightly enhanced proliferation in both models.
This suggests that the effect of the CD40 treatment lies in curbing the outflux from
the draining lymph node and that it very likely affects the proliferation rate dynamics
as well. Surprisingly, we do not find a different activation rate to be improving the fit,
although we would have expected this, as CD40 has been thought to play a role in the
priming of CD8 T cells [44, 45, 46, 47].
Discussion of the fit and direct fit to the cell proliferation profiles
The difference in β between treatment and control leads to significant differences in the
shape of the egress rate on days 2-5 (Fig. 3.12d). The fit to the overall cell numbers
works well (Fig. 3.12a & b). The steep initial increase of the cell numbers from 0 in the
draining lymph node is mainly determined by the source term of 14000cells/d, after which
the proliferation and egress rate shape the dynamics. The increasing egress rate together
with the decreasing proliferation rate in the draining lymph node (Fig. 3.12c), explains
the attenuated increase of cells in the draining lymph node. However the decrease of
cells in the draining lymph node after day 3 in the control is not captured. In the same
way we see a decrease of the mean number of divisions and of highly proliferated cells
on the seventh day in the draining lymph node in the control. Although, these effects
are not strong, it could point towards a more complicated dynamics or mechanism, e.g.
a more complicated time dependent egress dynamic, an additional generation dependent
egress rate or a death rate of cells in higher generations. But with the activation and
proliferation rate in the tumor already not being identifiable, introducing additional
parameters leads very likely to an over-parametrization. A look at the shape of the
absolute cell number increase for treatment and control in the tumor suggests that this
dynamic dictates the initial dynamics of the egress rate. Other egress rate options, like
a generation dependent egress, have been tested with less success, see also section 3.2.2.
In any case, the smaller cell number in the tumor in the treated setting is very likely the
reason for the smaller egress rate.
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Figure 3.12 (previous page): Fit of the best minimal model to the data of the time-resolved
experiment. a) & b) Fit to the absolute cell numbers in the draining lymph node (green) and
tumor (red) for the a) control and b) anti-CD40 treatment. c) Estimated proliferation rate in the
draining lymph node, which is the same for control and treatment. Filled area indicates the 95%
confidence interval. d) Estimated egress rates for the control (solid) and treatment (dashed).
Filled area indicates the 95% confidence interval. e) - h) Fit (dots) and prediction (circles) of
the proliferation data. Only the color-bordered bars are used for fitting. e) Fitted and predicted
cell division profiles and f) fitted mean number of divisions of the control. g) & h) Analogous
plots for the treatment setting. Errors have been estimated and are indicated by error bars.
Experimental data: Lena Kranz and Mustafa Diken.
The fit to the proliferation data, i.e. the frequency of cells in the 0th, 5+th and 6+th
generation (Fig. 3.12e & g) and the mean number of divisions (Fig. 3.12f & h), overall
works well and are mostly within the estimated error bounds. But, as expected, the
predicted frequencies of the cell division profiles from generation 1 - 4 or 1 - 5 are off,
as we only use the mean number of divisions to inform the fit. As discussed in section
2.3.2, it is not unexpected that the solution of an ordinary differential equation predicts
a more variable distribution of the cell division profiles than what is measured, even
when the mean number of divisions coincides. Nevertheless, fitting the BMM to the cell
division profile directly, instead of fitting it to the mean number of divisions result in
a similar fit (see suppl. Fig. B.4) and parameter estimates, which are well within the
confidence intervals of the BMM (compare suppl. Tab. B.1 and Tab. 3.3). Only the
initial proliferation rate in the draining lymph node with pdLN,0 = 1.2 1/d is just above
the upper boundary of the proliferation rate estimate of the fit to the mean number of
divisions. It is compensated by a faster decay rate of the proliferation α = 0.35 cells/d.
Obtaining similar parameter values for different observables speaks for the robustness of
the model fit to the data.
Estimated parameter values Apart from the activation rate and the proliferation rate
in the tumor, most parameters are well confined by their confidence intervals, which
have been obtained by calculating the profile likelihood (Tab. 3.3 and Fig. 3.13). The
proliferation rate in the tumor is estimated to be fast with a mean interdivision time of
6h and no upper bound. 6h is possible, since an interdivision time of ≈ 5.3h has been
measured in strongly activated (i.e. vaccination + IL-2) T cells in the spleen of tumor
bearing mice [144] and there are studies, which report even faster proliferation rates [135].
In consequence, when we fitted our model, we set the upper bound of the rate pT to 51/d,
which corresponds to a lower bound for the interdivision time of 4.8h. Nevertheless, the
interdivision time appears short in this setting, which is discussed in section 3.3.
The activation rate has no upper bound, i.e. can be arbitrarily fast. This means
that the time to first division is predicted to be the same as the interdivision time of
the subsequent divisions in the draining lymph node. This furthermore means that the
estimated proliferation rate is likely an average of both rates with a slow initial rate
estimate of pdLN,0 = 0.73 1/d (interdivision time 33h). The fact that the confidence
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interval of the decay rate α does not comprise 0 indicates that the proliferation is also
attenuated over time. The upper limit of the egress rate edLN,max = 0.46 1/d (waiting
time 52h) is also rather slow, meaning that only a small part of the cells in the draining
lymph node enter the tumor.
The source term of 14000cells/d appears to be large but plausible, given the high number
of transferred cells (5·106 cells). And considering that on average we find 11000 undivided
cells in the blood on all days for the control setting and 3100 cells with an increasing
tendency in the anti-CD40 setting (average of all days: 11000 ± 1100cells/d and 3100 ±
900cells/d respectively, see also suppl. Fig B.2b), the estimated parameter fits into the
picture. The significantly smaller undivided cell number in the tumor for the treatment
setting (83 VS 1000 cells) reflects the data well until day 4, see suppl. Fig. B.2a. This
data is indirectly used in the fit, as the frequency of undivided cells and the absolute cell
number in the tumor are both used as observables.
Table 3.3.: Estimated rates for the BMM, time-resolved experiment
Parameter Control 95%CI anti-CD40 95%CI
source 14000 cells/d [9100; 20000] " "
activation 31.0 1/d [3.4; inf] " "
pdLN,0* 0.73 1/d [0.53; 1.1] " "
α* 0.30 1/d [0.13; 0.48] " "
edLN,0** 0.001 1/d [0.0002; 0.002] " "
β** 2.4 1/d [1.8; 3.3] 0.89 1/d [0.53; 1.3]
edLN,max** 0.46 1/d [0.17; 1.0] " "
pT 4.0 1/d [1.6; inf] " "
Undivided 1600 cells [860; 2400] 83 cells [37; 150]
cells, tumor
sdabs 0.41 [0.30; 0.63] " "
sdMDiv 0.50 [0.35; 0.76] " "
sdGen,dLN 0.12 [0.084; 0.19] " "
sdGen,T 0.044 [0.030; 0.087] " "
* see eq.(3.1) **see eq.(3.2)
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Figure 3.13 : Profile likelihoods of the best minimal model for the time-resolved experiment.
All values besides the activation and the proliferation in the tumor are well constrained. The
red line denotes the threshold for the 95% confidence interval.
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3.2.5. Best minimal model for the proliferation-resolved experiment
The treatment dependent parameters in our best minimal model (BMM) for the
proliferation-resolved experiment are again the egress rate and the undivided cell number
in the tumor. Additionally the activation rate is different between the treatment and the
control. As this differs from the result obtained for the previous experiment, we check
how well the model can fit the data, if all parameters can differ between treatment and
control except for the activation rate. This is done in addition to the forward selec-
tion. The AIC is, as expected, worse than the one of our BMM as this model has more
parameters (∆AIC > 30), but we also find that the negative loglikelihood is worse by
∆negLL > 10 than our BMM. This implies that any model with the same number of
parameters as the BMM and with the same activation rate in both treatment and control
can achieve at most a fit, which will still be worse by ∆negLL > 10. In consequence, the
same activation rate for the control and treatment setting can be excluded.
It is interesting to see that the BMM confirms our conclusion from the time-resolved
experiment of an attenuated egress rate due to the anti-CD40 treatment and furthermore,
adds the expected difference in activation/priming [44, 45, 46, 47].
Discussion of the fit and fit to the mean number of divisions
The model fit of the best minimal model to the data can be seen in Fig. 3.14. The
agreement of the model fit with the absolute cell numbers looks good and the errors are
estimated to be small (rel. error sdrel = 0.26). However, the decline in cell numbers in
the draining lymph node after day 3 in the control is again not captured and could point
towards an additional mechanism governing its dynamics. But the decrease is far less
pronounced than in the time-resolved experiment data. The initial increase of absolute
cell numbers in the draining lymph node is explained by the large source term with
2.2 · 104cells/d. After this initial increase the dynamic is determined by the activation,
proliferation and egress rate. The stronger activation and the smaller egress rate for the
treatment setting lead to a higher predicted number of cells in the draining lymph node
and a smaller predicted number of cells in the tumor. Indeed, the smaller egress rate
is very likely the consequence lower cell numbers in the tumor in the treatment setting
and the enhanced activation rate for the treatment is determined by the differences in
the cell divisions profiles, which contain more strongly proliferated cells in the treatment
data.
The fit to the BrdU+/- fraction of each generation in the cell divison profile is accept-
able (Fig. 3.14 d) & f)). We furthermore see that the lack of BrdU+ cells in the undivided
generation and the relatively high fraction of BrdU+ cells (compared to the BrdU- cell
fraction) in higher generations can be explained in large parts with our model assuming
a short BrdU availability and a simple proliferation, see also discussion in section 3.1.2.
In some cases the CFSE data cannot be analyzed, see section 3.1.2. This is the case
for the tumor on day 3.75 in the treatment. For the tumor on day 2.75 in both treatment
and control the CFSE data for BrdU+ and BrdU- cannot be analyzed individually, but
the combined data can be such that this is used for the fit. In these three cases we
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fit the overall fraction of BrdU+ cells (Fig. 3.14 e & g, solid line). The agreement of
the fit with the data is mediocre, as opposed to the predicted frequencies (Fig. 3.14 e
& g, dashed line). The latter is not surprising as already the BrdU+/- frequencies in
individual generations are fitting well (Fig. 3.14 d & f).
Fit to the mean number of divisions It could be assumed that the fit to the overall
BrdU+ fraction in the tumor is neglected at the cost of fitting each generation individ-
ually. To test this we fit only the mean divison number and the overall BrdU+ fraction,
but the result looks similar (see suppl. Fig. B.5). In addition, for this fit all but one
parameter are well within the confidence interval of our BMM estimates (compare suppl.
Tab. B.2 to Tab. 3.4). Only the progression rate through the S phase in the fit to the
mean number of divisions is slightly slower (2.7 1/d) than the lower bound of the confi-
dence interval (2.8 1/d). Thus, the poor fit to the BrdU+ fraction in the tumor is not
a consequence of our choice of observables and we see that the fit is robust under the
change of observables.
Table 3.4.: Estimated rates for the BMM, proliferation-resolved experiment
Parameter Control 95%CI CD40 95%CI
source 22000 cells/d [14000; 26000] " "
activation 1.1 1/d [0.94; 1.3] 3.9 1/d [2.9; 6.2]
pG1,dLN,0* 10 1/d [7.5; 15] " "
α* 1.3 1/d [1.1; 1.5] " "
pS 3.1 1/d [2.8; 3.5] " "
edLN 0.31 1/d [0.23; 0.43] 0.035 1/d [0.023; 0.065]
pG1,T 1.7 1/d [1.1; 2.2] " "
Undivided 17000 cells [11000; 26000] 1600 cells [280; 3500]
cells, tumor
sdabs 0.26 [0.17; 0.47] " "
sdGen,dLN 0.011 [0.0091; 0.014] " "
sdGen,T 0.064 [0.049; 0.087] " "
* see eq.(3.1)
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Figure 3.14 (previous page): Fit of the best minimal model to the data of the proliferation-
resolved experiment. a) & b) Fit to the absolute cell numbers in the draining lymph node (green)
and tumor (red) for the a) control and b) anti-CD40 treatment. c) Estimated proliferation rate
in the draining lymph node, which is the same for control and treatment. Filled area indicates
the 95% confidence interval. d) Fitted (line) cell division profiles (bars) for the control setting.
If available, the fraction of BrdU+/- cells is fitted (solid line/dashed line) for each generation
otherwise the combined fraction is fitted (dotted line).1 e) Fitted (solid line) and predicted
(dashed line) total fraction of BrdU+ cells for the control setting. This is only fitted if the
BrdU+/- fractions are not available for single generations. f) & g) Analogous plots for the
treatment setting. Errors have been estimated and are indicated by error bars. Experimental
data: Lena Kranz and Mustafa Diken.
Estimated parameter values All parameters are well constrained by confidence inter-
vals which have been obtained by calculating the profile likelihood (Tab. 3.4, and Fig.
3.15). The initial proliferation rate in the draining lymph node is reasonably fast: Adding
the initial waiting time of the G1 phase (2.3h) and S/G2/M phase (7.8h), we obtain a
waiting time of 10.1h. This is very similar to the cell cycle phase times for activated OT-I
T cells in ref. [126], where they found an interdivision time of 10.1h and the length of the
S/G2M phase to be ≈ 7.2h. At the first measurement time point (2.75d), however, we
already have very slowly cycling cells with a waiting time of 96h, which implies that the
proliferation came almost to a halt at that point. The interdivision time in the tumor
of 22.3h is rather slow for activated T cells, but within a reasonable range if we consider
the immunosuppressive environment of tumors. Both proliferation rates are discussed in
more detail in section 3.3.
The egress rates of 0.35/d and 0.035/d are slow, but comparable to the rates estimated
with the best model fit to the first melanoma experiment.
The significantly smaller undivided cell number in the tumor for the treatment setting
reflects the data well, see suppl. Fig. B.2a. This quantity is indirectly fitted, as the
frequency of undivided cells and the absolute cell number in the tumor are both used as
observables.
The estimated influx of undivided cells into the draining lymph node with 2.2 ·104cells/d
seems high. But regarding the high number of transferred cells (5 · 106 cells), this is less
surprising. Furthermore, this influx rate is far smaller than the undivided cell number
found in the blood on both days with an average number of 1.2 · 105 ± 3 · 104cells/day in
the control setting and 105±2.9 ·104cells/day in the treatment setting, see also suppl. Fig.
B.2b. This makes the influx rate plausible.
We can further calculate the time to first division by adding the waiting times for the
activation and for division in the draining lymph node. We find that the time to first
division in the control of 32h agrees very well with the literature, where it is reported to
be between 24h and 48h [123, 145, 146]. However the time to first division predicted in
the treatment setting with 16h (CI: [14, 18]h) is quite fast.
1For each cell division profile we fit all fractions but one.
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Figure 3.15 : Profile likelihoods of the best minimal model for the proliferation-resolved ex-
periment. The red line denotes the threshold for the 95% confidence interval.
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3.3. Comparison of the results obtained from the melanoma
mouse model experiments
In this chapter we considered two distinct experimental data sets to inform our math-
ematical model: We have data from the time-resolved experiment (Exp. 1), where the
measuremnt time points span 5 days, and data from the proliferation-resolved experi-
ment (Exp. 3), where the measurment time pooints only span one day, but where we have
additional information on the proliferation. As expected the data of these experiments
exhibit some differences, e.g. in the absolute cell numbers of the recovered OT-I T cells,
the tumor sizes and the cell division profiles. Especially the absence of cells in higher
generations in Exp. 1 is remarkable. This leads to different basic model structures and
raises the question to what extent the mechanisms that determine the dynamics of the
OT-I T cells in the two experiments differ. This is discussed in the first part 3.3.1.
These differences between the experiments complicate the finding of commonalities of
the OT-I T cell dynamics and common effects of the anti-CD40 treatment. Still, already
by taking a closer look at the data we found similar tendencies in both experiments: 1) an
attenuated proliferation in the draining lymph node, which is contrasted to an ongoing
proliferation in the tumor 2) higher numbers of OT-I T cells in the tumor for the control
data 3) a higher number of divisions in the treatment data and 4) lower fraction of
undivided cells in the draining lymph node in the treatment data. To some extent these
dynamics and treatment induced differences are reflected in the best model fits: In both
experiments the proliferation dynamic in the draining lymph node is decreasing, while we
have a continued proliferation in the tumor. A curbed egress rate due to the treatment is
predicted in both experiments and an enhanced activation rate for the treatment setting
is predicted by the third experiment. How these largely concurring parameter estimates,
conclusions and selection of models for both experiments compare in detail and how this
is determined by the available data, is discussed in the second part, section 3.3.2.
3.3.1. Adaptations of the model and differences between the experiments
Differences in the experimental data lead to adapted models. Here we can distinguish
between simplifications and changes to the model structure, which do not necessary point
at different mechanisms, but need to be discussed here.
Simplifications are made where a less complex model fits the data similarly well. Al-
though there is evidence for a time dependent egress rate in the third experiment, it is not
necessary to describe the data, as only two consecutive time points have been measured.
Similarly it is unnecessary to distinguish between cell cycle phases in an experiment where
no BrdU has been measured, which could inform the length of the different phases.
A change to the model structure is done for the basic model of the time-resolved
experiment. In the respective data, we can see a sudden decrease of cells in higher
generations, which entails the necessity of a division stop mechanism in both organs in
addition to a time dependent decrease of the proliferation rate in the draining lymph
node. In principle, the idea that either only generation or time dependent mechanisms
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can explain the dynamics is neat, as we do not have to combine two different mechanisms.
But for this experiment using only a time dependent proliferation without a division
stop does not work. And the attempt to replace the time dependent proliferation with
generation dependent mechanisms cannot be rejected but worsens the fit (see section
3.2.2). In the third experiment, the BrdU measurements provide clear evidence of a time
dependent proliferation rate. Here, the time dependence cannot be replaced with only a
generation dependent proliferation, see section 3.2.2. Interestingly, although no division
stop mechanism is needed for the third experiment, we also see evidence of an additional
proliferation stop at a later generation than in the first experiment (after six divisions),
especially in the draining lymph node.
Overall, this leads to the conclusion that a time dependent decrease and very likely
a generation dependent stop is governing the proliferation rate in the draining lymph
node in both experiments but to different degrees. Similarly, a generation stop in the
tumor is likely in both experiments, but again to different degrees. In consequence, we
use both mechanisms for the time-resolved experiment and for the proliferation-resolved
experiment it suffices to only implement the time dependency, but this choice does not
imply a fundamental difference of mechanisms between the experiments. It is for example
conceivable that the higher tumor burden postpones the proliferation stop to a later
generation in the proliferation-resolved experiment.
3.3.2. Comparison of the parameter estimates
In spite of the differences between the experiments, fairly similar conclusions can be
drawn from the model fits to both experiments. In the following parameter estimates are
compared.
Egress rate Both experiments agree in so far as they confirm a curbed flux from the
draining lymph node to the tumor due to the treatment with anti-CD40. In addition,
the ratio between the egress rates of treatment and control are in the same range, see
Fig. 3.16b, with an average of 13.6 for the Exp. 1 and 8.8 for the Exp. 3.
But the initial dynamic of the egress rate varies, as we assume a constant rate in
the third experiment and a time dependent one in the first experiment, see Fig. 3.16a.
Substantiating a time dependent rate for the third experiment is difficult, as we only
have measurements from two consecutive days (time points indicated by red triangles
in Fig. 3.16a). Indeed, the introduction of this mechanism leads to a worse AIC. But
this difference (∆AIC = 2.5, see section 3.2.2) is small and the negative loglikelihood is
improved, i.e. the fit improves, which provides evidence for a time dependent egress rate
after all.
At the time points, where the third experiment was measured, days 2.75 and 3.75,
the egress rates are similar between the experiments (Fig. 3.16a), which leads to the
assumption that the egress rates in both experiments are conform, if they can be assessed.
For both experiments, we have more evidence for a time than a generation dependent
egress rate, but the difference is small. This is not surprising as the time and generation
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Figure 3.16 : Comparison of estimated egress rates between both experiments. a) Predicted
egress rate for treatment and control. b) Ratio of the estimated egress rates between control and
treatment.
dependent egress rate have a similar effect: An egress in higher generations implies an
egress at later time points and hence, both model predictions point at a similar mecha-
nism. With the evidence provided from testing both alternatives for both experiments,
it makes sense to focus on the time dependent mechanism, while keeping in mind that
the generation dependency is a possible explanation as well.
Proliferation rate For both experiments the average waiting time until proliferation is
shorter in the tumor with 6h (Exp. 1) and 22.3h (Exp. 3) than in the draining lymph
node, if the initial proliferation rate, which quickly decays in the draining lymph node, is
disregarded: In the first experiment the initial time to division is 33h and reaches 74h on
day 2.75. In the third experiment the initial time to division is 10.1h and increases rapidly
to 96h on day 2.75, see Fig 3.17. Thus, the estimates from both experiments agree that
the proliferation in the draining lymph node is slow after an initial rapid proliferation
phase. Indeed, an attenuated proliferation rate over time in the draining lymph node in
response to an immunogenic graft is reported in ref. [134]. It is also possible that due to
the large number of cells flooding the draining lymph node, a repeated encounter with
their antigen becomes unlikely at later time points and hence, many become inactive.
Compared to the large number of OT-I T cells in the draining lymph node, only few and
very likely active OT-I T cells enter the tumor, where they proliferate more strongly.
In any case, it is interesting to note, that the proliferation in the tumor is not only
needed to explain the data (see section 3.2.2) for both experiments, but that it is relatively
fast. This confirms the response of T cells reported in ref. [134] very nicely: In this study
Sutherland et al. claim that T cells are stimulated to have a “mezzanine” response in an
inflamed tissue due to the antigen presentation by parenchymal cells, which is distinct
from the primary and the secondary response of the immune system to an acute infection.
It is hard to judge how plausible the proliferation estimates are as it has not been
studied for this particular system, but one can put it into relation with studies of activated
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Figure 3.17 : Comparison of estimated interdivision times for both experiments
T cells. T cells are among the fastest dividing cells in the human body. In a B16 tumor
study, where T cells were treated with IL-2 and immunized with the tumor antigen,
they are reported to have an average interdivision time of only 5.3h [144] in the spleen.
But, in general activated and stimulated T cells in vitro and in vivo are reported to
have larger interdivision times of ≈ 8h − 13h, [125, 126, 102]. As no other immuno-
stimulatory agent apart from anti-CD40 has been applied in our system, we would expect
the proliferation to be in this range or slower, especially as tumor environments are known
to be immunosuppressive [139, 140]. Due to this considerations the 6h interdivision time
in the tumor for our time-resolved experiment seems slightly too fast and at odds with
the proliferation stop after a few divisions. On the other hand, the initial proliferation
rate in the draining lymph node of the proliferation-resolved experiment (10.1h) is well
within the expected range. In general, there is more reason to believe that the estimates
from the proliferation-resolved experiment are more accurate: First, the proliferation
parameters are better confined by the data, i.e. better identifiable (see Tab. 3.4), which
is probably due to the proliferative information obtained from both the BrdU and CFSE
staining. Secondly, our estimated length of the S/G2/M and G1 phase of 7.8h and 2.3h
agrees well with the directly measured interdivision time of stimulated OT-I T cells in
vitro [126], where the S/G2/M phase is claimed to occupy 72% of the average cell cycle
time of 10.1h. Although we do not follow the idea of a linear relationship between the
cell cycle length and the S/G2/M phase, see also refs. [127, 137, 112], this renders us
confident with the estimations obtained from the proliferation-resolved experiment.
Activation rate We would expect an enhanced activation in the anti-CD40 treated
group due to the reported importance of CD40 for T cell priming. In the time-resolved
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experiment we can unfortunately not identify this parameter. It can be arbitrarily fast
meaning that the rate of the first division in the draining lymph node is the same as
the general proliferation rate. As the time to first division is known to be larger than
the interdivision times of the following divisions [123, 145, 146], this again confirms that
the estimates of proliferation related rates might not be very accurate for the time-
resolved experiment. In contrast, the best fit to the proliferation-resolved experiment
predicts distinct and identifiable activation rates for treatment and control, where the
activation rate is four times larger for the anti-CD40 treated group. The improved
identifiability of the activation rate (and also of the proliferation rate in the tumor) in
the proliferation-resolved experiment is very likely due to the information contained in the
combined measurements of CFSE and BrdU. This turns out to be a useful combination
to understand proliferative dynamics.
Source term and undivided cell numbers We predict a high and continued influx of
cells into the draining lymph node in both experiments (Exp.1: 14000 1/d and Exp.3:
22000 1/d, see Tab. 3.5). This is likely the consequence of a high number of transferred
cells (5 million OT-I T cells). The rate, furthermore, does not exceed the number of
undivided cells in the blood, apart from the treatment setting in the first experiment
(see suppl. Fig. B.2b), which makes the influx rate plausible. The absolute numbers of
undivided cells in the tumor, of which we do not know whether they are an artefact, are
fitted well (Exp. 1, control: 1600 cells, Exp. 1, treatment: 83 cells, Exp. 3, control: 17000
and Exp. 3, treatment: 1600 cells, see Tab. 3.5 and suppl. Fig. B.2a). Interestingly, in
both experiments the number of undivided cells in the tumor is larger by an order of
magnitude for the control, which coincides with the generally higher cell numbers in the
tumor in the control setting. As the latter is explained by a larger egress rate, the same
explanation might be determining the numbers of the undivided cells, too. But a mere
egress of the activated undivided cells from the draining lymph node to the tumor in our
model could not explain the data (tried for the first experiment, not shown).
Both, the undivided cell number in the tumor as well as the source term, are larger
for the proliferation-resolved experiment, which reflects the higher cell numbers in the
tumor (see Fig. 3.2b).
61
Chapter 3. T cell dynamics in a melanoma mouse model
Table 3.5.: Table comparing selected parameters estimate from Exp. 1 and Exp. 3
Data source activation Interdiv. Time Interdiv. Undiv. cells
time* in to egress* time in tumor
[cells/day] [h] dLN [d] [d] tumor [h] [cells]
Contr Exp1 14000 0 3.6 2.9 6 1600
CD40 Exp1 " " " 92 " 83
Contr Exp3 22000 22 7.5 3.2 22 17000
CD40 Exp3 " 6.1 " 28 " 1600
*on day 3.25
3.3.3. Concluding remarks on the results of the melanoma mouse model
Although the decreased number of OT-I T cells in the tumor for the treatment setting
is unintuitive, this feature has been confirmed in all three experiments. The resulting
curbed influx into the tumor, which is predicted by both best minimal models, is at
first surprising, as this does not seem to reflect an enhanced tumor response. On the
other hand we observe more proliferated cells in the treatment setting, especially in the
proliferation-resolved experiment. This is confirmed by the best fitting models which
reveal an elevated activation rate (proliferation-resolved experiment) and evidence of an
increased proliferation (time-resolved experiment). These are plausible effects of an anti-
CD40 treatment on T cells which can be found in the literature [63, 62, 47, 44]. Putting
this together we draw the conclusion that the anti-CD40 treatment activates T cells more
strongly and induces a prolonged residence in the draining lymph node. Unfortunately,
when we checked for the surface markers CD27 and CD62L, we could not see a clearly
distinct dynamics between treatment and control (see suppl. Fig. B.3). But we see a
tendency towards a smaller fraction of CD27hi cells in the treatment setting either in the
tumor (Exp. 1) or in the draining lymph node (Exp. 3). The loss of CD27 is correlated
with the acquisition of a terminal effector phenotype [148, 149]. Taken together, one can
speculate that the prolonged residence can contribute to a more strongly activated and
arguably more terminal effector like phenotype. Whether these cells contribute better
to a T cell mediated antitumor response, of course, would need further investigation
and cannot be concluded from our conclusions so far or the diminished tumor growth
alone. The early growth inhibition of the tumor might alternatively also be a result of
the anti-CD40 acting on other immune cells in the tumor environment.
Independently of the anti-CD40 effect, we found that T cells divide fast in the tumor
for a minimum of two divisions and very likely even more. It is expected that T cells
continue to divide at the site of inflammation [134], yet a faster proliferation than in
the draining lymph node given the suppressive environment for T cell proliferation is
unexpected [150, 151].
62
CHAPTER 4
T cell dynamics in a pancreatic ductal adenocarcinoma mouse model
In this chapter we discuss and mathematically model the early dynamics of a T cell
tumor response and the effects of an agonistic anti-CD40 treatment on this dynamics
in a pancreatic ductal adenocarcinoma (PDAC) setting. Both the experiments and the
model are motivated by our investigation of the T cell response in a melanoma setting in
chapter 3. In this way we can compare the model predictions calibrated with data from
the non-orthotopic melanoma experiments with the results from an orthotopic pancreatic
cancer model.
Three PDAC experiments were conducted by our collaboration partners, where the
first experiment only comprises untreated mice and is analyzed at three measurement
time points. The second and third have a treatment and control group. The measurement
time points were motivated by our experiences with the melanoma experiments and the
first PDAC experiment. In general the experiments were of an explorative nature, with
a tumor cell line, which has been developed by our collaboration partners and few mice
per time point and treatment group. Hence, it is not our aim to develop an entirely new
model, but to test whether a similar model to the one established in chapter 3 can also
describe this data. This way, we intend to understand differences caused by the variation
of the tumor site and the tumor itself. In addition, with a model selection we retrieve
again the parameters which are significantly influenced by the treatment and compare
this to what we found for the melanoma setting. For this reason only data from the
second and third experiment are modeled, where we have data from both treatment and
control.
The first section 4.1 presents and discusses the data. The second section 4.2 discusses
the chosen model structure, other model alternatives, which have been considered, and
presents the best model fits for both experiments. The final section 4.3 reviews the
suitability of the data for this analysis, summarizes the insights obtained from modeling
and compares it to the results from the analysis of the melanoma experiment.
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All experiments in this chapter have been conducted by Susann Wendler, Aaron Ro-
driguez Ehrenfried and Isabel Poschke at dkfz (German Cancer Research Center) in
Heidelberg, Germany. The tumor cell line has been provided by Daniel Baumann and
additional experimental support was given by Daria Jaeger. The experiments and the
analysis of the flow cytometry data were jointly consulted with Isabel Poschke in order
to obtain adequate data for modeling.
4.1. Results of the pancreatic ductal adenocarcinoma mouse
experiments
4.1.1. Experimental setup
Our collaboration partners developed the pancreatic tumor cell line, which is taken from
genetically engineered mice expressing a mutated tumor supressor gene p53 and a proto-
oncogene Kras in the pancreas. By repeated injections of the cholecystokinin analogue
cearulein, which stimulates pancreatic secretion, a chronic pancreatitis was induced lead-
ing eventually to the development of a tumor. The particular tumor cell line, 30364-OVA,
was chosen due to its similarity to the human PDAC with respect to the histopathology.
It was subsequently engineered to express Ovalbumin via retroviral transfer such that it
has a mediocre immunogenicity.
In three experiments one million cells of 30364-OVA were injected orthotopically into
mice and the size was monitored via PET scan. The scan turned out to be hard to
interpret as signals were often diffuse. In consequence reliable tumor size data could not
be obtained. Nevertheless, the PET scan information was used to get a rough estimate of
the tumor sizes and after 31 to 38 days 5 · 106 CFSE-dyed OT-I T cells, which recognize
an Ovalbumin derived peptide, were injected intravenously, see Fig. 4.1. The number of
transferred cells was chosen to be high such that enough cells can be recovered for a sound
statistical analysis. On the same day, which is referred to as day 0, mice in the second and
third experiment were divided into two groups and received either an agonistic anti-CD40
antibody (3/23 mIgG1) or a control (PBS) intraperitoneally. Since the antibody, the
sequence of which was obtained from Prof. Martin Glennie (University of Southampton),
has a mouse and not a rat derived Fc part as opposed to the commercially available clone
3/23, it is less immunogenic and can be given several times. Here, the injection of 400µl
anti-CD40 was shared over two days (day 0 and day 1).
Samples from the blood, the tumor and two draining lymph nodes were read out on
day 2, 3 and 4 for the first experiment, 2 and 3 for the second experiment and 3 and 4
for the third experiment, which left us with 1-4 mice per time point and treatment group
(Fig. 4.1). Subsequently, the OT-I T cells and endogenous T cells in the samples were
identified and analyzed with flow cytometry. The cell numbers were extrapolated with
true count to the whole sample and eventually to the whole organ. In this context the
blood volume of a mouse was estimated to 1500µl. The proliferative information was
gained by recording the CFSE intensity with flow cytomertry and analyzing this data
with the methods introduced in section 2.1.
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Figure 4.1 : Overview over the PDAC experiments. The number of available mice at different
time points in the control (black) and treatment (orange) groups are indicated. Experiments
conducted by Susann Wendler, Aaron Rodriguez Ehrenfried and Isabel Poschke.
The exact times when the samples were taken are 7h less than specified in Fig. 4.1.
In all figures and calculations this is taken into account. The PDAC experiments are
numbered with roman numerals.
4.1.2. Changes induced by the anti-CD40 treatment and common
features of the experiments
Generally the data is sparse, as we do not have many analyzable mice per sample group,
i.e. samples from the same organ, with the same treatment and taken at the same time
point, see Fig. 4.1. For this reason data obtained from only one sample, i.e. one mouse,
is shown as well—without standard deviations—such that one can discern tendencies.
Furthermore, many samples do not have enough cells for our CFSE data analysis (> 15
cells). If we only have one mouse in a sample group we furthermore require the number
of measured cells to be greater than 50 for the CFSE analysis to be reliable. An overview
of the number of analyzable samples per sample group is given in Tab. 4.1. The number
of generations that can be distinguished for different organs, days and experiments are
found in the Tab. 4.2.
Absolute cell numbers In general, as opposed to experiment I, experiment II and III
have similar total cell numbers (see Fig. 4.2a and 4.2b). But the distinct dynamics of the
cell numbers in the treatment compared to the control in the tumor in experiment III is
curious, as this is not reflected in experiment II. The same holds for the opposing dynam-
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Table 4.1.: Number of samples available for CFSE intensity analysis in every
sample group
Experiment Day 2 Day 3 Day 4
dLN tumor dLN tumor dLN tumor
Exp 1 control 4 1 3 3 3 3
treated - - - - - -
Exp 2 control 2 1 1 1 - -
treated 3 0 2 3 - -
Exp 3 control - - 2 - 2 2
treated - - 3 1 3 -
Table 4.2.: Number of distinguishable generations in the CFSE
intensity analysis
Experiment Day 2 Day 3 Day 4
dLN tumor dLN tumor dLN tumor
Exp 1* 0-4 0-4 0-4 0-4 0-4 0-3
Exp 2* 0-4 0-3 0-3 0-3 - -
Exp 3* - - 0-5 0-5 0-5 0-5
*A distinction between treatment and control is not necessary for the
number of distinguishable generations, as the CFSE brightness should
be the same.
ics in the draining lymph node for experiment II, which is not reflected in experiment
III. This hints at a high variability of the absolute cell number measurements.
The decreased OT-I T cell numbers in the tumor for the treatment setting, which is
observed in the melanoma experiments, can only be suspected in the second experiment
(Fig. 4.2b). Equally, a treatment induced decrease of the tumor weight is only seen in
the second experiment, but not in the third (Fig. 4.3a). However, a treatment induced
effect is also far less clear if we only consider the tumor weights instead of the size in
the melanoma experiments (not shown). But unfortunately size measurements are not
available for the PDAC experiments, since the PET scan cannot be trusted.
A shared property with the results from the melanoma experiment is that the absolute
number of OT-I T cells in the tumor reflects their density in the tumor (Fig. 4.3b).
Cell division profiles In the draining lymph node we see an ongoing proliferation from
day 1.7 to day 2.7 in experiments I and II (Fig. 4.4 and Fig. 4.5). The change is less
pronounced from day 2.7 to day 3.7 in experiments I and III (Fig. 4.4 and Fig. 4.6). In
the tumor we also see a change from day 1.7 to 2.7 (Fig. 4.4 and Fig. 4.5, lower panel)
and from day 2.7 to 3.7 the proliferation seems to be attenuated as well. However, the
seemingly smaller difference between the cell division profiles of day 2.7 and day 3.7 is
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Figure 4.2 : Absolute numbers of OT-I T cells in a) draining lymph node and b) tumor for
control (solid) and treatment (dashed) in Exp. I (light blue), Exp. II (orange) and Exp. III
(purple). Experimental data: Susann Wendler, Aaron Rodriguez Ehrenfried and Isabel Poschke.
less certain, since the cells are already highly proliferated such that changes are not well
distinguishable.
In experiments II and III we can perceive that cells in the treatment setting have
proliferated stronger, especially in the draining lymph node. In order to be able to
compare these profiles between experiments, we consider the fraction of cells in the
generation 4+ directly (see Fig. 4.7), since three is the highest number of divisions that
can still be resolved by the CFSE analysis in all experiments. We see that the fraction of
highly proliferated cells are larger in experiment III in the draining lymph node, especially
in comparison to experiment II. Curiously we see the opposite tendency, when looking
at the proliferated cells in tumor. However, for the tumor reliable conclusions cannot
be drawn, as we have only one mouse for experiment II and III in the control setting
and all cells are in the generation 4+ in the treatment. From the observation of the
proliferation in the draining lymph node we conclude that the data—although exhibiting
similar characteristics—are not very well comparable and cannot be pooled.
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Figure 4.3 : a) Tumor weight and b) OT-I T cell density in the tumor for control (solid) and
treatment (dashed) in Exp. I (light blue), Exp. II (orange) and Exp. III (purple). Experimental
data: Susann Wendler and Aaron Rodriguez Ehrenfried and Isabel Poschke.
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Figure 4.4 : Cell division profile of the first experiment (only control). For reasons of better
comparability the profile on day 3.7 in the tumor is shown until Gen. 5+. Experimental data:
Susann Wendler and Isabel Poschke.
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Figure 4.5 : Cell division profile of the second experiment for control (left) and treatment
(right). For reasons of better comparability the profile on day 1.7 in the draining lymph node is
only shown until gen. 4+. For the fit gen. 4 is distinguished from gen. 5+. Experimental data:
Susann Wendler and Isabel Poschke.
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Figure 4.6 : Cell division profile of the third experiment for control (left) and treatment (right).
Experimental data: Susann Wendler, Aaron Rodriguez Ehrenfried and Isabel Poschke.
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Figure 4.7 : Frequency of cells in generation 4+ in the a) draining lymph node and b) tumor in
Exp. I (light blue), Exp. II (orange) and Exp. III (purple). Experimental data: Susann Wendler,
Aaron Rodriguez Ehrenfried and Isabel Poschke.
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4.2. Mathematical model describing the T cell dynamics in
a pancreatic cancer mouse model
In chapter 3 we developed a mathematical model describing the T cell response to the
subcutaneously injected melanoma cell line B16/OVA. By fitting a similar model to the
data from an orthotopic pancreatic ductal adenocarcinoma (PDAC) mouse model we aim
at understanding differences caused by the changed tumor site and tumor. Furthermore,
we pursue the question in how far the model fit can reveal treatment induced changes
and how these compare to the ones found in the melanoma mouse model fit. As only
experiment two and three had both treatment and control, we analyze these.
First, in section 4.2.1 we present the “basic model structures” for fitting the OT-I T
cell dynamics in both PDAC experiments. With the term “model structure” we refer
to a set of differential equations and observables. The “basic model structure” is the
model structure, which returns a good fit to both the treatment and control data and
is used for further analysis. Subsequently, in section 4.2.2, we discuss alternative model
structures, which we considered. Fitting the “basic model structure” to the treatment
and control data simultaneously gives rise to many nested models. These differ with
respect to the parameters, which are allowed to be different between the treatment and
the control setting. The best model among these is decided on with a model selection
and we can conclude whether different parameter estimates are required for explaining
the treatment and control data. The model selection and the results of the best model
fits are discussed in the section 4.2.3 for the second experiment and in section 4.2.4 for
the third experiment.
4.2.1. Basic model structure construction
Starting from the existing model structures found in the melanoma mouse experiment
(see section 3.2.1) we introduce extensions and simplifications with which we arrive at a
basic model structure, which can fit the treatment and control data independently, see
Fig. 4.8. These adaptations are discussed in the following. A more thorough discussion
of alternative model structures is found in the next section 4.2.2.
Undivided cells in the tumor and observables We first test whether undivided cells in
the tumor are needed to describe the data with our model. Since there are no undivided
cells in the tumor in the third experiment, we omitted the respective parameter as well
as the observable, i.e the fraction of undivided cells in the tumor. By not having this
parameter we implicitly assumed it to be zero and thus not contributing to the abso-
lute cell number in the tumor. In the second experiment we have a small fraction of
undivided cells in the tumor, especially on day 1.7 (see Fig. 4.5) and we aim to find out
whether the parameter for the undivided cells in the tumor is needed. To this end, we
test two alternative model structures by fitting them to the treatment and control data
simultaneuosly: one with the undivided cells as a parameter and the other, where this
parameter is fixed to zero. For both fits the observable for the undivided fraction of cells
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in the tumor is used and all parameters are allowed to be different between treatment
and control except for the errors and the source term. This is the most general choice of
parameters, as we do not expect these parameters to be changed by the treatment. The
option with the undivided cells only improves the fit slightly, but has a decidedly worse
AIC (∆AIC= 16.8), due to the added complexity. Thus, in the basic model structures for
both experiments, we do not introduce a parameter for the undivided cells in the tumor.
Without this parameter the model predicts no undivdided cells in the tumor at all, since
we excluded the possibility of undivided cells egressing from the draining lymph node
to the tumor, see in section 3.2.1. Thus, we omit the frequency of the 0th generation
in the tumor as an observable, as well. The fitted observables for both experiments are
now the absolute cell numbers, the mean number of divisions (see section 2.3.3) and the
fraction of cells in the n+th generation in both compartments and the 0th generation in
the draining lymph node.
Error estimation We again estimate the errors and have three error parameters: a
relative error for the absolute cell numbers sdabs, an absolute error for the mean number
of divisions sdMDiv and—in contrast to the melanoma models— the same absolute error
for the draining lymph node and the tumor, sdGen, for the fraction of cells in generation
0 and n+. Due to the little data available we do not distinguish anymore between the
two compartments for the estimation of sdGen. Since the relative error for the absolute
cell numbers, sdabs, gets large when estimated, we introduce an upper bound of 0.7. This
is motivated by the upper bounds of the 95% confidence intervals of the error parameter,
sdabs, of the melanoma fit, see Tab. 3.3 and 3.4.
Proliferation stop We try different generation stop mechanisms in the draining lymph
node and the tumor, which are discussed in detail in section 4.2.2.
After testing these options, for the second experiment we decide for a simple contin-
ued proliferation. For the third experiment a division stop at generation six in both
compartments improves the model significantly and is thus chosen for its basic model
structure.
Time dependent rates Like in the melanoma experiments the proliferation is time
dependent in the draining lymph node with
pdLN (t) = pdLN,0 e
−αt, (4.1)
where pdLN,0 is the proliferation rate at t = 0 and α is the decay rate. The parameter α
is constrained to be positive, such that we only consider decreasing proliferation rates, as
the initial proliferation of T cells is expected to be fast and then decaying [135, 102, 136].
Since no BrdU is measured, we do not distinguish between cell cycle phases. A time
dependent egress rate as in the time-resolved melanoma experiment (see eq. (3.2)) is not
included, but discussed in the section on alternative models (4.2.2).
72
4.2. Mathematical model describing the T cell dynamics in a pancreatic cancer mouse
model
e      
Draining lymph node 
Active, 
Gen 0  
Inactive, 
Gen 0 
pdLN (t)
 
pdLN (t) source  act. Active, 
Gen 1 ...  
Tumor 
Active, 
Gen 1 ...  
pT  
dLN 
Figure 4.8 : Basic model structure applied for both experimental data sets. States are in black
and parameters are in blue. States: Active cells continue dividing in the second experiment in
both compartments. For the third experiment a division stop after 6 generations is introduced in
both compartments. Parameters: Exponential decay of the proliferation rate in the draining
lymph node pdLN (t) in both experiments.
Summary of the basic model structure
We have in total r=9 parameters for the basic model structures of both experiments (Fig.
4.8). These are a source rate, an activation rate, a proliferation rate in the draining lymph
node pdLN defined by pdLN,0 and α, a proliferation rate in the tumor pT , an egress rate
edLN and three error parameters: a relative error for the absolute cell numbers sdabs,
an absolute error for the mean number of divisions sdMDiv and an absolute error for
the frequencies of cells in generation 0 and n+ in the draining lymph node and tumor,
sdGen. We have 26 and 24 observables for the second and third experiment respectively
(see suppl. section C.2).
4.2.2. Alternative models
In this section a more thorough discussion of the considered alternatives during the con-
struction of the basic model structure is presented. For each alternative model structure
we compare the model, where all parameters are chosen to be different between the treat-
ment and control, but for the errors and the source term. The latter was set to be the
same as there is no good reason to assume that the errors or the number of inactive cells
entering the draining lymph node are influenced by the treatment.
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Similar model structure changes are summarized and discussed in groups. The AIC
and the negative loglikelihood of the best performing model structure of each group is
noted. The latter is calculated following eq. (2.7) without the constant term.
Obviously, we cannot check all possible model alternatives and we focus on varying
the division stop mechanisms and time dependent rates, with plausible alternatives. We
furthermore pursue the question whether proliferation in the tumor is necessary.
General considerations about time dependent and generation dependent rates, the
necessity of a proliferation in the tumor, the introduction of a death rate and the compa-
rability of the different division stop mechanisms are discussed in section 3.2.2 in detail
and are not repeated here. Here, we add a remark on the death rates and on the effect
of introducing a division stop into the model.
Death rate Similar to the melanoma experiments, we extend the basic model structure
by introducing either the same constant death rate in all compartments or only in the
tumor. This should be identifiable, although we expect the death rate to be compensated
by the source term to some degree, see section 3.2.2 and suppl. section A.2. We fit the
extended model simultaneously to the treatment and control data with all parameters
different between the treatment and control, but for the source and error terms. We only
test this for the third experiment, since the data of the second experiment is too sparse
to select models, which will be discussed later in this section. We find, that only the
model with the death rate in all compartments improves the fit (∆negLL = 4), but the
AIC is still worse due to the increase in model complexity (∆AIC > 10). Hence, the
improvement is not large enough to justify the introduction of this additional parameter.
The evidence for an overall death rate is still noteworthy. Indeed, we see similar
fractions of dead OT-I T cells in the draining lymph node and the tumor, when comparing
the life/dead gates of the flow cytometry analysis. This is not the case for the melanoma
experiments, where we tend to find more dead cells in the tumor than in the draining
lymph node. Still, we have an overall higher fraction of dead cells in the pancreatic
experiment in comparison to the melanoma experiment. The observations in the data
are also reflected in the fits to the melanoma data, see section 3.2.2: The introduction
of death rates did not improve the fit to the data of the time-resolved experiment and
in the case of the proliferation-resolved experiment we only find evidence for a death
rate in the tumor. But as discussed in section 3.2.2, when interpreting these tendencies
care must be taken: For one thing, the identifiability of the death rate is impeded by
the estimation of the source term and furthermore, comparisons between the life/dead
gate fractions can only be made to a certain extent between different organs, time points
and even less between different experiments. The latter is due to the fact that different
amine reactive dyes are used in the PDAC and melanoma experiment. Hence, some part
of the difference between the experiments might be the consequence of different staining
protocols.
Although we do not introduce a death rate, from these observations we can still con-
clude that an overall death rate is more likely than in the melanoma experiment.
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Effect of division stop mechanisms Division stop mechanisms can reconcile large ab-
solute cell numbers with a cell division profile, which does not have a large fraction of
highly divided cells. It allows the cells to divide and increase without overpopulating
higher generations. This is the reason why the fit to the data of the third experiment
performs much better with a divisions stop mechanism than with a continued prolifera-
tion. In the case of the third experiment, this is remarkable since a division stop does
not suggest itself, when looking at the cell division profiles (Fig. 4.6), as opposed to the
cell division profiles in the first melanoma experiment, see section 3.1.
Alternative models for the second experiment
The performance of the basic model structure (Fig. 4.8) for the second experiment is
compared to alternative model structures in the following. If fitted to both the treatment
and control data simultaneously with all parameters different except for the source term
and the errors, the basic model structure returns a fit with an AIC of 210.8 and a negative
loglikelihood of 48.4.
General remarks None of the alternative model structures discussed in the following
improve or worsen the fit by much. The same holds if the number of parameters which can
be different between treatment and control is changed within the same model structure.
In both cases the fit is not improved or worsened beyond ∆negLL= 5.
In consequence, none of the following model structures, with the same model com-
plexity, i.e. the same number of parameters, can be rejected. And more complex model
structures are discarded in terms of the AIC, since the improvement of the fit is always
outcompeted by the increasing number of parameters: for example, the introduction of a
dynamic egress rate or a generation dependent proliferation, which in principle improve
the fit slightly (∆negLL = 3.5 and 0.9 respectively) are worse by ∆AIC > 20.
We observe a similar situation, when a model selection as is described in section 3.2.3
for one of the alternative model structures is conducted. During this selection we change
the number of parameters which can be different between the treatment and control for
the given model structure. Since additional parameters do not improve the fit by much,
the model, where all parameters are the same between the treatment and the control,
i.e. the one which has minimum complexity, performs best.
Altogether, the data seems too sparse to distinguish between models. Reasons for this
are discussed in detail in the last section of this chapter, see section 4.3.1. Still, in the
following we point out tendencies, when we test alternative model structures with 1)
different generation stop mechanisms and 2) a generation dependent egress replacing the
proliferation in the tumor.
1) A division stop can also explain the data We try proliferation stops in the drain-
ing lymph node after four, five and six generations with either a division stop in the
same generation in the tumor or two more possible divisions after entering the tumor.
The latter mechanism is motivated by the basic model structure of the first melanoma
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experiment. All models, including our basic model structure with a continued prolifera-
tion, are within an ∆AIC=5, as they have the same complexity. If a proliferation stop
is considered, interestingly the models perform better the earlier the proliferation stop
is. The division stop after four generations in both compartments performs best among
the tried model structures and performs equal to our basic model structure. Thus, we
also try this with only a division stop in the draining lymph node, which improves the
fit by a ∆AIC=4.5. We test this model structure further and a model selection returns
a best minimal model, where—as expected—all parameters are the same for the treat-
ment and the control. It is ∆AIC=2.6 better than the best minimal model of our basic
model structure. As the improvement is not large we stay with the default option of a
continued proliferation, as is done in the case of the basic model structure for the the
proliferation-resolved melanoma experiment. We conclude that we have evidence for a
proliferation stop in the draining lymph node, that we have slightly less evidence for a
continued proliferation or any of the other division stop mechanisms, but cannot reject
any of these options.
2) Replacing the proliferation in the tumor with a generation dependent egress rate
leads to a worse fit We replace the proliferation in the tumor with exponentially and
linearly increasing generation dependent egress rates, as well as independent egress rates
for each generation. The latter includes a factor, which is estimated and transforms
the individual egress rates of the control to the ones of the treatment, as otherwise the
model structure would have too many parameters. All perform slightly worse in terms of
the negative loglikelihood and the latter has too many parameters and is rejected thus.
The model structures with an exponentially and linearly increasing generation dependent
egress rate have the same complexity, but perform slightly worse and lead to a ∆AIC=5.3
worse fit. These model structures cannot be rejected, but are less likely.
Alternative models for the third experiment
The basic model structure of the third experiment, see Fig. 4.8, includes a division stop
after six generations, both in tumor and the draining lymph node. Fitting it with all
parameters being different but for the errors and the source term, we obtain AIC of 152.1
and a negative loglikelihood of 16.7. In the following we explore 1) whether division
stop mechanisms are needed and which perform best, 2) whether we can replace the
proliferation in the tumor with a generation dependent egress rate or a time dependent
egress rate and 3) whether a time dependent egress rate improves the fit.
We do not test a generation dependent proliferation rate instead of the time dependent
one, since already a constant proliferation rate fits the data well in the best minimal model
of our basic model structrue, see section 4.2.4.
1) A division stop after six generations in both compartments performs best The
basic model structure includes a division stop at generation six. Considering the cell
division profiles a division stop before generation six is not possible, see Fig. 4.6.
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We furthermore test division stops at generation seven in both compartments, as well
as a division stop after generation six in the draining lymph node with either a continued
proliferation in the tumor or two more possible divisions in the tumor. The latter mech-
anism is motivated by the basic model structure for the first melanoma experiment. And
we explore whether a generation dependent exponentially decreasing proliferation rate
in both compartments performs better. All these model structures are different ways of
introducing a special case of a division destiny, see section 3.2.2. Finally we also test,
how a continued proliferation in both compartments performs.
All models with a division stop perform similar (∆AIC = 2) and better than mod-
els with an exponentially decreasing generation dependent proliferation or a continued
proliferation (∆AIC > 10). The latter performs worse because a division stop mecha-
nism can reconcile high absolute cell numbers with a relatively small fraction of highly
divided cells. The division stop mechanism prevents an overpopulation of these higher
generations. In consequence the fit with the continued proliferation underestimates the
absolute numbers at the cost of fitting the last generation accurately.
Among the tested model alternatives with a division stop, a stop at generation six in
the draining lymph node and a continued proliferation in the tumor performs best with
AIC = 155.7 and a negative loglikelihood of 18.5. But this is still ∆AIC = 3.6 worse than
the fit with our basic model structure, where the divisions stops after six generations in
both compartments.
From this analysis, we can conclude that some kind of division stop mechanism is
needed to explain the data and that among these our basic model structure with a
division stop after generation six in both compartments performs best.
2) The proliferation in the tumor cannot be replaced with a generation dependent
egress rate Here, we try several model structures, where the proliferation in the tumor
is replaced by different egress mechanisms, which are described earlier in this section 4.2.2,
when the alternative models for the second experiment are discussed. Furthermore, a
time dependent logistic egress rate is tested, which is motivated from the basic model
structure of the time-resolved melanoma experiment. All models are ∆AIC = 39 worse
than our discussed model structure and the best (linear generation dependent egress rate)
leads to an AIC of 197.1 and a negative loglikelihood of 39.2.
We conclude that a proliferation in the tumor is needed in our model to explain the
data.
3) A time dependent egress rate does not improve the fit We try a time dependent
logistic egress rate, which is motivated by the basic model structure of the first melanoma
experiment, to see whether this improves the fit and performs better in terms of the AIC.
However the fit returning a negative loglikelihood of 16.7 is not improved, leads to an
AIC of 250.2 (∆AIC = 98.1 worse) and is accordingly rejected.
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4.2.3. Model selection for the identification of the treatment induced
changes in the second experiment
We aim at finding parameters which need to be different between the treatment and the
control, when fitting both data sets simultaneously. This is achieved by performing a
model selection, see section 3.2.3, with the basic model structure for the second exper-
iment (Fig. 4.8). The selection is conducted by increasing the number of parameters
which can be different between treatment and control, Θdiff , in a step wise fashion and
keeping the models which improve the fit in every round. We again consider the mod-
els within ∆AIC < 4 of the global best model and determine the best minimal model
(BMM), which is the model with the fewest parameters among these.
The fit does not improve much by increasing Θdiff (max. ∆negLL = 6.5), such that
all complexer models perform worse with respect to AIC. As a consequence the BMM
is the model, where all parameters are the same. It is also the global best model and
closely followed with an AIC difference between 1.2 and 5 by all combinations where
single parameters are different between the treatment and control. Among these the
models with a different proliferation in the tumor and a different egress rate perform
slightly better (∆AIC = 1.2 und ∆AIC = 2.7). Indeed, compared to the BMM the most
striking improvement of the model fit where Θdiff comprises all parameters (i.e. full
model) is the fit to the absolute cell numbers in the tumor. This is owing to a different
proliferation rate in the tumor and a different egress rate (suppl. Fig. C.3). However,
the improvement of the negative loglikelihood is small and shows that the differences
between the treatment and control data do not suffice to justify the introduction of more
parameters to explain these differences. Additional measurements at later time points
could resolve this to some extent, see discussion in section 4.3.
Challenging tendencies in the data Even between the prediction of the full model
and the data there are still some discrepancies, which are also problematic in our best
minimal model fit (Fig. 4.9):
First, the mean number of divisions seems to contradict the high number of proliferated
cells in the tumor in the treatment setting (Figs. 4.9 f and g) and can neither be reconciled
with the slower proliferation in our BMM nor with the faster one in the full model
(interdivision times of 18.5h and 7.5h, respectively). The problem very likely arises
from the fact that there are only few cells in the generations 1-3, from which the mean
number of divisions is calculated. Thus, their fractions are not reliable and the observable
calculated from them poorly reflects the mean number of divisions.
Secondly, the dynamic of the absolute cell numbers in the draining lymph node for the
control is difficult to reconcile with the respective cell division profiles, see Fig. 4.9 a and
d. The number of cells in the draining lymph node increases fast, but is then followed by
a steep decline from day 1.7 to day 2.7, which contradicts the increasing number of cell
divisions in the same time period. A sudden death leading to a loss of cells in the range of
an order of a magnitude seems unlikely, too. In any case, it is necessary to consider that
the first time point in the draining lymph node stems from mice with strongly varying
total cell numbers (1.7 · 103 VS 1.1 · 104) and the second time point stems from only one
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mouse, so this decline should not be overrated.
Thirdly, the exact opposite tendency is seen for the absolute cell numbers in the drain-
ing lymph node in the treatment setting. It points at a strong increase of cell numbers
from day 1.7 to 2.7 (Fig. 4.9b). This implies a fast exponential growth and—extrapolating
this to early time points with a straight line—a small contribution from the source term.
But the cell division profile on day 1.7 contradicts a fast proliferation. A slow activation
and a consecutive fast proliferation is equally unlikely due to the small cell number in
the undivided generation. The profile likelihood (see Fig. 4.10) suggests that a time
dependent increase of the proliferation in the draining lymph node, i.e. a negative decay
rate α, can reconcile the small number of divisions on day 1.7 with the more highly
proliferated cells on day 2.7 and the rapid increase of the absolute cell numbers. As this
is an unlikely mechanism (see the discussion of time dependent parameters in section
3.2.1), we exclude this possibility by setting the lower bound of the decay parameter α
to zero.
In general, the fit to the cell division profiles on day 1.7 is posing a problem (Fig. 4.9 d
and f). By modeling cell divisions with an ODE we assume an exponentially distributed
waiting time until division, whereas cells are known to have a finite interdivision time.
This leads to a distribution of the waiting time with a smaller coefficient of variation,
especially at early time points, see section 2.3. In consequence, cell division profiles
obtained from the measurement and from the model solution have different variances,
which impedes a good fit.
When we fitted our best minimal model to the cell division profiles directly instead of
the mean number of divisions, the model performed similar and we had the same issues
which are mentioned above (not shown).
Estimated parameters It is important to mention that the mediocre fit to the data
makes a sound interpretation difficult. Still, as the fit is in parts describing the data
well, it is worth while having a look at its predictions.
The estimated parameters and their confidence intervals can be found in Tab. 4.3.
Compared to the melanoma experiments the influx (source term) is smaller by far, which
is remarkable as the same number of OT-I T cells have been transferred. Indeed, in this
experiment we also see far less undivided cells in the blood, which are even too small to
explain the source term alone, see suppl. Fig. C.1. Another source replenishing the cells
in the blood is likely.
The activation rate cannot be constrained with this model. As it can be arbitrarily
fast it implies that the time to first division is not distinguishable from the following
interdivision times. The interdivision times in the draining lymph node and the tumor
are similar (19h and 18.5h respectively). Both are somewhat slower than can be expected
from recently and optimally activated T cells (10.1h in vitro [126]). As contrasted to the
melanoma experiments there is only little evidence of a decreasing proliferation rate and
the best fit predicts a constant proliferation rate over time, see Fig 4.9 c. The waiting
time for egress of 5d is slow, but comparable to the rates, which have been observed in
the melanoma experiments, see section 4.3.
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Conclusion In conclusion, we see hints towards a changed proliferation and egress rate
induced by the anti-CD40 treatment, but they are not significant. These could perhaps
be substantiated with more data.
The fact that it is difficult to make a distinction between different model options, i.e.
the ∆AIC does not differ significantly for the different model options, has likely two
reasons. On the one hand the data is not informative and sparse and on the other
hand, there are opposing tendencies in the data, which lead to different models returning
similarly mediocre fits.
Since we cannot distinguish very well between different model options and since the
chosen best minimal model does not fit the data well, it is hard to draw reliable conclu-
sions. Both, the hints towards an enhanced egress and proliferation rate, as well as the
fact, that the best model does not predict any effect induced by the anti-CD40 treatment,
have to be interpreted cautiously.
Table 4.3.: Estimated rates for the BMM, second PDAC ex-
periment
Parameter Control 95%CI CD40 95%CI
source 290 cells/d [66; 590] " "
activation 7.0 1/d [1.4; Inf ] " "
α* 0 1/d [0; 0.30] " "
pdLN * 1.3 1/d [1.0; 2.0] " "
edLN 0.20 1/d [0; 2.0] " "
pT 1.3 1/d [0.70; 1.9] " "
sdabs 0.70 [0.50; 0.70] " "
sdGen 0.11 [0.082; 0.19] " "
sdMDiv 0.44 [0.28; 0.83] " "
* see eq.(3.1)
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Figure 4.9 (previous page): Fit of best minimal model to the data of the second experiment.
a) & b) Fit to the absolute cell numbers in the draining lymph node (green) and tumor (red) for
the a) control and b) anti-CD40 treatment. c) Estimated proliferation rate in the draining lymph
node, which is the same for control and treatment. Filled area indicates the 95% confidence
interval. d) - g) Fit (dots) and prediction (circles) of the proliferation data: Only the color-
bordered bars are used for fitting. d) Fitted and predicted cell division profiles and e) fitted mean
number of divisions of the control. f) & g) Analogous plots for the treatment setting. Errors
have been estimated and are indicated by error bars. Experimental data: Susann Wendler and
Isabel Poschke.
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Figure 4.10 : Profile likelihoods of the best minimal model for the second PDAC experiment.
Lower thresholds are set to 0. Upper threshold is introduced for the relative error for the absolute
cell numbers, sdabs, at 0.7. The red line denotes the threshold for the 95% confidence interval.
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4.2.4. Model selection for the identification of the treatment induced
changes in the third experiment
It is our aim to find parameters which need to be different between treatment and control,
when fitting both data sets of experiment III simultaneously. To this end, we perform a
model selection as described in section 3.2.3 with the basic model structure of the third
experiment (Fig. 4.8). This model includes a proliferation stop after six divisions. During
the process of a model selection the number of parameters which can differ between
treatment and control, Θdiff , are increased in a step wise fashion, the best models in
each step is kept for the next round and thus a global best model among these models
is found. We consider the models within ∆ AIC< 4 of the global best model and choose
the model with the smallest number of parameters among these, to which we refer as the
best minimal model (BMM).
Here, the BMM predicts higher proliferation rates in the draining lymph node pdLN and
the tumor pT in the treatment setting. The second best model (∆AIC = 2.2) additionally
predicts an enhanced activation rate for the treatment setting. With ∆AIC = 8 models
follow which predict further parameters to be different besides the proliferation rates,
but these do not improve the fit with respect to the negative loglikelihood.
The fit to the proliferation data, i.e. the mean number of divisions and the cell division
profiles, performs well (see Fig. 4.11 c - f). Indeed, the frequencies of the cell division
profiles are predicted perfectly and the corresponding errors sdGen are estimated to be
very small, such that this can be seen as a sign of an over-parameterization. On the
other hand, the prediction of the absolute cell numbers is mostly at the borders of the
estimated error boundaries, but still satisfactory. The only data point which the model
fails to explain is the absolute cell number in the tumor on day 3.7 in the control. As the
corresponding mean number of divisions, as well as the cell division profile, are explained
well by the fit, there appears to be a discrepancy between the absolute cell numbers and
proliferation data. Since the accuracy of the absolute cell number measurement could
very well vary between different read out days and organs, it is conceivable that our error
model is not adequate and some measurements are subject to a higher variability than
is estimated here.
Fit to the cell division profiles To test whether our results are robust with respect to
the choice of the observables for the proliferation data, we perform a direct fit to the
cell division profile instead of the mean number of divisions. Indeed, the direct fit to
the cell division profile and the prediction of the fractions in the cell division profile,
when fitting the mean number of divisions, are similar, compare suppl. Fig. C.3 and Fig.
4.11. Furthermore, the fit to the absolute cell numbers is similar and most estimated
parameters of the direct fit to the cell division profiles are within the confidence bounds of
our best minimal model fit to the mean number of divisions. Only the proliferation rates
are predicted to be slightly smaller, which is counteracted by a very fast activation rate:
The interdivision time for the control is 13h (contrasted to 11.7h) for both compartments
and for the treatment setting 7.3h in the tumor and 8.3h in the draining lymph node
(contrasted to 6.4h and 6.7h). The activation has no upper bound, implying that the
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time to first division is the same as the interdivision times of the subsequent divisions.
This suggests that the fit, except for the identifiability of the activation rate, is fairly
robust with respect to the choice of the observables.
Table 4.4.: Estimated rates for the BMM, third PDAC experiment
Parameter Control 95%CI CD40 95%CI
source 230 cells/d [92; 390] " "
activation 2.1 1/d [1.7; 3.2] " "
α* 0.05 1/d [0; 0.085] " "
pdLN * 2.1 1/d [1.9; 2.2] 3.7 1/d [3.5; 4.0]
edLN 0.12 1/d [0.028; 0.31] " "
pT 2.05 1/d [1.97; 2.14] 3.6 1/d [3.4; 3.8]
sdabs 0.58 [0.38; 1.2] " "
sdGen 0.004 [0.0029; 0.0070] " "
sdMDiv 0.33 [0.20; 0.67] " "
* see eq.(3.1)
Estimated parameters The estimated parameters and their confidence intervals can
be found in Tab. 4.4. All parameters are well constrained—however, in the case of the
relative error estimate sdabs and the decay rate α with an upper (0.7) or lower bound (0
nicefrac1d) respectively, which were set to ensure plausible parameter ranges. Like in
the model fit to the second experiment, compared to the melanoma experiments the
source term is smaller by far, which is remarkable given that the same number of OT-I
T cells have been transferred. Indeed, in this experiment we even see less undivided cells
in the blood than in the second experiment, such that these are too few to explain even
the small influx rate, see suppl. Fig. C.1. It is therefore plausible to assume that the
undivided cells in blood are replenished by other reservoirs of T cells like the spleen.
The time to division is similar for the draining lymph node and the tumor and distinct
for the treatment and control setting. The estimated interdivision time for the treatment
with 6.4h (tumor) and 6.7h (draining lymph node) is fast compared to the interdivison
time measured for optimally activated cells in vitro of 8h− 13h [125, 126, 102]. On the
other hand, these studies confirm the interdivision time of 11.7h estimated in the control
setting for both the tumor and the draining lymph node.
The egress rate of 0.12 1/d, i.e. a waiting time to egress of 8 days, is slow. But
it coincides well with the dynamic range of the rates estimated in the first melanoma
experiment and the constant rates estimated in the third melanoma experiment. The
latter are included in the 95% confidence interval.
The activation rate of 2.1 1/d lies between the estimated activation rates of the third
melanoma experiment with 1.1 1/d for the control and 3.9 1/d for the treatment.
By summing the interdivision time in the draining lymph node to the waiting time
until activation we obtain the time to first division with 23h and 18h for the control
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and treatment respectively. Especially the latter (CI: [14; 21]h) is at the fast end of
the measured times to first division, which are reported to be between 24h and 48h
[123, 145, 146].
Conclusion The fit to the data of the third PDAC experiment performed well and is a
contrast to the mediocre fit to the second experiment. This might be due to the later
measurement time points, at which we have more cells, leading to less variable measure-
ments and hence, resulting in less contradicting tendencies in the data. In addition, we
have more proliferative information, i.e. we can distinguish more generations in the cell
division profiles. These characteristics of the data contribute also to the fact that we
can differentiate better between model alternatives. Although we still suspect an over-
parametrization, the parameters are well constrained and realistic and we can determine
which of them are influenced by the treatment. These are the proliferation rates in the
draining lymph node and tumor, which is not surprising given that these differences can
already be seen in the data. Furthermore, we have evidence for an enhanced activation
rate, which was expected, since CD40 is reported to play an imported role during priming
[44, 45, 46, 47].
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Figure 4.11 (previous page): Fit of the best minimal model to the data of the third ex-
periment. a) & b) Fit to the absolute cell numbers in the draining lymph node (green) and
tumor (red) for the a) control and b) anti-CD40 treatment. c) Estimated proliferation rate in
the draining lymph node for control (solid line) and treatment (dashed line). Filled area indicates
the 95% confidence interval. d) - g) Fit (dots) and prediction (circles) of the proliferation data.
Only the bordered bars are used for fitting. d) Fitted and predicted cell division profiles and e)
fitted mean number of divisions of the control. f) & g) Analogous plots for the treatment. Errors
have been estimated and are indicated by error bars. Errors of the cell division profiles are very
small such that only the horizontal line is visible. Experimental data: Susann Wendler, Aaron
Rodriguez Ehrenfried and Isabel Poschke.
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Figure 4.12 : Profile likelihoods of the best minimal model for the third PDAC experiment.
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cell numbers, sdabs, at 0.7. The red line denotes the threshold for the 95% confidence interval.
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4.3. Review of the results of the pancreatic ductal
adenocarcinoma experiments
In the following, we discuss the results of the fit to the data of the pancreatic ductal
adenocarcinoma (PDAC) mouse model experiments. In section 4.3.1 we focus on the
performance of the fits and explain, why we do not consider the second experiment any
further. In section 4.3.2 we summarize the fitting results from the PDAC experiment,
compare it to the results from the melanoma experiments and point out how this reflects
the characteristics found in the data analysis of the PDAC experiments.
4.3.1. Challenges when fitting the sparse data of the PDAC experiments
Fitting a model, which is motivated from the melanoma experiment, can explain the data
of the PDAC experiments to different degrees. Unfortunately both modeled experiments
have less data than the melanoma experiments: there are two measurement time points
and no additional proliferative information, e.g. BrdU.
This, however, is not problematic for the third experiment, where the data can be well
explained by the model. Here, a likely over-parametrization can be inferred from the very
small estimate of the error for the fraction of cells in different generations (sdGen = 0.004,
[0.0029; 0.0070]). Nevertheless, the data suffices to distinguish different model options.
In the second experiment, however, the sparsity of the data is worse, as we can only
distinguish the fractions of cells in different generations until the third or fourth division.
This leaves this experimental data with almost no information on the proliferative activ-
ity. In addition, the early time point (day 1.7), where the few distinguishable generations
could be informative, cannot be well described with our fit (Fig. 4.9 d and f). This is the
likely consequence of the exponentially distributed waiting time until division assumed
in our model, but cells are known to have a finite interdivision time. The model thus
predicts a higher variance with respect the distribution of cells in different generations
compared to the distribution resulting from the measurements (discussed in section 2.3).
Furthermore, in the second experiment we do not only have the problem of a lack of data
to inform a model, but also tendencies in the data, which are difficult to reconcile. A
detailed description of these is found in section 4.2.3.
All of this contributes to the phenomenon that a range of different model structures
returns equally mediocre fits. Hence, models with the same complexity have a similar
AIC. Models with a more complex proliferation mechanism, which in principle improve
the fit, are rejected, since the small improvement does not suffice to justify the increased
complexity. For example, all models with and without different division stop mechanisms
and consequently different proliferation rate estimates still perform similar and span a
small range of AICs, since they have the same complexity. In contrast, during the
model selection, we reject models, which improve the fit by introducting a treatment and
control specific proliferation and egress—the improvement is not enough to compensate
the increased model complexity.
We can conclude that less variable data and more measurements, perhaps also at later
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time points, would improve the ability to distinguish different model options. But as it
is, there is uncertainty about the correctness of the basic model structure that we choose
for the second experiment and consequently about the resulting parameter estimates.
Hence, the parameters of the second experiment are not discussed, when we compare the
results from the PDAC experiments to the results from the melanoma experiments in
the next section.
4.3.2. Comparison of the results of the PDAC and melanoma experiments
For reasons discussed in the previous section 4.3.1, we focus on the best minimal model
fitting results of the third PDAC experiment and compare it to the results of both
melanoma experiments. The studied murine tumor models are clearly different between
the PDAC and the melanoma experiment with respect to the tumor micronenvironment,
the tumor location and the method applied for its inoculation. Given these differences
it is surprising to see that a similar model can fit all three data sets. The model fitted
to the third PDAC experiment is a mixture of the model structure of both melanoma
experiments: It includes a division stop like the model for the first melanoma experiment
and has a constant egress rate over time as in the model for the third melanoma experi-
ment. In the following we discuss in how far the parameters, model alternatives and the
predicted treatment induced changes of the best minimal model of the PDAC experiment
compare to the results from the melanoma experiments and how this is determined by
the available data.
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Figure 4.13 : a) Absolute cell number of OT-I T cells in the in the draining lymph node and
b) density of OT-I T cells in the tumor. Plots for melanoma experiment 1 and 3 and in PDAC
experiment III.
Comparison of the proliferation dynamics When discussing the results of the
melanoma experiments in section 3.3.1, we conclude that a decreasing proliferation over
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time is governing the dynamics of the OT-I T cells in the draining lymph node. We
furthermore argue, that a divison stop mechanism is needed for the first experiment and
that there is evidence for it in the third experiment. By testing alternative model struc-
tures, we confirm a division stop mechanism for the model fitting the PDAC data, too.
The decreasing proliferation, however, is not necessary to explain the data. Indeed, when
regarding the profile likelihood of the best minimal model of the PDAC experiment, we
can see that a constant proliferation, i.e. the decay of the proliferation rate equaling
zero, is well within a confidence interval of 95%. This is also reflected in the maximum
likelihood estimate of the best minimal model leading to a faster and an almost constant
proliferation in the draining lymph node for both the treatment and the control, see
Fig. 4.14 a. The proliferation in the tumor is fast as well, but comparable to what is
estimated in the melanoma experiments, see Tab. 4.5. Considering the differences in the
cell divisions profiles of the melanoma and PDAC experiments, the faster proliferation
estimates for the PDAC model are not surprising.
Comparison of the proliferation rates Regarding the results of the PDAC experiment,
we find that the initial interdivision time in the draining lymph node, which does not
increase by much over time, and the interdivision time in the tumor are the same (control:
11.7h and 11.7h, treatment: 6.4h and 6.7h). The interdivision time for the control is
what can be reasonably expected of activated T cells as discussed in section 3.3.2. It
is furthermore similar to the fastest proliferation rate, which we estimate for the third
melanoma experiment. In the same section we discuss that rates estimated from this
melanoma experiment are credible, due to the additional BrdU measurements and a
better identifiability. In consequence we tend to believe the interdivision time estimate
in the tumor of the third melanoma experiment (22h) and doubt the unexpectedly fast
interdivision time in the tumor of the first melanoma experiment (6h). Interestingly
the latter rate is now confirmed by the proliferation rate estimates of the PDAC model.
We have a proliferation stop after a few divisions in both experiments with these fast
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proliferation rate estimates. Hence, there is also the possibility, that instead of a slow
proliferation cells can continue to rapidly divide after entering the tumor, but are stopped
after a few divisions.
Absolute numbers Another noteworthy difference in the data is that far less cells can
be found in the draining lymph node in the pancreatic experiment, although the same
number of OT-I T cells have been transferred in all experiments. To a lesser extent this
is also the case in the tumor. Indeed, the number of OT-I T cells in the draining lymph
node is an order of magnitude larger in the melanoma experiments, see Fig. 4.13a. This
is also reflected in the best minimal model estimates of the source term, which is two
orders of magnitude smaller for the PDAC experiment, see tab. 4.5. Intriguingly, the
density of OT-I T cells in the tumor is comparable for all experiments, see Fig. 4.13b.
These observations coincide well with the hint towards dying cells in all organs in the
PDAC experiment, which stands in contrast to the evidence of cell death being confined
to the tumor compartment in the melanoma experiments, as is discussed in section 4.2.2.
Activation rate Both in the PDAC experiment and the third melanoma experiment we
clearly see more highly proliferated cells in the anti-CD40 treatment setting, especially
in the draining lymph node. In the model fit to the PDAC experiment, this is mainly
attributed to a changed proliferation rate, but there is also strong evidence for an addi-
tionally enhanced activation rate. A correct estimate of the activation rate very likely
depends on the availability of undivided cells in the draining lymph node, which do not
exist for the measurements of the PDAC experiment, since the cells have divided too
often. Thus, if the the information on the undivided cells was given, it would be interest-
ing to see whether the results with respect to the anti-CD40 effect would coincide better
with the results obtained from the third melanoma experiment: The latter attributes the
difference of the cell proliferation profiles solely to a changed activation rate.
Interestingly the activation rate estimates of these two experiments are comparable, as
the PDAC model estimate is in between the activation rate estimates of the treatment
and control of the third melanoma experiment, see tab. 4.5.
How realistic the activation rates of these two experiments are, can be indirectly as-
sessed, by comparing the time to first division. It is calculated by summing the waiting
time until activation and the waiting time until proliferation in the draining lymph node.
These are similar for the treatment setting of the third melanoma experiment with 16h
(CI: [14; 18]h) and the treatment setting of the PDAC experiment with 18h (CI: [14; 21]h).
Since this is on the fast side of the values found in the literature, which are reported to be
between 24h and 48h, see refs. [123, 145, 146], this points at a slight overestimation of the
proliferation or activation rate. On the other hand, the waiting time estimated for the
control setting of the third melanoma experiment with 32h and the PDAC experiment
with 23h are realistic.
Unfortunately the fit to the first melanoma experiment returns an unidentifiable activa-
tion rate, which can be arbitrarily fast, such that the interdivision time of the subsequent
divisions (33h, initially) is the same as the time to first divison. The lacking distinction
91
Chapter 4. T cell dynamics in a pancreatic ductal adenocarcinoma mouse model
between the first and the subsequent divisions is certainly to be doubted and the esti-
mated interdivison time could be an average of the two. Hence, the estimated rate for
the time to first division, i.e. 33h initially, is likely a lower estimate for the real time to
first division and with this likely in the expected range.
Table 4.5.: Comparison of selected parameter estimates from the third PDAC and both
melanoma best model fits
source rate waiting time egress rate interdivision
[cells/day] activation [h] [1/d] time tumor [h]
Exp. 1 contr. 14000 0.8 see Fig. 4.14 6
melanoma [9100; 20000] [0; 7.2] [0; 15]
treat. " " see Fig. 4.14 "
" " "
Exp. 3 contr. 22000 22 0.31 22.3
melanoma [14000; 26000] [18; 26] [0.23; 0.43] [18.5; 29.2]
treat. " 6.1 0.035 "
" [3.9; 8.3] [0.023; 0.065] "
Exp. III contr. 230 11 0.12 11.7
PDAC [92; 390] [7.5; 14] [0.028; 0.31] [11.2; 12.2]
treat. " " " 6.7
" " " [6.3; 7.2]
Time dependency and treatment induced effects on the egress rate As opposed
to the first melanoma experiment, a time dependent increase of the egress rate for the
PDAC experiment is not needed. Since the change in the egress rate within 24h is not
expected to be large, inferring a dynamic rate from two measurement time points on
consequtive days turns out to be difficult (measurement time points are indicated with
red triangles in Fig. 3.16a)—a problem, which has been already discussed for the third
melanoma experiment in section 3.3.2. But in contrast to the latter case a model with a
time dependent egress rate for the PDAC experiment does not perform better even when
the increase in model complexity is disregarded. Furthermore, in contrast to the results
from the melanoma experiments the egress rate of the PDAC model fit seems not to be
influenced by the anti-CD40 treatment either. This is very likely a consequence of the
similar absolute OT-I T cell numbers in the tumor for both treatment and control, which
are different in the melanoma experiments.
We could conclude that the egress rate in the PDAC experiment is neither time nor
treatment dependent. However, this rate is not well constrained. This becomes obvious,
when comparing the rate and its error bounds to the rates in the first melanoma exper-
iment in Fig. 4.14b. In addition, the egress rates of both treatment and control of the
third melanoma experiment are within the error bounds of the PDAC egress rate, see
Tab. 4.5. Since the confidence interval encompasses almost the whole dynamic and treat-
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ment dependent range of the melanoma egress rates, it is conceivable that constraining
the egress rate better could reveal a time and/or a treatment dependency, after all.
In any case it is interesting to note, that the egress rate is similar in all three ex-
periments, suggesting that the small rate is independent of the cell numbers and the
proliferative activity in the draining lymph node and of the tumor setting.
Concluding remarks
All in all, it is satisfactory that the model structure, which has been developed for the
melanoma experiments, can explain the data obtained from the PDAC experiments, al-
beit to different degrees. The PDAC experiments have an explorative character and we
see that especially for the second experiment we would need more measurement time
points, better CFSE measurements and perhaps additional information on the prolifer-
ation, e.g. with BrdU. Nevertheless, the third experiment yields interesting insights into
the dynamics of the naive T cell response to the PDAC tumor with generally comparable
rates to the ones found for the melanoma setting. In addition, for all experiements we
find that the anti-CD40 treatment has an effect on the number of divisions transferred
OT-I T cells do. But, as we will continue to discuss in the next chapter, our analysis
of the PDAC experiment suggests a slightly different mechanism leading to this effect.
From the model selection we infer that this is the consequence of an enhanced prolifera-
tion and to a lesser degree of a stronger activation/priming of naive T cells. In contrast,
the literature and the melanoma experiments rather suggest the latter to be affected by
an anti-CD40 treatment [44, 45, 46, 47].
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CHAPTER 5
Discussion
In this thesis we introduced a suitable data-preprocessing method and combined it with
data-driven modeling to understand the influence of an immunomodulatory intervention
on the T cell dynamics in a tumor context. The close alignment of the model with
the data yielded a detailed insight into the naive T cell tumor response and enabled
us to exclude plausible model alternatives. In the end, this gave us the possibility to
discern tumor and tumor site effects on the T cell dynamics and to understand treatment
effects of the immunostimulatory agonistic antibody against CD40. To our knowledge a
mechanistic understanding of this treatment option’s effect on the T cell compartment
has not been investigated yet, despite its use in various clinical trials against different
tumors. Consequently, through this work we contribute to a quantitative understanding
of T cell migration, activation and proliferation in two tumor settings under an anti-CD40
treatment.
Analyzing dye dilution measurements
In the second chapter we introduce a flexible mixture model for the analysis of dye dilu-
tion measurements to obtain information on the proliferative activity of cells in vivo. Cell
proliferation dyes like Carboxyfluorescein succinimidyl ester (CFSE), where the fluores-
cence intensity is halved with each division of the cell, are widely used and in consequence
many methods for its analysis have been developed. But mostly these methods have been
optimized for data from in vitro measurements [152, 114, 113, 119], where the noise re-
lated broadening and overlap of the fluorescence peaks in different generations, i.e. the
number of divisions a cell has accomplished, is not strongly impeding the analysis. In
this work, we account for the additional variability in in vivo data, by consequently using
data inherent information, i.e. the shape of the undivided and autofluorescence peaks.
The mixture model is built by halving the dye intensities of an undivided model peak
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taken from the data and by convoluting the constructed model peaks with the autoflu-
orescence intensities in a discrete manner by sampling. Subsequently the kernel density
estimates are calculated and the mixture model is smoothed. This is then binned in the
same way as the data and the model is fitted to the data. In this way one obtains the
relative weights for each model peak. As opposed to other approaches [114, 113] it is not
linked to a division cascade model, but simply gives back the fraction of cells in differ-
ent generations. This provides the possibility to use this information without having to
incorporate the analysis of the CFSE profiles into a proliferation model. Furthermore,
with this scheme different CFSE profiles can be flexibly combined for simultaneous op-
timization, but it also leaves the possibility to stay with a separate analysis of the data,
if this is needed due to differences in the CFSE brightness.
We tested our method for six experimental data sets provided by two different collab-
oration partners and got satisfactory results. The variability in the different data sets
motivated the introduction of flexible parameters with which one can change the binning
of the data, the range and distance of initial CFSE intensities to be tested and the number
of model peaks to be used. We also added the possibility to use a lognormal distribution
for the description of an undivided/single model peak, if the data of an undivided peak
is not at hand.
In summary this method provides the possibility to pass the CFSE intensities of the
samples to be analyzed to the algorithm together with an undivided model peak, if
available, and an autofluorescence peak. It returns the distribution of cells in different
generations and if needed also for jointly optimized results of different samples. With this
we present an opportunity to flexibly and accurately analyze dye dilution measurements.
To provide complementary proliferative information, it proved to be helpful to add
BrdU, which is incorporated by dividing cells, shortly before the measurement time
points. The knowledge about the short BrdU availability [133] and the assumption
that the average S/G2/M phase length does not change a lot [126, 112], enabled us to
incorporate the BrdU dynamics into the model in a simple way. This resulted in well
identifiable and realistic estimates of the activation rate and dwelling times in S/G2/M
and G1 phase.
T cell proliferation in response to different tumors
While the CD8+ T cell response has been studied in close accordance with experimental
data in contexts like the acute [115] and chronic immune response [105], so far we do not
know of similar approaches that describe the T cell response to tumor. Focusing only on
the T cells in the tumor-immune cell interaction enabled us to integrate relevant external
influences into the parameters of interest and simplify the model in a way, which leaves
these parameters identifiable with the given data. The basis of the model is built in line
with the well established dynamics of T cells in an acute infection setting: naive T cells
are attracted to and activated in the draining lymph node and subsequently proliferate
and egress to the tumor (site of infection). Starting from this basic model we tested
plausible variations by changing the time and division dependency of variables, while
keeping the complexity of the model within limits.
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Two tumor models were considered in this thesis: melanoma and pancreatic ductal ade-
nocarcinoma. Being an immunogenic tumor most advances in the field of immunotherapy
have been achieved by studying responses to treatment strategies in melanoma [74]. The
hope to find transferable results in this model, as well as the need for new treatment
strategies for melanoma itself motivated its choice. Here, we analyzed data from two
experiments with the well established subcutaneous murine B16/OVA model, which is
not physiological with respect to the inoculation site, but should reflect the principle
dynamics of a T cell response to tumor and the effect of an anti-CD40 treatment on it.
Equipped with our experiences and the mathematical model established and adjusted
with the first melanoma experiment, we moved on to a pancreactic cancer model and
applied a similar experimental setup and model. This tumor is more physiological due to
its orthotopic inoculation site and was developed to be close to the clinical setting in so
far as it resembles the histopathology of human PDAC—a tumor for which therapeutic
options are urgently needed.
Although the data of both melanoma experiments vary with respect to the absolute
recovered T cell numbers and the proliferative data, the models predict a similar dynamic.
We confirm a time dependent decrease of the proliferation in the draining lymph node and
an on average faster proliferation in the tumor, albeit only for two divisions in the time-
resolved experiment. This proliferation at the tumor site is likely needed, since model
alternatives, where highly proliferated cells can preferentially egress into the tumor and
thereby replace the proliferation, could not explain the data. The nature of the PDAC
experiments, discussed in chapter 4, was more explorative with few measurement time
points, but we succeeded in fitting a similar model to the more informative experiment
among them. Here, the proliferation in the tumor could be confirmed in the same way.
Overall, we obtained interdivision time estimates for the tumor ranging from 6h to 22h,
where the shorter interdivision time—although not unrealistic [144]—is fast, even for
optimally activated T cells (8 to 13h, see refs. [125, 126, 102]).
Further similarities in spite of the differences between the tumor settings are the initial
interdivision times in the draining lymph node. They range from 7 to 12h, but for the
initial interdivision time estimate in the best model fit of the first melanoma experiment
with 33h—a fit where the identifiability of proliferation associated rates was generally
more challenging. This might point at a weakness of the approach which only uses
CFSE to inform these parameters. Indeed, without the combination of both BrdU and
CFSE measurements, we observed also in other cases (not the best model fits) that
we could not identify the activation rate, which was then estimated to be arbitrarily
fast. This in turn implies that the time to first division has the same length as the
consecutive interdivision times, which we know to be unrealistic [123, 145, 146]. On the
other hand, the combination of both proliferative dyes turned out to be a useful tool to
determine proliferation rates and provided good fits. For example, the estimated initial
interdivision times in the melanoma experiment using BrdU are surprisingly close to the
reported interdivision times of activated OT-I T cells in ref. [126]: the authors measure
an average cell cycle time of 10.1h and find that 72% of the time is spent in S/G2/M.
Although the implied linear relationship between the length of the S/G2/M phase and
97
Chapter 5. Discussion
the total cell cycle time in this study is debatable [127, 137, 112] and not used in our
model assumption, we find astoundingly similar results with a dwelling time of 2.3h in
the G1 phase and 7.8h in the S/G2/M phase.
A noteworthy difference between the model fits of the two tumor settings is the pre-
diction of a fast continued proliferation in the draining lymph node in PDAC as opposed
to an attenuated proliferation over time in melanoma. These differences could already
be guessed by observing the more highly proliferated cells in the PDAC data. Modeling,
in addition, suggested a moderatly higher proliferative activity in the tumor, since the
fast proliferation is kept up for six generations.
This phenomenon can be attributed to the different tumor cell lines and their microen-
vironment and immunogenicity, but also other reasons can be considered. We already
suggested that an overpopulation of the draining lymph node might dampen the prolifer-
ative response, as we have an order of magnitude more cells in the melanoma experiments.
But also different tumor inoculation sites can lead to differences in its local architecture,
which influences the immune response. For example it is reported, that the tumor site
changes the lymph node like vasculature in B16 melanoma [153], as well as the devel-
opment of tertiary lymphoid structures (TLS) [154, 155]. In addition, the differences
in infection sites are known to have various influences on the dendritic cell priming and
T cell homing [156, 157, 158]. With respect to the TLS, however, we know that most
likely both tumors did not develop these, since it is unlikely in primary subcutaneuous
murine melanoma [155] and our collaboration partners have not observed TLS in their
30364-OVA cell line, so far. Bearing in mind the studies concerning the lymph node
like vasculature in tumors, the mathematical model could be expanded to include a sep-
arate naive T cell recruitment and activation rate for the tumor. Indeed, naive T cell
recruitment and activation is reported in ref. [153, 159]. But this is not easily induced in
an effective manner [160]—not least due to the metabolic activity of melanoma produc-
ing lactate [161], which creates a hostile environment, especially for naive T cells [162].
Furthermore, these model parameters would be hard to identify due to the increased
complexity. In consequence, neither the literature nor the feasibility strongly suggested
the introduction of this mechanism. All in all, the studies on the site-dependency of the
TLS and the lymph node like vasculature still permit the assumption of an influence of
the tumor location on the proliferation dynamics.
However, the difference of the proliferative activity between the PDAC and melanoma
setting is put into perspective by the fact that in all three experiments we found evidence
for cells to stop after a certain number of divisions. This in particular means that the fast
proliferation in the draining lymph node in the PDAC setting will eventually also come
to a halt. It is noteworthy that an attenuated proliferation over time and a division stop
mechanism were not interchangeable, i.e. could be distinguished by fitting the respective
model. The division stop mechanism was introduced when a large absolute cell number
needed to be reconciled to a CFSE profile with relatively few cells which have divided
often, such that cells could divide and accumulate without overpopulating the higher
generations. Although we cannot tell from our study how the abrupt division stop is
regulated, it could be the result of a division destiny—a concept, in which the number of
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divisions a cell undergoes, i.e. their division destiny, is determined before its first division
and influenced by early costimulatory signals [108]. Interestingly the generation in which
the proliferation in the tumor stops is different between the two melanoma experiments.
This might be a consequence of a general variability between the experiments, but a likely
explanation is the tumor size, which correlates with the number of divisions a cell did.
It remains to be investigated, whether the observed difference is indeed a consequence of
a larger tumor, entailing, for example, a higher concentration of antigens, cytokines and
more costimulation by other immune cells. These stimuli could then lead to an increased
mean division destiny [108]. For future investigations a way to test this hypothesis
would be to measure antigen concentrations as a proxy for the stimulation of T cells in
the draining lymph node.
Altogether, we observed different ceasing mechanisms for the proliferation in the drain-
ing lymph node (division stop and the attenuated proliferative activity). In the tumor
the likely division destiny provides an interesting contrast to the fast proliferation, which
could not be explained by other mechanisms. Yet a fast proliferation at the site of in-
flammation is in principle not unexpected. In refs. [134, 138] it has been shown that the
highly proliferated cells at these sites are not the consequence of a preferential egress of
highly divided cells from the draining lymph node, but the result of local proliferation,
which we also suggest with our analysis. Furthermore, this is in line with various mea-
surements of Ki-67 in CD8+ T cells at the tumor site [163, 164, 165] or measurements
of T cell proliferation in the tumor [159]. Nevertheless, a continued proliferation at the
tumor site would have been unexpected: The tumor environment consists of a variety of
immunosuppressive myeloid and lymphoid cells, suppressive metabolites and cytokines,
which casts doubt on the ability of T cells to proliferate there [151, 166, 167]. For this
reason, our study, which predicts a moderately fast proliferation and a likely cessation
after a few divisions suggests a realistic mechanism.
Distinct death rates due to different tumors? The enhanced proliferation in the pan-
creatic model compared to the melanoma model is contrasted by lower OT-I T cell
numbers in all organs. A possible explanation is the higher fraction of dead cells among
the transferred T cells seen in the life/dead gate of the flow cytometry analysis. This
difference between the experiments was more pronounced in the draining lymph node,
although in general a limited comparability of these gates has to be taken into account.
Interestingly, the tendency of an overall death rate in the pancreatic cancer experiment
was confirmed by fitting corresponding models, in spite of the limited identifiability of
the death rate. Indeed, the introduction of an overall death rate—as opposed to one only
in the tumor—improved the fit, which was not the case for the melanoma experiment.
Yet, an introduction of this rate into the model of the pancreatic cancer experiment could
not be justified by the improvement, due to the increase in model complexity. In the
melanoma experiment, we had either no evidence for a death rate or evidence for a death
rate which is confined to the tumor.
It would not be surprising for PDAC to be giving rise to an immunosuppressive tumor
environment with cells controlling an effective immune response [73] and it is interesting
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to note, that the melanoma might be creating a similarly hostile tumor microenvironment.
But with this observation, we can assume that the pancreatic tumor unlike melanoma
induced a systemic immunosuppressive response which goes beyond the immediate tumor
environment. Death in the periphery can affect several T cell subsets [162, 168] and is
reported to be triggered by different mechanisms than in the tumor environment, for
example by not properly activated dendritic cells or a cessation of cytokines and growth
factors [169]. Whether a mechanism like an activation induced death is really contributing
to this phenomenon, would need further investigation.
It is noteworthy that these differences between the two tumor settings, i.e. T cell death
and proliferation, are more pronounced in the draining lymph node and not in the tumor
environment. Since studies report the importance of the systemic immune response as
opposed to the local response in the tumor during tumor rejection [170], it would be
interesting to better understand in further studies how and with what consequences the
pancreatic tumor shapes the T cell response to the same antigen outside of the tumor.
The effect of anti-CD40
The treatment of immunologically cold tumors still poses a challenge for immune therapy,
which established itself as a fourth pillar in cancer therapy. A recent review by Vonder-
heide, ref. [4], suggests anti-CD40 treatment as an option to aid the conversion of a cold
tumor into a hot one and in order to fully exploit the potential of other immunotherapeu-
tic interventions and chemotherapies [65, 63, 57]. Indeed, on its own its treatment effects
so far are limited [57, 63, 60], which we could confirm with the analyzed experiments.
In the melanoma experiments we could perceive a slightly decreased tumor growth, but
no effect was observed in the PDAC experiments. Nevertheless, with our modeling ap-
proach we could point out mechanisms and dynamics of T cells which are influenced by
the anti-CD40 treatment. This was achieved by determining parameters which need to
be different, if both the treatment and the control data are fitted simultaneously.
The egress rate is attenuated by the anti-CD40 treatment The perhaps most sur-
prising finding was the attenuated egress of T cells under treatment in both melanoma
experiments. With our modeling of the time-resolved melanoma experiment which en-
compassed a time range of 5 days we could, furthermore, identify an increasing egress
rate in a time dependent manner. In contrast, when fitting the proliferation-resolved
melanoma experiment, the time dependence could not be well resolved. A reason could
be that the measurements span only one day. Still, there was evidence for this mech-
anism, as its introduction improved the fit—albeit not sufficiently to justify the added
model complexity. For the PDAC experiment in turn, there was no indication of a time
or treatment dependent egress, but the rate is also poorly constrained. Indeed, its confi-
dence boundary largely overlaps with the confidence boundaries of the other egress rates,
irrespective of their time and treatment dependency. The similar range of these rates is
surprising, given that many factors like the local vasculature and tumor microenviron-
ment influence the egress rate (and probably more than they influence the proliferation
rate).
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In both melanoma experiments we could on average confirm a tenfold decrease of
the egress rate due to the treatment. The rates are comparable from day 3 onwards,
which happens to be the earliest measurement time point for the proliferation-resolved
melanoma experiment and implies that further measurement time points might have
revealed a similar time dependency. In the experiment where we could resolve the time
dependency, the egress starts to increase from day 2 onwards in the control and from
day 4 onwards in the treatment setting. A similar range for the initiation of egress
is reported in an acute infection setting and a setting where T cells are activated by
antigen loaded dendritic cells, see refs. [171, 172]. Interestingly the authors claim that
T cells with a higher affinity to the presented antigen remain longer in the lymph nodes
and spleen (> 4days) than low affinity T cells, which interact less stably with dendritic
cells. Indeed, it has been shown that an anti-CD40 treatment enhances the interaction
between dendritic cells and T cells [173]. In consequence, one could speculate that this
mechanism is enhancing the dwelling time in the draining lymph node. On the other
hand, in ref. [171] it is reported that the prolonged dwelling time is correlated with the
slower development of an effector phenotype, which we cannot confirm with our data—if
at all, we see a slightly increased proportion of CD27low cells due to the treatment,
which is indicative of a more terminal effector phenotype. To analyze and compare this
further, future work could incorporate measurements of granzyme B (GzmB), which is
expressed by effector cells, or measurements of the transcriptional factors regulating the
effector functions, like the basic leucine zipper transcription factor, ATF-like (BATF) and
interferon-regulated factor 4 (IRF4), which are mentioned in ref. [171]. Furthermore in
order to have a more direct measurement of the propensity to egress one could investigate
the expression of sphingosine 1-phosphate receptor type 1 (S1PR1) on T cells, which
controls their exit from the lymph node [174] and should be internalized upon T cell
activation [38]. This mechanism would be of particular interest since it provides a direct
link between the egress rate, which according to our analysis is attenuated by the anti-
CD40 treatment and the activation rate, which we found to be increased by the treatment.
Does anti-CD40 influence the activation and/or the proliferation? The results of the
proliferation-resolved melanoma experiment, the PDAC experiment and to some degree
the time-resolved melanoma experiment agree in so far as we can discern more highly
divided cells in the anti-CD40 treatment setting. The explanation obtained from the
model fit however vary slightly. The model fit to the data of the melanoma experiment
with additional proliferative information (BrdU) unambiguously points at an enhanced
activation rate of T cells, which could be expected from the literature [38]. There is also
evidence for an altered activation in the pancreatic model, however to a lesser degree than
an enhanced proliferation. Finally we have evidence towards an increased proliferation at
early time points in the time-resolved melanoma experiment, albeit in combination with
an unidentifiable activation rate, such that it is hard to draw a conclusion concerning
this rate from the model fit. Thus, having either an unidentifiable activation rate or no
undivided cells to inform this rate properly in the PDAC experiment, there is no real
counterargument to the evidence of an enhanced activation obtained from the fit to the
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data combining BrdU and CFSE. The increased proliferation cannot be rejected, but is
more arguable.
This conclusion contributes to the answer of the question raised in a recent review
paper [4], whether an anti-CD40 treatment is recruiting new naive T cells to respond to
tumor and/or is just enhancing the proliferation of already activated T cells. Here, we
provide evidence that previously naive T cells are more strongly activated, i.e. recruited,
as a consequence of the anti-CD40 treatment. The second part of the question is harder
to answer: although there is evidence of an enhanced proliferation, it is weaker and we
do not know whether this is just a consequence of the enhanced activation or a separate
mechanism acting on already activated cells. To pursue this question further, a future
study could test the effect of anti-CD40 on already activated T cells with a similar
approach as is presented here.
In principle, the fact that slightly different anti-CD40 antibodies were used could con-
tribute to the observed differences between the PDAC and the melanoma setting. But
personal communication with my collaboration partners suggest, that the anti-CD40 ef-
fect should be similar and furthermore, the constant part is known to bind to the same
Fcγ receptor [18, 21]. In consequence, it is unlikely that a significant difference can
stem from the distinct antibodies. Our observation that for the PDAC experiment the
anti-CD40 effect is leaning more towards an enhanced proliferation than activation could
also be affected by the fact that the administration was shared between two days. This
means that half of the dosis was applied one day later than in the melanoma experiment.
Another point of concern could be, that we have a PBS control (as opposed to an isotype
control) in the PDAC setting such that we do not know whether the observed effects of
anti-CD40 in this experiment might also be caused by unspecific activation. But as the
observed anti-CD40 effects in the PDAC setting are similar to the ones in the melanoma,
this does not seem very likely either. Nevertheless, in order to rule out these possibilities
one would need to perform the experiments with the same anti-CD40 antibody, the same
administration time points and the same isotype control.
An interesting question which is beyond the scope of this work, is whether the anti-
CD40 treated T cells can also provide a better tumor killing capacity either phenotyp-
ically or as a whole due to increased numbers. In any case, this effect, if existent, is
expected to be small [57, 63, 60]. Although at early time points we seem to have fewer T
cells in the tumor of the anti-CD40 treated mice, it is conceivable that they increase more
at later time points due to a delayed egress and an increased proliferation and activation.
A follow-up over an extended period of time would be needed to resolve these longterm
dynamics. As for the phenotype of a single T cell, it would be expedient to conduct
killing essays and to check with different markers, whether the cells have acquired better
effector functions: So far in our study neither our measurements of CD62L and CD27,
with the help of which effector and memory T cells can be distinguished [38, 148, 149],
nor the activation and exhaustion marker PD-1 (not shown) were differently expressed
in different organs or showed conspicuous tendencies over time. Furthermore, the atten-
uated growth of the tumor cannot necessarily be attributed to the anti-CD40 treatment
effect on naive T cells, which need to be activated first, because the decelerated growth
102
starts shortly after the beginning of the treatment. Hence, a direct effect of anti-CD40
on immune cells in the tumor environment seems more likely.
In summary, in this work, we show how a data-driven modeling approach can reveal
new aspects of an already well studied immunotherapeutic treatment option. To this
end, we introduced a generally applicable method for the analysis of cell proliferation
dye measurements. By exploiting the proliferative measurements analyzed with this
method and combining them with the information from absolute cell number counts, we
could establish a data-driven model. This sheds light on the way an anti-CD40 treat-
ment shapes the dynamics of the T cell tumor response. We can conclude that it is
affecting this response in at least two ways—through an enhanced activation of naive
T cells and through their retention in the draining lymph node—and provide, herewith,
a good starting point for follow-up studies. Future studies investigating the predicted
anti-CD40 effect on the naive T cell response could be performed, for example, by mea-
suring the delay in the upregulation of egress surface markers (e.g., S1PR1) or effector
molecules (e.g., granzyme B). In addition, the treatment’s influence on the proliferative
capacity of already activated T cells could be tested. Furthermore, research on other
immunotherapeutic treatments using a similar approach, as is outlined in this thesis,
could be conducted. Results from these studies should contribute to inform optimized
treatment schedules to mount a successful and lasting immune response against cancer.
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APPENDIX A
Supplementary information to the solution of ordinary differential
equations for birth models
A.1. Solving an ordinary differential equation for a birth
model with a time dependent proliferation rate
Consider the following differential equation for a birth model where the proliferation rate
k changes in time:
d
dt
G0(t) = −k(t)G0(t)
d
dt
G1(t) = 2k(t)G0(t)− k(t)G1(t)
d
dt
G2(t) = 2k(t)G1(t)− k(t)G2(t)
...
Here, Gi(t) is the number of cells which divided i times. We want to derive a solution
for Gi(t), with the initial conditions G0(0) = G0 and Gi(0) = 0 ∀i ∈ N∗. G0(0) is the
initial number of undivided cells.
We write the indefinite integral of k(t) as Fk(t) with ddtFk(t) = k(t). We furthermore
define K(t) :=
(∫ t
0k(t
′) dt′
)
. For the expression K(t) it thus follows
d
dt
K(t) =
d
dt
(∫ t
0
k(t′) dt′
)
=
d
dt
(Fk(t)− Fk(0)) = d
dt
Fk(t) = k(t). (A.1)
In the following we would like to show that
Gn(t) =
2nG0
n!
K(t)ne−K(t) (A.2)
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by employing a mathematical induction.
Show that the statement holds for n = 0
The solution for G0(t) is
G0(t) = b0e
−K(t), (A.3)
where b0 has to be defined by initial conditions.
We show this by calculating
d
dt
G0(t) = b0(−k(t))e−K(t) = −b0k(t)e−K(t) (A.3)= −k(t)G0(t).
Determine b0 by plugging in initial conditions:
G0(0) = b0e
−K(0) != G0,
so b0 = G0 and we obtain:
G0(t) = G0e
−K(t). (A.4)
Our statement is true for n = 0.
Induction step
The induction hypothesis is
Gn(t) =
2nG0
n!
K(t)ne−K(t) (A.5)
and under this assumption we show that
Gn+1(t) =
2n+1G0
(n+ 1)!
K(t)n+1e−K(t) (A.6)
can solve
d
dt
Gn+1(t) = 2k(t)Gn(t)− k(t)Gn+1(t). (A.7)
We calculate
d
dt
Gn+1(t) =
(A.6)
2n+1G0
(n+ 1)!
(
(n+ 1)Kn(t)k(t)e−K(t) − k(t)K(t)n+1(t)e−K(t)
)
= 2k(t)
2nG0
n!
Kne−K(t) − k(t) 2
n+1G0
(n+ 1)!
Kn+1(t)e−K(t)
= 2k(t)Gn(t)− k(t)Gn+1(t)
and see that (A.6) solves the equation, if (A.5) is true.
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A.2. Solving an ordinary differential equation for birth
models with a source term
To gain an intuition how a continuous influx of undivided cell changes the dynamics and
in how far a death rate in all organs could be compensated by an influx, we calculated
the solution to the following simplified model.
Assume a cell proliferation with exponential waiting times with a general death rate d
and a proliferation rate k
d
dt
src(t) = −d · src(t)
d
dt
G0(t) = src(t)− (k + d) ·G0(t)
d
dt
G1(t) = 2k ·G0(t)− (k + d) ·G1(t)
d
dt
G2(t) = 2k ·G1(t)− (k + d) ·G2(t) (A.8)
...,
where the src is the influx of undivided cells from an outside compartment and Gi(t) is
the number of cells which divided i times. We want to derive a solution for Gi(t) with
the initial conditions src(0) = src0 and Gi(0) = 0 ∀i ∈ N0. src0 is the initial influx of
undivided cells.
In all basic model structures in this work, we have no death rates. In these cases, by in-
troducing a constant influx term (i.e. src = const.), we implicitly assume a compartment
outside, which is either very large or steadily replenished, such that it can continuously
provide the same number of cells at all times. If we assume that the compartment is very
large a death rate should not change the influx dynamics. If we think of it in terms of a
replenished compartment the introduction of a death rate for the source term, as is done
in (A.8), makes sense. As the solution of (A.8) is neat and provides an intuition for this
model, it is presented here.
The first equation in eq. A.8 yields
src(t) = src0 · e−dt. (A.9)
In the following we show that
Gn(t) =
2nsrc0
k
e−dt
(
1−
n∑
i=0
(kt)i
i!
e−kt
)
, (A.10)
with mathematical induction.
This solution means that all generations Gn(t) scale with e−dt, which can be compen-
sated by src0 at single time points. This is not the case anymore if we have no death
rate in the source term. We can, furthermore, see that the second term in the bracket is
a cumulative Poisson distribution ranging from 0 to n.
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Show that the statement holds for n = 0
To solve
d
dt
G0(t) = src(t)− (k + d)G0(t) = src0e−dt − (k + d)G0(t) (A.11)
use variation of parameters. The solution of the homogeneous equation G˙0(t) = −(k +
d)G0(t) is G0(t) = b0 · e−(k+d)t and to solve the inhomogeneous equation we use the
Ansatz:
G0(t) = b0(t)e
−(k+d)t (A.12)
with its derivative
d
dt
G0(t) = −b0(t)(k + d)e−(k+d)t + d
dt
(b0(t)) e
−(k+d)t
=
(A.12)
−(k + d)G0(t) + d
dt
(b0(t)) e
−(k+d)t (A.13)
Now equate (A.11) and (A.13)
− (k + d)G0(t) + d
dt
(b0(t)) e
−(k+d)t = src0e−dt − (k + d)G0(t)
and we obtain
d
dt
b0(t) = src0e
kt.
A general solution for b0(t) is then
b0(t) = src0
∫
ekt
′
dt′ =
src0
k
ekt + b0,0, (A.14)
where b0,0 is a constant which has to be determined by the initial condition. Now insert
(A.14) in (A.12) and obtain:
G0(t) =
(src0
k
ekt + b0,0
)
e−(k+d)t. (A.15)
For G0(0)
!
= 0 we obtain
b0,0 = −src0
k
. (A.16)
Inserting (A.16) into (A.15), we have
G0(t) =
src0
k
e−dt
(
1− e−kt
)
,
with which we showed (A.10) for n = 0.
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Induction step
Assuming that (A.10) holds, we have to show that
Gn+1(t) =
2n+1src0
k
e−dt
(
1−
n+1∑
i=0
(kt)i
i!
e−kt
)
. (A.17)
solves
d
dt
Gn+1(t) = 2k ·Gn(t)− (k + d) ·Gn+1(t). (A.18)
The derivative of (A.17) is calculated:
d
dt
Gn+1(t) = (−d)2
n+1src0
k
e−dt
(
1−
n+1∑
i=0
(kt)i
i!
e−kt
)
+
2n+1src0
k
e−dt
(
−(n+ 1)k
n+1tn
(n+ 1)!
e−kt − (−k) (kt)
n+1
(n+ 1)!
e−kt
−nk
ntn−1
n!
e−kt − (−k)(kt)
n
n!
e−kt...− k
1!
e−kt − (−k)kt
1!
e−kt
−(−k) 1
0!
e−kt + k − k
)
.
The expression in the first line simplifies to −d ·Gn+1(t). In the case of the remaining
expressions we add a +k − k inside of the brackets. Then we summarize all terms with
the multiplicative factor of (−k) in front and the extra −k and obtain −k ·Gn+1(t) and
are left with
d
dt
Gn+1(t) = −d ·Gn+1(t)− k ·Gn+1(t)
+
2n+1src0
k
e−dt
(
−k
n+1tn
n!
e−kt − k
ntn−1
(n− 1)!e
−kt...− ke−kt + k
)
.
(A.19)
Taking k out of the brackets we have:
d
dt
Gn+1(t) = −d ·Gn+1(t)− k ·Gn+1(t)
+2k
−2nsrc0
k
e−dt
(
−(kt)
n
n!
e−kt − (kt)
n−1
(n− 1)!e
−kt...− e−kt + 1
)
(A.20)
and by using (A.10) we have
d
dt
Gn+1(t) = −(k + d) ·Gn+1(t) + 2k ·Gn(t). (A.21)
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B.1. Supplementary figures to the data
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Figure B.1 : OT-I T cell density in the tumor. The density of OT-I T cells is smaller in the
anti-CD40 treatment setting
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Figure B.2 : Number of undivided cells in the a) tumor and b) blood for the time-resolved
(Exp. 1) and the proliferation-resolved (Exp. 3) experiment: anti-CD40 treatment (dashed) and
control (solid).
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Figure B.3 : Fraction of CD62Lhi(left column) and CD27hi(right column) cells in the draining
lymph node (green) and tumor (red) for both the time-resolved experiment (Exp.1, upper lane)
and the proliferation-resolved experiment (Exp.3, lower lane).
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B.2. Differential equations and observable functions of the
mathematical model
B.2.1. Time-resolved model
Differential equations for the time-resolved model Differential equations used to de-
scribe the dynamics of proliferating cells in the draining lymph node:
˙InaktdLN = −act · InaktdLN + source
˙Akt0dLN = act · InaktdLN − pdLN ·Akt0dLN
˙Akt1dLN = 2pdLN ·Akt0dLN − (pdLN + edLN ) ·Akt1dLN
˙Akt2dLN = 2pdLN ·Akt1dLN − (pdLN + edLN ) ·Akt2dLN
...
˙Akt4dLN = 2pdLN ·Akt3dLN − (edLN ) ·Akt4dLN
p˙dLN = −α · pdLN
e˙dLN = β · edLN · (1− edLN/edLN,max). (B.1)
Here, AktXdLN is reperesenting the “activated T cell in generation X in the draining
lymph node”. InaktdLN stands for the inactive undivided cells. The division stops after
generation 4. The last two lines are determining the time dependency of the proliferation
pdLN and the egress edLN , such that the proliferation decays exponentially with time and
the egress grows logistically in time. The initial values are 0, but for the rates (pdLN,0
and edLN,0).
Differential equations governing the proliferating cells in the tumor:
˙Akt1T,1 = edLN ·Akt1dLN − pT ·Akt1T,1;
˙Akt2T,1 = 2pT ·Akt1T,1 − pT ·Akt2T,1
˙Akt3T,1 = 2pT ·Akt2T,1
˙Akt2T,2 = edLN ·Akt2dLN − pT ·Akt2T,2;
˙Akt3T,2 = 2pT ·Akt2T,2 − pT ·Akt3T,2
˙Akt4T,2 = 2pT ·Akt3T,2
...
˙Akt4T,4 = edLN ·Akt4dLN − pT ·Akt4T,4;
˙Akt5T,4 = 2pT ·Akt4T,4 − pT ·Akt5T,4
˙Akt6T,4 = 2pT ·Akt5T,4. (B.2)
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Here, AktXT,Y is representing the “activated T cell in generation X in the tumor, which
entered the tumor in generation Y”. With this we can keep track of the history of the
cell, i.e. at which generation it entered the tumor and ascertain that it divides only twice
more. In contrast to the draining lymph node, in the tumor there is no equation for
undivided cells InaktT , as this is a parameter and not a state.
Observable for the time-resolved model The set of observable functions g com-
prises the following quantities of interest: absolute cell number in draining lymph node
(AbsdLN ) and tumor (AbsT ), mean number of division for the generations 1 to 4 or 5
for draining lymph node and tumor (MDivdLN,5+ or MDivdLN,6+ and MDivT,5+ or
MDivT,6+) and the fraction of cells in generation 0 (ReldLN,0 and RelT,0) and genera-
tions 5+ or 6+ (ReldLN,5+ or ReldLN,6+ and RelT,5+ or RelT,6+). Note in the following
that the mean number of divisions is normalized by cells from generation 1 to 4 or 5,
which are also the generations contributing to the numerator. Here, we note the observ-
able function for the measurement days 4 and 7, where we could obtain the fractions of
cells in the generation 0 to 4. The equations are analogous for the case, where we have
the fractions for the generations 0 to 5.
AbsdLN = InaktdLN +Akt0dLN ...Akt4dLN
MDivdLN,5+ =
Akt1dLN + 2 ·Akt2dLN + 3 ·Akt3dLN + 4 ·Akt4dLN
Akt1dLN +Akt2dLN +Akt3dLN +Akt4dLN
ReldLN,0 =
InaktdLN +Akt0dLN
AbsdLN
ReldLN,5+ = 0 (B.3)
AbsT = InaktT +Akt1T,1 +Akt2T,1...Akt4T,4 +Akt5T,4 +Akt6T,4
MDivT,5+ =
Akt1T,1 + 2(Akt2T,1 +Akt2T,2) + ...+ 4(Akt4T,2 +Akt4T,3 +Akt4T,4)
AbsT − (InaktT +Akt5T,3 +Akt5T,4 +Akt6T,4)
RelT,0 =
InaktT
AbsT
RelT,5+ =
Akt5T,3 +Akt5T,4 +Akt6T,4
AbsT
(B.4)
In summary, for each measurement time point we have 2 ·8 observables (treatment and
control) and in total we have four measurment time points, which gives us 64 observables.
From this we have to substract three, as we do not have information on the cell division
profiles in the tumor on day two for the treatment setting, i.e. we do not haveMDivT,5+,
RelT,0 and RelT,5+ such that we are left with 61 observables.
134
B.2. Differential equations and observable functions of the mathematical model
B.2.2. Proliferation-resolved model
Differential equations for the proliferation-resolved model Differential equations gov-
erning the proliferation of BrdU- cells in the draining lymph node:
˙InaktdLN,B− = −act · InaktdLN,B− + source
˙Akt0dLN,G1,B− = act · InaktdLN,B− − pG1,dLN ·Akt0dLN,G1,B−
˙Akt0dLN,S,B− = pG1,dLN ·Akt0dLN,G1,B− − pS ·Akt0dLN,S,B−
˙Akt1dLN,G1,B− = 2pS ·Akt0dLN,S,B− − (pG1,dLN + edLN ) ·Akt1dLN,G1,B−
˙Akt1dLN,S,B− = pG1,dLN ·Akt1dLN,G1,B− − (pS + edLN ) ·Akt1dLN,S,B−
...
˙Akt6+dLN,G1,B− = 2pS · (Akt5dLN,S,B− +Akt6+dLN,S,B−)− (pG1,dLN + edLN ) ·Akt6+dLN,G1,B−
˙Akt6+dLN,S,B− = pG1,dLN ·Akt6 +dLN,G1,B− − (pS − edLN ) ·Akt6+dLN,S,B−
p˙G1,dLN = −α · pG1,dLN . (B.5)
Here, AktXdLN,Y,B− is reperesenting the “activated T cell in generation X in the drain-
ing lymph node in cell cycle phase Y, which is BrdU-”. G1 stands for the G1 phase
and S for the combination of the phases S, G2 and M. The BrdU+ cell dynamics are
governed by analogous equations. Initially all states (BrdU+ and BrdU-) are zero and
all states with BrdU+ remain zero until the time point of BrdU administration. At the
time point of BrdU injection all BrdU- cells in our S phase (AktXdLN,S,B−) become
BrdU+ (AktXdLN,S,B+), such that their numbers are transferred from the former com-
partment to the latter and the proliferation continues. As a consequence, we do not
have inactive BrdU+ cells (InaktdLN,B+) and active undivided BrdU+ cells in the G1
phase (Akt0dLN,G1,B+), as there is no prior state, for which BrdU- cells can turn BrdU+
and can enter into these compartments. Thus, compared to the equations governing the
dynamics of the BrdU- cells (B.5), the equations for the BrdU+ cells lack the first two
equations and the third equation lacks the input from the activated undivided cells in
G1. In generation 6+ the equations are written such that the proliferation continues and
cells alternate between the G1 and our S phase. The last line is determining the time
dependency of the proliferation pG1,dLN and has the initial value pG1,dLN,0 .
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Differential equations governing the proliferation of BrdU- cells in the tumor:
˙Akt1T,G1,B− = −pG1,T ·Akt1T,G1,B− + edLN ·Akt1dLN,G1,B−
˙Akt1T,S,B− = pG1,T ·Akt1T,G1,B− − pS ·Akt1T,S,B− + edLN ·Akt1dLN,S,B−
˙Akt2T,G1,B− = 2pS ·Akt1T,S,B− − pG1,T ·Akt2T,G1,B− + edLN ·Akt2dLN,G1,B−
˙Akt2T,S,B− = pG1,T ·Akt2T,G1,B− − pS ·Akt2T,S,B− + edLN ·Akt2dLN,S,B−
...
˙Akt6T,G1,B− = 2pS (Akt5T,S,B− +Akt6T,S,B−)− pG1,T ·Akt6T,G1,B−
+ edLN ·Akt6dLN,G1,B−
˙Akt6T,S,B− = pG1,T ·Akt6T,G1,B− − pS ·Akt6T,S,B− + edLN ·Akt6dLN,S,B− (B.6)
As opposed to the draining lymph node there are no undivided cells InaktT , as this is
a parameter and not a state and stays constant over time. Cells from generation X and
phase Y can enter from the draining lymph node (AktXdLN,Y ) into the corresponding
tumor state (AktXT,Y ) with rate edLN . The rest works analogously to the draining
lymph node.
Observables for the proliferation-resolved model The set of observable functions g
comprises the following quantities of interest: absolute cell number in draining lymph
node (AbsdLN ) and tumor (AbsT ) and, if available, the fraction of BrdU+ and BrdU-
cells for each generation from 0 to 5+ or 6+ in the draining lymph node (ReldLN,0,B− and
ReldLN,0,B+ to ReldLN,5+,B− or ReldLN,6+,B− and ReldLN,5+,B+ or ReldLN,6+,B+) and
the tumor (analogous observables as for the draining lymph node). As the information
comprised in the fractions is not independent, the last fraction is not used for the fit and
if two or more fractions sum up to ≤ 2%, all of these are not used for the fit and the
respective observable functions are omitted accordingly. If only one fraction is omitted
(in this example: ReldLN,5+,B+), for the draining lymph node we would obtain:
AbsdLN = InaktdLN,B− +Akt0dLN,G1,B− +Akt0dLN,S,B−...Akt6+dLN,S,B−
+Akt0dLN,S,B+ +Akt1dLN,G1,B+...Akt6+dLN,S,B+
ReldLN,0,B− =
InaktdLN,B− +Akt0dLN,G1,B− +Akt0dLN,S,B−
AbsdLN
ReldLN,0,B+ =
Akt0dLN,S,B+
AbsdLN
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ReldLN,1,B− =
Akt1dLN,G1,B− +Akt1dLN,S,B−
AbsdLN
ReldLN,1,B+ =
Akt1dLN,G1,B+ +Akt1dLN,S,B+
AbsdLN
...
ReldLN,5+,B− =
Akt5dLN,G1,B− +Akt5dLN,S,B− +Akt6dLN,G1,B− +Akt6dLN,S,B−
AbsdLN
.
If the information on the fraction of BrdU+/- cells in different generations is available
in the tumor data, the analogous observable equations can be applied. The only exception
is the undivided fraction of cells, where we do not distinguish between BrdU+/-. Here,
we use the combined fraction RelT,0 instead, since we assume all these cells to be inactive.
Although the real state of these cells is not quite clear (see section 3.2.1), at least the
number of BrdU+ cells in this fraction is negligible.
If the fractions of cells in different generations are not identifiable even when BrdU+
and BrdU- cells are combined, the absolute cell numbers AbsT and the total fraction of
all BrdU+ cells RelT,all,B+ are used as observables. If the combined BrdU+ and BrdU-
fraction of cells for each generation is available, these can be used as observables and we
obtain
AbsT = InaktT +Akt1T,G1 +Akt1T,G2M ...+Akt6+T,S
Akt1T,G1,B+ +Akt1T,G2M,B+...Akt6+T,S,B+
RelT,all,B+ =
Akt1T,G1,B+ +Akt1T,G2M,B+...Akt6+T,S,B+
AbsT
RelT,0 =
InaktT
AbsT
RelT,1 =
Akt1T,G1,B− +Akt1T,S,B− +Akt1T,G1,B+ +Akt1T,S,B+
AbsT
...
RelT,4 =
Akt4T,G1,B− +Akt4T,S,B− +Akt4T,G1,B+ +Akt4T,S,B+
AbsT
,
where we again omit the last fraction (RelT,5+).
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Number of Observables In total we have 79 observables.
For the fit to the treatment and control data on day 3: 2 observables from the absolute
cell numbers, 13 observables for the BrdU+ and BrdU- fractions of cells in the generations
0 to 6+ of the draining lymph node, 5 observables for the BrdU+/- combined fractions
of cells in the generations 0 to 5+ of the tumor and one for fitting the total fraction of
BrdU+ cells in the tumor. This gives us 21 observables and if we combine the ones from
the treatment and control we obtain 42 in total.
For the fit to the control data on day 4 we have 2 observables from the absolute cell
numbers, 11 observables for the BrdU+ and BrdU- fractions of cells in the generations 0
to 5+ of the draining lymph node, 9 observables for the BrdU+ and BrdU- fractions of
cells in the generations 1 to 5+ of the tumor and one from the the undivided number of
cells in the tumor. This leaves us with 23 observables.
For the fit to the treatment data on day 4 we have 2 observables from the absolute cell
numbers, 11 observables for the BrdU+ and BrdU- fractions of cells in the generations
0 to 5+ of the draining lymph node, none for the cell division profile in the tumor and
one for fitting the total fraction of BrdU+ cells in the tumor. This leaves us with 14
observables.
B.3. Best model fits with different observables
The best minimal model was found by conducting a model selection with a fit to the mean
number of divisions for the time-resolved experiment (section 3.2.4) and a direct fit to
the cell division profile for the proliferation-resolved experiment (section 3.2.5). Here,
in Figs. B.4 and B.5, we show results for the best minimal models fitted to observables,
which are swapped between the two experiments. The similarity of the results show the
robustness of the fits: For the time-resolved experiment compare Tab. 3.3 and Tab. B.1
and for the proliferation-resolved experiment compare Tab. 3.4 and Tab. B.2.
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Figure B.4 (previous page): Fit of the best minimal model to the data of the time-resolved
experiment using the cell division profiles as observables. a) & b) Fit to the absolute cell numbers
in the draining lymph node (green) and tumor (red) for the a) control and b) anti-CD40 treat-
ment. c) Estimated proliferation rate in the draining lymph node, which is the same for control
and treatment. Filled area indicates the 95% confidence interval. d) Estimated egress rate for
the control (solid) and treatment (dashed). Filled area indicates the 95% confidence interval.
e) - h) Fit (dots) and prediction (circles) of the proliferation data. Only the color-bordered bars
are used for fitting. e) Fitted and predicted cell division profiles1 and f) predicted mean number
of divisions of the control. g) & h) Analogous plots for the treatment setting. Experimental
data: Lena Kranz and Mustafa Diken.
Table B.1.: Estimated rates for the BMM,
time-resolved experiment, fit to cell division
profile
Parameter Control CD40
source 11000 cells/d "
activation 6.7 1/d "
pdLN,0* 1.2 1/d "
α* 0.35 1/d "
edLN,0** 0.0005 1/d "
β** 2.8 1/d 0.97 1/d
edLN,max** 0.35 1/d "
pT 3.3 1/d "
Undivided 1400 cells 100 cells
cells, tumor
sdabs 0.41 "
sdGen,dLN 0.13 "
sdGen,T 0.13 "
* see eq.(3.1)
1For each cell division profile we fit all fractions but one. If the sum of more than one fraction is ≤ 2%,
these are not used for fitting instead.
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Figure B.5 (previous page): Fit of the best minimal model to the data of the proliferation-
resolved experiment using the mean number of divisions as observables. a)& b) Fit to the
absolute cell numbers in draining lymph node (green) and tumor (red) for the a) control and b)
anti-CD40 treatment. c) Estimated proliferation rate in the draining lymph node, which is the
same for control and treatment. Filled area indicates the 95% confidence interval. d) - i) Fit to
the proliferation data. Only the color-bordered bars are used for fitting. d) Fitted (dots) and
predicted (circles) cell division profiles for the control setting. e) Fitted (dots) mean number
of divisions for the control. f) Fitted (solid line) total fraction of BrdU+ cells for the control
setting. g) - i) Analogous plots for the treatment setting. Experimental data: Lena Kranz and
Mustafa Diken.
Table B.2.: Estimated rates for the BMM,
proliferation resolved experiment, fit to mean
number of divisions
Parameter Control CD40
source 21000 cells/d "
activation 1.1 1/d 4.1 1/d
pG1,dLN,0* 12 1/d "
α* 1.4 1/d "
pS 2.6 1/d "
edLN 0.28 1/d 0.034 1/d
pG1,T 1.9 1/d "
Undivided 15000 cells 1700 cells
cells, tumor
sdabs 0.26 "
sdMDiv 0.24 "
sdGen,dLN 0.017 "
sdGen,T 0.11 "
* see eq.(3.1) **see eq.(3.2)
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C.1. Supplmentary figures to the data
2 3 4 2 3 4
0
100
200
time [d]
ce
ll c
ou
nt
Exp. II
Exp. III
control
treatment
Figure C.1 : Absolute number of undivided cells in the blood in the second (left) and third
(right) PDAC experiment
C.2. Differential equations and observable functions of the
mathematical model
Differential equations used to describe the dynamics of proliferating cells in the draining
lymph node of PDAC experiments are the same as the equations for the time-resolved
melanoma experiment, see section B.2.1 and eqn. (B.1). We use the same abbreviations
for the parameters and variables. The only difference to the equations for the time-
resolved experiment is that the cells continue to divide beyond the fourth division: The
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model of the second pancreatic experiment describes an ongoing division and the model
for the third pancreatic experiment includes a division stop in the sixth generation.
For the second pancreatic experiment this means that the last line describing the
dividing cells would be
˙Akt4dLN = 2pdLN ·Akt3dLN − edLN ·Akt4dLN + pdLN ∗Akt4dLN (C.1)
indicating a continued proliferation after the fourth division (further generations do not
need to be calculated, as we can only resolve 4 generations in the data). The equations
for the proliferation in the tumor for the second experiment are analogous and only differ
in so far as we have an ingress into this compartment. The corresponding last line would
be
˙Akt4T = 2pdLN ·Akt3T + edLN ·Akt4dLN + pdLN ·Akt4T . (C.2)
For the third pancreatic cancer experiment the last line in the draining lymph node is
˙Akt6dLN = 2pdLN ·Akt5dLN − edLN ·Akt6dLN (C.3)
meaning that the proliferation stops in the sixth generation. The equations for the
proliferation in the tumor are analogous and only differ in so far as we have an ingress
into this compartment. The corresponding last line would be
˙Akt6T = 2pdLN ·Akt5T − edLN ·Akt6dLN . (C.4)
Observable functions We have an analogous set of observable functions as for the time-
resolved melanoma experiment, see section B.2.1 and eqn. (B.3). The only differences are
that the mean number of division has contributions from generation 1 to 3 (MDivdLN,4+)
for the second experiment and 1 to 5 (MDivdLN,6+) for the third experiment, and that
the fraction of cells in the last generation (ReldLN,4+ and ReldLN,6+) are not equal to
zero.
Observable function for the second experiment:
AbsdLN = InaktdLN +Akt0dLN ...Akt4dLN (C.5)
MDivdLN,4+ =
Akt1dLN + 2 ·Akt2dLN + 3 ·Akt3dLN
Akt1dLN +Akt2dLN +Akt3dLN
ReldLN,0 =
InaktdLN +Akt0dLN
AbsdLN
ReldLN,4+ =
Akt4dLN
AbsdLN
.
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Observable function for the third experiment:
AbsdLN = InaktdLN +Akt0dLN ...Akt6dLN (C.6)
MDivdLN,6+ =
Akt1dLN + 2 ·Akt2dLN ...+ 5 ·Akt5dLN
Akt1dLN +Akt2dLN + ...Akt5dLN
ReldLN,0 =
InaktdLN +Akt0dLN
AbsdLN
ReldLN,6+ =
Akt6dLN
AbsdLN
.
In the tumor compartment we have an additional difference to the observable functions
of the melanoma experiment. Here, we don’t have a parameter describing the number of
undivided cells such that the model predicts no cells for the corresponding observable.
In consequence, the observable is disregarded, see section 4.2.1.
Observable function for the second experiment:
AbsT = Akt1T + ...+Akt4T (C.7)
MDivT,4+ =
Akt1T + 2 ·Akt2T + 3 ·Akt3T
Akt1T +Akt2T +Akt3T
RelT,4+ =
Akt4T
AbsT
.
Observable function for the third experiment:
AbsT = Akt1T + ...+Akt6T (C.8)
MDivT,6+ =
Akt1T + 2 ·Akt2T ...+ 5 ·Akt5T
Akt1T +Akt2T + ...Akt5T
RelT,6+ =
Akt6T
AbsT
.
In summary, for each measurement time point in both experiments we have 2 · 7
observables (treatment and control) and in total we have two measurment time points,
which gives us 28 observables. From this we have to substract 2 in the second experiment,
as we do not have any information on the cell division profiles in the tumor on day two
for the treatment setting, i.e. we do not have MDivT,4+ and RelT,4+, and we are left
with 26 observables. In the third experiment, we do not have any information on the
cell division profiles in the tumor on day three for the control setting and day four for
the treatment setting, i.e. we do not have MDivT,6+ and RelT,6+, and we are left with
24 observables.
C.3. Alternatives to the best model fits
Fit of full model to the data of the second PDAC experiment The fit to the data
of the second experiment is challenging and different model options could not be distin-
guished properly, such that in our best minimal model all parameters are the same for
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the treatment and the control. Here, we present the fit of the full model (Fig. C.3), where
all parameters can be different but for the source term and the errors, as we assume that
they are not influenced by the treatment. In this way, we show how well a model with the
given basic model structure can in principle approximate the data and illustrate which
part of the data is still difficult to explain as is discussed in section 4.2.3.
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Figure C.2 (previous page): Fit of full model to the data of the second experiment. a) & b)
Fit to the absolute cell numbers in the draining lymph node (green) and tumor (red) for the a)
control and b) anti-CD40 treatment. c) Estimated proliferation rate in the draining lymph node.
Filled area indicates the 95% confidence interval. d)-g) Fit (dots) and prediction (circles) of the
proliferation data. Only the color-bordered bars are used for fitting. d) Fitted and predicted cell
division profiles and e) fitted mean number of divisions for the control. f) & g) Analogous plots
for the treatment setting. Experimental data: Susann Wendler.
Table C.1.: Estimated rates for the
full model, second PDAC experiment
Parameter Control CD40
source 650 cells/d "
activation 31 1/d 7.8 1/d
pdLN* 1.4 1/d 1.3 1/d
α* 0 1/d 0 1/d
edLN 1 1/d 0.02 1/d
pT 1 1/d 3.2 1/d
sdabs 0.53 "
sdMDiv 0.48 "
sdGen 0.10 "
* see eq.(3.1)
Fit of best minimal model to changed observables of the third PDAC experiment In
section 4.2.4, we ask whether the fit is robust under a change of observables. A direct fit
to the cell division profiles, see Fig. C.3, instead of the mean number of divisions yields
similar results, compare Tab. C.2 and Tab. 4.4.
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Figure C.3 (previous page): Fit of the best minimal model to the data of the third experiment
using the cell division profiles as observables. a) & b) Fit to the absolute cell numbers in the
draining lymph node and tumor: a) control b) anti-CD40 treatment. c) Estimated proliferation
rate in the draining lymph node, which is the same for control and treatment. Filled area
indicates 95% confidence interval. d) - g) Fit (dots) and predictions (circles) of the proliferation
data. Only the color-bordered bars are used for fitting. d) Fitted and predicted cell division
profiles 1 and e) fitted mean number of divisions for the control. f) & g) Analogous plots for the
treatment setting. Experimental data: Susann Wendler and Aaron Rodriguez Ehrenfried.
Table C.2.: Estimated rates for the
BMM, third PDAC experiment, fit to
cell division profile
Parameter Control CD40
source 200 cells/d "
activation 370 1/d "
pdLN* 1.8 1/d 2.9 1/d
α* 0.001 1/d "
edLN 0.1 1/d "
pT 1.8 1/d 3.3 1/d
sdabs 0.56 "
sdGen 0.025 "
* see eq.(3.1)
1For each cell division profile we fit all fractions but one. If the sum of more than one fraction is ≤ 2%,
these are not used for fitting instead.
150
Table of abbreviations
AIC Akaike information criterion
APC antigen presenting cell
BMM best minimal model
BrdU Bromodeoxyuridine
CFSE carboxyfluorescein succinimidyl ester
CI confidence interval
CV coefficient of variation
negLL negative loglikelihood
ODE ordinary differential equation
PDAC pancreatic ductal adenocarcinoma
S1PR1 sphingosine 1-phosphate receptor type 1
TCR T cell receptor
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